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Abstract 
Background: Gestational diabetes mellitus (GDM) has adverse effects on the level of docosahexaenoic 
acid (DHA) in phospholipids of maternal and cord red blood cells and cord plasma. This finding was of 
major concern because DHA is vital for maternal wellbeing and health, and for optimal development of 
foetal brain and retina. GDM is also associated with increased oxidative stress. There is controversy 
about omega-3 LCPUFA supplementation and oxidative damage. This ambiguity needs to be explored 
to reveal its role as modulator of oxidative stress in GDM.  
Specific Aims: To investigate if (1) GDM adversely affects the plasma omega-3 and omega-6 long-
chain polyunsaturated fatty acid (LCPUFA) levels in pregnant women. (2) High BMI is associated with 
adverse plasma fatty acid profile in GDM women. (3) Supplementation with DHA-enriched formula, 
enhances the level of the nutrient in the GDM women and their neonates. (4) Antioxidant vitamins 
status is enhanced by DHA-enriched supplementation in GDM women and their newborns.  
Methods: Women with (n = 142; 72 active-group, 70 placebo) and without gestational diabetes (n = 28; 
10 active-group, 18 placebo) were supplemented from the recruitment (at Newham University Hospital, 
London) until delivery. Both active- and placebo-groups received 2 capsules of either DHA-enriched 
formula or high oleic acid sunflower seed oil respectively. Each active supplement capsule contained 
300 mg of DHA, 42 mg of eicosapentaenoic acid (EPA) and 8.4 mg of AA, and placebo 721 mg of oleic 
acid. Blood samples taken from the mothers at recruitment and delivery (maternal and cord) were 
analysed for plasma fatty acid composition and antioxidant vitamins levels.  
Results: At recruitment, no significant difference was found in the DHA level in plasma phospholipids 
(CPG, 4.9% vs. 4.4%, P > 0.05) and neutral lipids (CE, 0.9% vs. 0.9%, P > 0.05), (TG, 0.9% vs. 0.9%, 
P > 0.05) between healthy pregnant and GDM women respectively. When categorized on the basis of 
their BMI, obese and over-weight GDM women had lower omega-3 (ALA, P < 0.05) and higher omega-
6 PUFA (AA, P < 0.05) levels as compared to normal-weight GDM women. A total of 140 women 
completed the trial. GDM active-group compared with GDM placebo-group had significantly higher 
percentage of DHA in plasma CPG (4.4% vs. 3.7%, P < 0.05), CE (1.1% vs. 0.9%, P < 0.05), and TG 
(1.2% vs. 0.8%, P < 0.05) at delivery. There was no significant difference in the cord plasma [CPG 
(5.4% vs. 5.8%, P > 0.05), CE (1.1% vs. 1.0%, P > 0.05), TG (2.9% vs. 3.3%, P > 0.05)] DHA between 
GDM placebo and active-treatment groups. Though not significantly, the levels of vitamin A and β-
carotene were reduced, however, the level of vitamin E was comparable between GDM and healthy 
pregnant women, at recruitment (P > 0.05). At delivery, no significant difference was found in maternal 
plasma vitamin A (21.1 µg/dl vs. 18.0 µg/dl, P > 0.05), vitamin E (1.4 mg/dl vs. 1.4 mg/dl, P > 0.05) 
and β-carotene (16.1 µg/dl vs. 11.1 µg/dl, P > 0.05) levels between GDM placebo- and active-treatment 
groups. Neonatal plasma antioxidant vitamins levels were also comparable between GDM active-
treatment and placebo groups (P > 0.05).  
Conclusion: The present study shows that the plasma DHA and AA levels are not compromised by 
gestational diabetes in pregnant women. It may be that the comparable plasma DHA and AA levels 
observed in the GDM women is linked to a failure to incorporate these fatty acids into the phospholipids 
of the red cell membrane and/or impaired placental transport. Moreover, the majority of samples were 
collected during the third trimester (between 28-32 weeks), so it is plausible that the duration of the 
diabetes was very short to produce an obvious adverse effect on the plasma DHA and AA levels. 
Additionally, this study shows that higher pre-pregnancy BMI is associated with higher n-6 PUFA and 
lower n-3 PUFA levels in GDM women. However, it is difficult to establish whether BMI causes 
adverse fatty acids profile, or whether the direction of this association is reversed.  
This unique study also demonstrated that supplementation with a daily dose of DHA (600mg) 
from diagnosis until delivery was effective in enhancing the level of the nutrient in plasma of GDM 
women but not foetal. The inefficacy of the supplement to improve foetal status suggests that the 
transfer of DHA across the placenta may be impaired in the GDM women. This finding has implications 
for the management of neonates born to GDM women because they are born with a lower level of DHA 
and the condition is considered to be linked with a risk of neuro-developmental deficit. We suggest that 
the provision of a DHA supplement should be integrated with the antenatal care of pregnant women 
with gestational diabetes to optimize foetal development and avert maternal DHA depletion in 
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pregnancy. Also, the babies of the GDM women, particularly those not sucking mother’s milk, similar 
to those who born prematurely require formula milk containing a higher level of DHA.  
 This study demonstrates that DHA-enriched supplement did not improve yet not deteriorate 
the antioxidant vitamins status in GDM women. This may be because of small dose and short duration 
of supplementation. We can allude that the moderate amounts of omega-3 LCPUFA in dietary intake for 
longer duration may reduce the incidence and complications associated with oxidative stress in diabetic 
pregnancy. 
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1.1 Study overview 
The significance of essential fatty acids (EFAs) and their long-chain 
polyunsaturated fatty acids (LCPUFAs) in human development discovered its origin in 
1929 when Burr and Burr explained linoleic acid’s essentiality. They observed that the 
deficiency of linoleic acid in laboratory animals led to the symptoms of dermatitis, 
infertility and growth retardation, after its removal from their diets. The cure of these 
symptoms by vegetable oil supplementation further supported the essentiality of 
certain fatty acids as dietary constituents (Lauritzen et al. 2001). Hansen and co-
workers studied the fatty acid deficiency in humans (Innis 2000). The essentiality of 
omega-3 fatty acids in “new-born” nutrition was not well-recognised until 
demonstrated by Holman in 1982. According to him, lack of omega-3 fatty acids are 
linked with clinical anomalies, such as weakness, paresthesia, impaired vision and 
inability to walk in a 6-years old child (Hadders-Algra 2004). At the same time, 
evidence was collected that omega-3 deficient diets induce some visual deformities in 
subhuman primates (Groen et al. 2005).  
In last ten years or so, scientists have recognised the significance of omega-3 
LCPUFAs during gestation and early life of child’s development. It has been explained 
that sufficient levels of omega-3 fatty acids boost the growth of the foetal and infant 
brain and may increase cognitive development. Omega-3 fatty acids are also essential 
for maternal wellbeing. Recent research shows that omega-3 fatty acid intake by 
pregnant women decreases the risk of infection, allergies and asthma in infants 
(Velzing-Aarts et al. 2001). Omega-3 fatty acids, not only provide shelter from 
cardiovascular disease (Kris-Etherton et al. 2003), lower triglyceride levels (Von-
Schacky and Harris 2007) but also have a significant effect on maternal health during 
pregnancy (Szajewska et al. 2006; Greenberg et al. 2008). They also may protect from 
preeclampsia (Kemse et al. 2014), reduce the possibility of preterm labour (Saccone 
and Berghella 2015) and the risk for perinatal and postpartum depression (Sallis et al. 
2014).  
Currently, considerable developments are under way on the understanding of 
physiological functions of LCPUFAs in animals and humans and their role in curing 
many diseases. The rectification of maternal and feotal plasma omega-3 LCPUFAs 
levels particularly Docosahexaenoic acid (DHA) by supplementing the gestational 
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diabetic women with DHA-enriched formula is the primary focus of this thesis. In 
addition, the effect of DHA-enriched supplementation on antioxidant vitamins status in 
GDM women and their babies has also been investigated in this study.  
1.2  Fatty acids 
1.2.1 Introduction  
Fatty acids are aliphatic mono-carboxylic acids occurring mainly in natural 
triglycerides. All fatty acids have a single carboxyl group at the end of a hydrocarbon 
chain that ranges in length mostly from 4 to 20. With some exceptions, they contain an 
even number of carbon atoms, because, in the human body, fatty acid synthesis 
involves the addition of 2 carbon atoms. Hence, it is said that fatty acids are made up 
of carbon chains with a methyl group at one end (designated Omega, ω) and a carboxyl 
group attaches at the other end of the molecule (Figure 1.1). Alpha (α) carbon is the 
carbon atom that lies next to the carboxyl group while the beta (β) carbon lies next to 
α-carbon.  
 
 
CH3 – (CH2)n – CH2 – CH2 – COOH 
 ω  β         α 
Figure 1.1. Essential features of a fatty acid structure. 
 
 
  Fatty acids either free or as a part of complex lipids, play some vital roles in 
metabolism, acting as major metabolic fuel (storage and transport of energy), as 
essential components of all membranes and as gene regulators. Fatty acids are one of 
the substrates involved in energy production by β-oxidation to maintain metabolic 
homeostasis (IUPAC 2007). 
 
 
  4 
1.2.2 Nomenclature 
  There are several systems of nomenclature for fatty acids. The most common 
are described underneath (IUPAC 2007). 
1.2.2.1 Trivial/Common nomenclature: It is the most common naming system used 
in literature, which includes non-systematic and historical names. The most frequently 
occurring fatty acids also have trivial names along with their systematic names. These 
names mostly do not follow any pattern, but they are often unambiguous and concise. 
Common names usually reflect the source or the name of the discoverer. For example, 
palmitic acid from palm oil or mead acid named so after James Mead. 
1.2.2.2 Systematic nomenclature: Systematic or IUPAC (The International Union of 
Pure and Applied Chemistry) names are derived so after the standard rules of IUPAC 
made for the nomenclature of organic chemistry, published in 1979 (Rigaudy and 
Klesney 1979), accompanied by a recommendation published particularly for lipids in 
1977 (IUPAC-IUB 1977). Counting begins with the carbon of carboxylic acid end to 
the methyl end. Double bonds are labelled with cis- trans- notation wherever found 
appropriate. This notation is mostly more verbose than common nomenclature, but 
technically, it has the advantage of being more clear and descriptive. For example, 9-
octadecenoic acid. 
1.2.2.3 Delta nomenclature: In Delta nomenclature, Δx indicates the position of 
double bonds with reference to the carboxyl acid end (IUPAC-IUB 1977). A cis- or 
trans- prefix precedes each double bond that indicates the conformation of the 
molecule around the bond. For example, "cis-Δ9, cis-Δ12 octadecadienoic acid” is 
designated as linoleic acid. This nomenclature is less verbose than systematic 
nomenclature but technically is not more clear or descriptive.  
1.2.2.4 n-nomenclature: n-x or omega-x nomenclature, both specifies names for 
individual compounds and classes them by their likely biosynthetic features in animals. 
A double bond is positioned on the Xth carbon-carbon bond, counting from the 
terminal methyl carbon (termed as n or ω) toward the carbonyl carbon. For example, 
α-linolenic acid is classified as an n-3 or omega-3 fatty acid, so its biosynthetic 
pathway is expected to be alike with other compounds of this type. In nutritional 
literature, the notation ω-x, omega-x, or "omega" is commonly popular, but in 
technical documents, IUPAC has disapproved it for n-x notation. For example, cis-Δ9, 
cis-Δ12 octadecadienoic acid is notated as 18:2n-6.  
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1.2.3  Classification of fatty acids 
The predominant fatty acids are the straight chain and can be categorised as 
saturated and unsaturated fatty acids. This classification is made on the presence of 
double bonds and its number in their hydrocarbon chain (DeFilippis and Sperling 
2006). 
1.2.3.1 Saturated fatty acids 
Saturated fatty acids (SFAs) have no double bond in their hydrocarbon chain. 
Therefore, they are saturated with hydrogen (double bonds decrease the number of 
hydrogens on each carbon). SFAs consist of the only single bond. Thus, each carbon 
atom in the hydrocarbon chain has two hydrogens (except for the ω carbon at the 
methyl end which has three hydrogens). Most of the SFAs occurring in nature are 
unbranched and have even numbers of carbon atoms. They have a general formula R-
COOH, in which R group is a straight chain hydrocarbon of the form CH3(CH2)X. 
SFAs are very stable as they are least reactive chemically. The melting point of SFAs 
increases with chain length. The single bonds of the SFAs give them a fully extended 
and relatively linear structure so that these types of fatty acid can be packed very 
closely with almost crystalline structure. The longer chain fatty acids are solid at room 
temperature.  
Saturated fatty acids are further classified into three subgroups; short, medium 
and long. Short chain fatty acids consist of less than 8-carbon atoms. The important 
members of this group are butyric (4:0) and caproic (6:0) acids (occurring mainly in 
milk fat). The second subgroup, medium chain fatty acids are fatty acids with the 
carbon atoms ranging from 8-14. Capric acid (10:0), lauric (12:0) and myristic acid 
(14:0) are members of this group. Among them, myristic acid (14:0) has a widespread 
occurrence, but occasionally as a major component. The long chain fatty acids are the 
fatty acids with 16 carbon atoms or more. Palmitic acid (16:0) is the most commonly 
occurring saturated fatty acid in animals, plants and microorganisms. Stearic acid 
(18:0) is also a vital member of this group and is the main fatty acid in animals and 
some fungi though a minor constituent in most plants (Ratnayake 2008; Olsen et al. 
2009), (Figure 1.2). 
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CH3 - (CH2)5 - CH2 - CH2 - CH2 - CH2 - CH2 - (CH2)3 - CH2 - COOH 
 
Figure 1.2. Saturated fatty acid, Palmitic Acid (C16:0). 
 
 
 
1.2.3.2 Unsaturated fatty acids 
Unsaturated fatty acids consist of a hydrocarbon chain with single or more 
double bonds. Monounsaturated fatty acids (MUFAs, monoenoic) have one double 
bond in their hydrocarbon chain. While, polyunsaturated fatty acids (PUFAs, 
polyenoic) have two or more double bonds usually separated by a single methylene 
group in a carbon skeleton (De-fillipis and Sperling 2006). 
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1.2.3.2.1 Monounsaturated fatty acids   
MUFAs contain a single carbon-carbon double bond located in different 
positions. The presence of a single double-bond in the structure offers two possible 
patterns; cis and trans. Cis configuration results in a non-straight structure, which 
confers more fluidity to the membranes as compared to the trans configuration.  Trans 
fatty acids are, in fact, straight chains with properties similar to saturated fatty acids 
and they increase membrane rigidity. Many fatty acids in the trans structure are not 
present in nature and may be produced by hydrogenation of unsaturated oils during 
industrial processing and in the digestive tract of ruminants. Cis configuration gives a 
bend in the linearity of the hydrocarbon chain making these fatty acids not to be 
packed as tightly as the saturated fatty acids. The thermodynamical stability of cis fatty 
acids is less than the trans forms. Therefore, they have lower melting points as 
compared to the trans fatty acids or their saturated counterparts. The melting point of 
unsaturated fatty acids decreases with increasing unsaturation (Olafsdottir et al. 2010; 
Szajewska et al. 2012).  
The most common MUFAs have a chain length of 16-22 with a double bond in 
the cis configuration. All naturally occurring unsaturated fatty acids of mammals 
(especially in the cell membranes) are of the cis configuration (Shantha and  
Napolitano 1992; Weijers 2012). The double bond is most likely located at the Δ9 
position. Oleic acid (cis-9-octadecenoic, 18:1n-9) is the commonest cis-MUFA, and it 
is also the most widely distributed amongst all natural lipids. Palmitoleic acid (16:1n-
7) is also present widely in plants, animals and microorganisms and is one of the major 
components in some seed oils (Rustan and Drevon 2005), (Figure 1.3). 
 
 
 
CH3 - (CH2)5 - CH2 - CH2 - CH = CH - CH2 - (CH2)5 - CH2 - COOH 
 
Figure 1.3. Monounsaturated fatty acid, Oleic Acid (C18:1n-9). 
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1.2.3.2.2 Polyunsaturated fatty acids 
Polyunsaturated fatty acids (PUFAs) consist of two or more double bonds. 
The double bonds can be uninterrupted (allenic), one-methylene-interrupted or 
polymethylene-interrupted. Most animal cells have one-methylene-interrupted 
double bonds. In PUFAs, the presence of several double bonds lowers their melting 
point compared to SFAs of the same length and produces extremely flexible 
molecules. Therefore, high "fluidity" of the cell membrane is usually associated 
with the presence of increased number of unsaturated fatty acids (Gunstone 1999; 
Ruxton et al. 2004).  
The two biologically important subclasses of PUFA are n-3 (ω-3) and n-6 (ω-6) 
fatty acids. These fatty acids are defined according to the location of first double bond 
from their methyl end. Alpha-linolenic acid (ALA) is an example of n-3 fatty acid. It is 
denoted as 18:3n-3 which indicates that this fatty acid has three double bonds in 18 
carbon chain length and the first double bond is located at third carbon from the 
methyl (omega) end. Linoleic acid (LA) is an example of n-6 fatty acids. It can be 
expressed by nomenclature as 18:2n-6 which indicates that this fatty acid has two 
double bonds in the chain length of 18 carbon atoms, and the first double bond is at the 
sixth carbon position from the methyl (omega) end. n/ω-3, n/ω-6 and n/ω-9 are the 
most important families, in term of an extent of occurrence and human health and 
nutrition. All of these are metabolised using the same group of enzymes (Ruxton et 
al. 2004), (Figure 1.4). 
LA (18:2 ω-6) is a major fatty acid, present in plant lipids. Animals get it 
mostly from the dietary plant oils. Throughout the animal kingdom, arachidonic acid 
(20:4 ω-6) is found as a major component of membrane phospholipids, but very less 
amount of it is present in the diet. ALA (18:3 ω-3) is present in higher plants (soya 
bean oil and rapeseed oils) and algae. Eicosapentaenoic (EPA; 20:5 ω-3) and 
docosahexaenoic acids (DHA; 22:6 ω-3) are chief fatty acids of marine algae, fish oils 
and fatty fish. DHA is found in higher concentrations, especially in the phospholipids 
in the brain, retina and testes. Besides their vital role as an integral part of the cell 
membranes, PUFAs serve as the major constituents of plasma lipoprotein 
phospholipids, triglycerides, and cholesterol esters. ω-6 and ω-3 fatty acids cannot 
be inter-convertible, and both are essential nutrients (Le et al. 2009).  
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CH3 - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 - (CH2)5 - CH2 - 
COOH 
 
α-linolenic acid (ALA, C18:3n-3) 
 
 
 
 
 
 
CH3 - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 
- CH = CH - (CH2)2 - CH2 - COOH 
 
Eicosapentaenoic acid (EPA, C20:5n-3) 
 
 
 
 
 
CH3 - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 
- CH = CH - CH2 - CH = CH - CH2 - CH2 - COOH 
 
Docosahexaenoic acid (DHA, C22:6n-3) 
 
 
CH3 - CH2 - CH2 - CH2 - CH2 - CH = CH - CH2 - CH = CH - CH2 - (CH2)5 - CH2 - 
COOH 
 
Linoleic acid (LA, C18:2n-6) 
 
 
CH3 - (CH2)3 - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = CH - CH2 - CH = 
CH - (CH2)2 - CH2 - COOH 
 
Arachidonic acid (AA, C20:4n-6) 
 
 
 
Figure 1.4. Nutritionally important polyunsaturated fatty acids. 
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1.2.4  Dietary sources of LCPUFAs 
The n-3 and n-6 PUFAs are essential fatty acids (cannot be synthesised in the 
body) derived mainly from food. Eicosapentaenoic (EPA), docosapentaenoic (DPA) 
and docosahexaenoic (DHA) acid are ω-3 LCPUFAs that are synthesised in the human 
body from ALA. Arachidonic acid (AA) is another physiologically significant n-6 
LCPUFA that is derived from LA. Since LA is abundant in the human diet, the 
quantity of AA available almost always exceeds the level required to maintain the 
metabolic needs. ω-6 fatty acids are abundantly present in liquid vegetable oils, 
including soybean, corn, safflower oil and cottonseed oils (Calder 2015). In rodents, 
AA alone has been reported to be as effective as LA in preventing symptoms of 
essential fatty acids deficiency (EFAD), (Thomasson, 1962; Hansen et a1. 1986). 
These studies demonstrate that AA can replace LA as the sole source of dietary 
omega-6 fatty acids (Le et a1. 2009). Unlike n-6 fatty acids, n-3 fatty acids do not 
occur in large amounts in plants food and western human diet. Moreover, ALA 
conversion process to EPA and DHA in humans is not efficient as it is only converted 
5-10% to EPA and merely 2-5% to DHA (Arterburn et  a1. 2006).   
N-3 fatty acids are abundantly present in fish and shellfish. In fact, fish-oil 
supplements typically contain 30-50% of n-3 Fatty acids (Russo 2009). Therefore, 
major contributors of n-3 PUFAs in the diet are fish and other seafood. Some other 
dietary sources are chicken, eggs, soybean oil and canola oil. Other food products that 
provide fewer amounts of n-3 PUFAs include legumes, green vegetables, cauliflower, 
ground beef and whole milk (Burdge and Calder 2005). The main sources of n-3 
LCPUFAs are fish and other aquatic animals. n-3 LUPUFAs produce by 
phytoplankton and other aquatic plants in the deep sea which are consumed by fish and 
other oceanic organisms regularly (Arterburn et al. 2006). Some fish and shellfish like 
salmon, herring, sardines and tuna have a significant quantity of EPA and DHA. Some 
researchers investigated that some fungi and alga are also good sources of DHA, and 
these have been cultivated, commercialised and mass-produced to supply the infant 
formula and maternal health industry (Harris 2004; Howe et al. 2006). 
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1.2.5  Consumption of n-3 fatty acids and recommendations 
As per WHO suggestions, the dietary recommendation of n-3 PUFAs for the 
general population is 0.3 to 0.5 gm/day of EPA and DHA, and 0.8 to 1.1gm/day of 
ALA (WHO 2008). During pregnancy, DHA intake should be increased to 0.2 gm/day 
from seafood or some other sources of omega-3 LCPUFAs (Koletzko et al. 2007). The 
current adequate intake (AI) for ALA issued by the Institute of Medicine of the 
National Academies, USA (2005) is 1.6gm/day for men 19-47 years and 1.1gm/day for 
women  19-47 years. The physiological potency of DHA and EPA is greater than 
ALA. Moreover, there is a substantive increase in the evidence about the health 
benefits of omega-3 LCPUFAs (Mozaffarian and Rimm 2006). The recommendations 
of International Society for the Study of Fatty  Acids and Lipids (ISSFAL) for 
minimum DHA and EPA intake is 500 mg/day (ISSFAL 2004). In USA, the total 
intake of  omega-3 fatty acids is 1.6 g/d approximately, and only 0.1-0.2 g/d is coming 
from EPA and DHA (Kris-Etherton et al. 2000). In Japan, n-3 PUFAs intake is about 
1-2 g/d (Sugano & Hirahara 2000). In Canada, the recommendations on total n-3 fatty 
acid intake is 1.2-1.6 g/d (Scientific Review Committee 1990).  
In the UK, the Committee on Medical Aspects of Food and Nutrition Policy 
recommends that the intake of eicosapentaenoic acid and docosahexaenoic acid be 0.2 
g/d or 1.5 g/wk (Kris-Etherton et al. 2002). The ISSAFL has proposed an adequate 
intake of EPA plus DHA to be 0.65 mg per day and even more in the case of pregnant 
and lactating women (Kolanowski et al. 2007; Arab-Tehrany et al. 2012). Intake of 
polyunsaturated fat appears higher among South Asians with P:S (PUFA: SFA) ratios 
than the British population (McKeigue et al. 1985, 1988; Reddy and Sanders 1992; 
Smith et at. 1993; Sevak et al. 1994). In a study of Gujerati Hindus, McKeigue et al. 
(1985) found that LA accounted for most of the high polyunsaturated fat intakes, as 
would be expected from a mainly vegetarian population. In contrast, dietary intakes of 
omega-3 LCPUFAs and their levels in plasma lipids were low. However, levels of 
omega-3 long-chain fatty acids in Muslim Bangladeshis in East London were high, 
presumably reflecting a higher intake of fatty fish in the diet (McKeigue and Marmot 
1988; 1991). Another important and controversial point of view regarding the n-6/n-3 
fatty acids is their ration role in health and disease (Crawford 2000; Griffin 2008; 
Simopoulos 2009). Nevertheless, it can be stated that an adequate intake of both n-3 
and n-6 fatty acids, is essential for good health (Willett 2007). 
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1.2.6  LCPUFAs and cell membrane 
Cell membranes enclose the cell and separate cell contents from the 
extracellular environment. They do not only serve as barriers to protect the cells from 
the outside environment but also play important roles in cell shape maintenance, solute 
transport and signal transduction in and out of the cell, cell-cell identification and 
communication. These membranes consist of two layers of amphipathic lipids, proteins 
and carbohydrates. However, the proportions of these components vary wildly between 
cell types, as well as between the same cells of different animal species. In mammalian 
cells, the lipid bilayers are composed of phospholipids, sphingolipids, cholesterol, and 
glycolipids, among which cholesterol occupies 30%, glycolipids 5% while 
phospholipids (61%) are the most abundant. The lipid fatty acid configuration of the 
membranes influences their physical properties, particularly the membrane fluidity (i.e. 
packing of lipids in the membrane bilayer). Which is determined by; 1) the nature of 
fatty acid chains; 2) the amount of cholesterol and 3) interaction of both polar and non-
polar lipids and between lipids and proteins (Simons and Sampaio 2011; van Meer and 
de Kroon 2011). 
According to Lauritzen et al. (Lauritzen et al. 2001), LCPUFAs are acylated to 
membrane phospholipids often in sn-2 position and make-up about 21-36% of the total 
fatty acid in cell membranes. Various processes influence distribution of the LCPUFAs 
in plasma and red blood cells such as dietary intake, intestinal absorption, metabolism 
and storage, and exchange among compartments, however, the typical composition of 
each lipid class is distinctive. In human plasma, CPG (69% of PLs), cholesterol esters 
(28% of total cholesterol) and triglycerides are dominant lipids classes. Whereas, in 
RBC, phosphatidylcholine (CPG, 29%), sphingomyelin (26%), 
phosphatidylethanolamine (EPG, 31%); and SPG and phosphatidylinositol (Pl),(13.2 
%) are the major classes of phospholipids (Rise et al. 2007). 
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1.2.6.1 Cell membrane structure and organisation 
Garth Nicolson and Jonathan Singer suggested the fluid mosaic model of 
membrane structure in 1972. It is now broadly accepted as the basic model for the 
organisation of all biological membranes. In this model, membranes are observed as 
two-dimensional fluids in which proteins are embedded in lipid bilayers (Cooper 
2000). This membrane model has proved to be a very useful hypothesis in explaining 
many phenomena taking place in biological membranes, notably the distribution of 
molecular components in the membrane (Vereb et al. 2003).  
 
 
 
 
Figure 1.5. Schematic cross-sectional view of cell membrane (adopted from 
https://en.wikipedia.org/wiki/Fluid_mosaic_model). 
 
The core structure of cell membranes establishes on the lipid bilayer which is 
the oldest but still approved molecular model of cellular structures (Gorter and Grendel 
1925). In this model, the membrane is composed of two opposing lipid leaflets, with 
membrane proteins inserted across the bilayer or bound to either side of the leaflets 
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(Figure 1.5). It is, of course, a self-assembled system in itself. Membrane lipids have a 
polar hydrophilic phospholipid head group and hydrophobic tails (fatty acyl groups). 
This amphipathic character drives them to self-assemble into a bilayer, with the 
hydrophilic heads facing outside into the aqueous environment and the hydrophobic 
tails are hidden inside (pointed towards each other). This bilayer serves as a barrier for 
polar and charged solutes, helping to maintain electrochemical gradients across the 
membrane (van Meer and de Kroon 2011).  
Plasma membranes of animal cells consist of four major species of 
phospholipids; choline phosphoglyceride (CPG/PC), ethanolamine phosphoglyceride 
(EPG/PE), Serine phosphoglyceride (SPG/PS), and sphingomyelin (SPM/SM). Almost 
half of the lipids in most membranes consist of these above-mentioned phospholipids, 
scattered asymmetrically between the two halves of the membrane lipid bilayer. Outer 
leaflet of the plasma membrane is mainly composed of choline-phospholipids (CPG 
and SPM) whereas amino-phospholipids (EPG and SPG) are the predominant 
phospholipids of the inner leaflet. A fifth phospholipid, phosphatidylinositol (PI), is 
also confined to the inner half of the membrane. Quantitatively, PI is a minor 
membrane component, but it plays a significant role in cell signalling. The head groups 
of both SPG and PI are negatively charged, so their dominance in the inner leaflet 
yields a net negative charge on the cytosolic surface of the plasma membrane (Cooper 
2000).  
1.2.6.2 Membrane lipids 
It becomes increasingly evident that membrane lipids, independently and 
together with proteins, play a crucial role in the regulation of cell functions 
(Williamson et al. 2003; Lee 2005). It includes; cellular metabolism (Di Paolo and De 
Camilli 2006; Worgall 2008), signal transduction (Wymann and Schneiter 2008), 
regulation of gene expression (Sampath and Ntambi 2004; Sampath and Ntambi 2005) 
and are the major determinant of cell membrane fluidity and permeability (van Meer et 
al. 2008). The major structural lipids in mammals membranes are the 
glycerophospholipids, sphingolipids and sterols, particularly cholesterol, the main 
component of animal cell membrane lipids (van Meer et al. 2008; Mannock et al. 
2010).  
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1.2.6.2.1 Membrane Sphingolipids 
Sphingolipids are vital cell components, mainly residing in the external layer of 
the plasma membrane. Sphingosine is an 18-carbon monounsaturated alcohol 
containing an amino (-NH2) group. A long-chain fatty acid (22-26 carbons) is attached 
to sphingosine (2-amino-1,3-dihydroxy-octadec-4-ene) to its -NH2 group (amide 
linkage) forming what is called ceramide (Figure 1.6). Thus, ceramide is sphingosine-
fatty acid complex (Merrill 2002). The major sphingolipids in mammalian cells are 
sphingomyelins (SMs) and the glycosphingolipids (GSLs), (Sonnino et al. 2006).  
 
 
 
 
 
Figure 1.6. The structure of sphingosine and ceramide (Narayan and Thomas 
2011).  
 
1.2.6.2.1.1 Sphingomyelin 
Sphingomyelins (SPM/SMs) constitute the most common sphingolipids in 
mammalian membranes (Talbott et al. 2000). These molecules have the structure 
ceramide-phosphocholine (polar head group) or ceramide-phosphoethanolamine (polar 
head group). The acyl group is generally saturated (16:0, 18:0, 22:0, 24:0) or 
monosaturated (18:1, 20:1, 22:1, 24:1) fatty acids (Byrdwell and Perry 2007). 
Sphingomyelin (ceramide-1- phosphorylcholine) is most abundantly present in the 
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outer layer of the plasma membrane (Ramstedt and Slotte 2002; Daleke 2008). Tissues 
in which SPM is the predominant phospholipid include the sheath of nerve cell axons, 
myelin (25%) and erythrocytes (18%), (Ramstedt and Slotte 2002). SPM synthesis 
occurs in the lumen of the Golgi as well as on the cell membrane (Huitema et al. 
2004). The synthesis process which is catalysed by SM synthase (SMS) involves the 
transfer of phosphocholine from phosphatidylcholine onto ceramide, yielding 
diacylglycerol in the process (Villani et al. 2008; Gault et al. 2010). Because SM 
Synthase activity directly regulates the level of ceramide and diacylglycerol, it has also 
been suggested to play a vital role in regulating cellular functions (Gault et al. 2010). 
Sphingomyelin’s high packing density and affinity for sterols helps in providing a 
rigid barrier to the extracellular environment and plays a role in the formation of lipid 
rafts, signal transduction and membrane trafficking (Holthuis et al. 200l; Ohanian and 
Ohanian 2001; Tafesse et al. 2007), (Figure 1.7). 
 
 
 
Figure 1.7. Structure of sphingomyelin (adopted from 
http://2012books.lardbucket.org/books/introduction-to-chemistry-general-organic-and-
biological/s20-03-membranes-and-membrane-lipids.html). 
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1.2.6.2.1.2 Glycosphingolipids 
Glycosphingolipids (GSLs) contain mono-, di- or oligosaccharides, based on 
glucosylceramide (GlcCer) and sometimes galactosylceramide (GalCer), (van Meer 
and Lisman 2002). In other words, GSLs are formed when one or more sugars are 
attached to ceramide at its terminal -OH group (Sonnino et al. 2006). The major GSLs 
in animal cell membranes are cerebrosides and gangliosides (Hakomori 2003). 
Cerebrosides also called monoglycosylceramides have the ceramide linked through an 
amide bond to glucose (glucocerebroside) or galactose (galactocerebrosides). 
Cerebrosides particularly occur in neuronal tissues (Tan and Chen 2003), and they 
appear to regulate the specific aspects of neuronal differentiation, proliferation, 
survival and apoptosis (Buccoliero and Futerman 2003). Glycosphingolipids are 
involved in the regulation of signalling through the growth factor and adhesion 
receptors (Odintsova et al. 2006; Sonnino and Prinetti 2010). 
1.2.6.2.2  Cholesterol 
Cholesterol is the most abundant animal sterol. It is a major and essential lipid 
component of the plasma membranes of the cells of higher animals. It is also found in 
lower concentrations in certain intracellular membranes in vesicular communication 
with the plasma membrane (Mannock et al. 2010). It typically accounts for 20-25% of 
the lipid molecules in the plasma membrane (Ikonen 2008), but it can increase up to 
50% in red blood cells (Rog et aI. 2009). Structurally, cholesterol is a steroid built 
from four linked hydrocarbon rings attached to hydrocarbon tail at one end, and the 
hydroxyl group to the other end (Figure 1.8). Cholesterol affects cellular processes by 
interacting both with other membrane lipids and with specific proteins. Due to the rigid 
sterol backbone, cholesterol is preferably positioned in close proximity to the saturated 
hydrocarbon chains of neighbouring lipids. Therefore, resulting in increased lateral 
ordering of membrane lipids, and consequently affects the biophysical properties of the 
membrane, by decreasing fluidity and reducing the permeability of polar molecules 
(Simons and Vaz 2004; Ikonen 2008). Moreover, sterol-induced alterations in 
membrane biophysical properties and direct interaction with proteins could affect the 
cell membrane protein functions and cell signalling (Lee 2004; Olkkonen et al. 2006; 
Raychaudhuri and Prinz 2010).  
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Figure 1.8. Structure of cholesterol (Chiang et al. 2007). 
 
 
 
 
1.2.6.2.3  Phosphoglycerides 
Phosphoglycerides are the most abundant cell membrane lipids in virtually all 
mammalian membranes. Phosphoglycerides consist of a glycerol core binding to a 
phosphate group (hydrophilic head) and two fatty acids (hydrophobic tail). According 
to the structure of the head group, phosphoglycerides are classified into choline (CPG), 
ethanolamine (EPG), serine (SPG), and inositol phosphoglycerides (IPG), phosphatidic 
acid (PA), phosphatidylglycerol (PG) and cardiolipin (Figure 1.9). Choline 
phosphoglyceride accounts for >50% of the phospholipids in most eukaryotic 
membranes (van Meer et al. 2008). In phosphoglycerides, the hydrocarbon chain at the 
sn2 position is always ester-linked to the glycerol moiety, while the sn1 position can 
be linked via an ester, ether or a vinyl ether bond. The length of the alkyl chain 
typically varies from 14 to 24 carbons and the number of double bonds from 0 to 6. 
The alkyl chain in the sn1 position is usually saturated or monounsaturated, while that 
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in the sn2 position is often polyunsaturated (Hermansson et al. 2011). Because of the 
large number of different alkyl chain combinations, each phospholipid class, in turn, 
consists of numerous molecular species that have the same head group but differ in 
respect of acyl chains (Han and Gross 2005; Taguchi and Ishikawa 2010). Besides 
serving as the key structural component of membranes, many phosphoglycerides also 
have other functions particularly in signalling transduction (O'keefe 2002; Fernandis 
and Wenk 2007; Meyer zu Heringdorf and Jakobs 2007; Guan and Wenk 2008). A 
brief description of various types of phosphoglycerides is given below;  
• Phosphatidic acid (PA): In these acids, one of the fatty acids of a triacylglycerol is 
replaced by phosphoric acid. These are parent compounds of all 
glycerophospholipids (Vance and Vance 2004). 
• Choline phosphoglycerides (CPG): These are derivatives of L-phosphatidic acid in 
which choline (a nitrogenous base) joins to phosphoric acid (phosphatidic acid + 
choline = CPG). In other words, these are phosphatidylcholines. Choline is 
trimethylethanolamine and is a quaternary ammonium compound which is as 
strongly basic as NaOH. Both of its structural fatty acids may be 
saturated/unsaturated, or one may be saturated while the other is unsaturated. They 
are the most abundant of the phospholipids in cell membranes, serum and bile. 
• Ethanolamine phosphoglycerides (EPG): These are structurally identical with CPG 
except that the base choline is replaced by ethanolamine, forming phosphatidyl-
ethanolamine. 
• Serine phosphoglycerides (SPG): These are structurally identical with CPG except 
that the base choline is replaced by serine, forming phosphatidyl-serine. 
• Inositol phosphoglycerides (IPG): Contain inositol base (Smith et al. 2005). 
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Figure 1.9. Choline and ethanolamine phosphoglycerides located in cell 
membranes (adopted from http://www.ncbi.nlm.nih.gov/books/NBK22361/). 
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1.2.7  Biosynthesis of long chain polyunsaturated fatty acids  
When obtained from the diet, LA and ALA are further metabolized by Δ6 
desaturation (process of elimination of two hydrogen atoms from the fatty acid carbon 
chain), elongation (process of addition of two carbon atoms in the hydrocarbon chain 
of fatty acid), and Δ5 desaturation to form arachidonic acid (AA) and eicosapentaenoic 
acid (EPA), respectively. In vivo, LA (18:2n-6) is desaturated by the action of Δ6 
desaturase to γ-linolenic acid (GLA, 18:3n-6) by inserting a double bond between the 
sixth and seventh carbon. GLA is then converted to dihomo-γ-linolenic acid (DHGLA, 
20:3n-6) by the action of elongase enzyme (with an addition of two carbons). DHGLA 
is further transformed to AA (C20:4n-6) by Δ5 desaturase, with the addition of a 
double bond between fifth and sixth carbons. Similar to the ω-6 pathway, the ω-3 
pathway is mediated by the same set of enzymes that convert LA to AA. In the ω-3 
pathway, ALA is transformed by Δ6 desaturase, then elongated and desaturated to EPA 
(C20:5n-3), docosapentaenoic acid (DPA, C22:5n-3), and docosahexaenoic acid 
(DHA, C22:6n-3), respectively (Ferdinandusse et al. 2001; Sprecher 2002; Le et al. 
2009), (Figure 1.10). 
The formation of LCPUFAs can take place in multiple organs e.g. brain 
(Moore et al. 1991), retina (Rotstein et al. 1996) and intestines (Garg et al. 1988) but 
mainly in liver (Voss et al. 2000). All reactions occur in the endoplasmic reticulum 
except the final reaction which takes place in the peroxisome, resulting in the 
formation of DHA and osbond acid (C22:5n-6) respectively. The formation of osbond 
acid and DHA was earlier thought to be catalysed by a Δ4 desaturase, but is in fact, a 
retro-conversion: elongation and Δ6 desaturation followed by translocation to the 
peroxisome and β-oxidation shortening the acyl chain to a 22 carbon LUPUFAs 
(Sprecher 2002). 
If there is an insufficient supply of LCPUFAs to meet the physiological 
requirements, the body starts to synthesise certain other fatty acids with a similar 
molecular structure but without the same functions. These fatty acids are not present 
normally in the body (or present in low concentrations) and can, therefore, be used as 
LCPUFAs status markers. A general deficiency of LCPUFAs is indicated by a higher 
level of mead acid (C20:3 n-9). Deficiency of DHA results in increased production of 
osbond acid (C22:5 n-6), (Burdge and Calder 2005). 
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Figure 1.10. A general pathway for the conversion of LA and ALA into their 
LCPUFAs (Innis 2003). 
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1.2.8  Biomedical importance of ω/n-6 and ω/n-3 LCPUFAs 
1.2.8.1  Biomedical importance of ω-6 (arachidonic acid) 
The AA, ω-6 fatty acid, is present in all cell membranes and contributes up to 
15% of the total fatty acids in phospholipids. Various studies have indicated that the 
low quantity of AA in maternal and cord blood is related to reduced head 
circumference and low birth weight (Crawford et al. 1989; Leaf et al. 1992), intra-
uterine growth retardation (Vilbergsson et al. 1994) and impaired growth in preterm 
infants (Carlson et al. 1993). AA is a precursor of important signalling compounds 
called eicosanoids which include prostaglandins (PGs), prostacyclins, thromboxanes, 
leukotrienes and lipoxins (De Caterina and Basta 2001; Funk 2001; Calder et al. 2015b; 
Turcotte et al. 2015). These biologically active compounds have various roles in the 
regulation of immune response, inflammation and pain, smooth muscle contraction, 
platelet aggregation, renal electrolyte regulation and tumour cell proliferation (Vachier 
et al. 2002; Ferrucci et al. 2005; Simopoulos 2009; Turcotte et al. 2015).  
1.2.8.2 Biomedical importance of ω-3 (EPA and DHA) 
Cell membranes contain modest amounts of EPA and greater amounts of DHA. 
An exception is membranes of the brain (grey matter) and eye (rod outer segments), 
which contain high amounts of DHA (Crawford et al. 1976; Skinner et al. 1993; 
Makrides et al. 1994). Increased intake of ω-3 LCPUFAs (particularly EPA and DHA) 
is characterised by increased amounts of these fatty acids in membranes of many cell 
types (Calder 2014). Many but not all of the functional effects of ω-3 LCPUFAs rely 
on their incorporation into cell membrane phospholipids (Calder 2014). The structure 
of ω -3 LCPUFAs, particularly DHA, means that they have a strong influence on the 
physical properties of membranes into which they are incorporated, on membrane 
protein function, and on lipid raft formation (Calder 2015a). The vital role of DHA in 
visual function relates explicitly to the environment that DHA-rich phospholipids 
provide for rhodopsin, which optimises the function of this protein in signal 
transduction (Niu et al. 2004). As a result of their effects on membrane-generated 
intracellular signals, EPA and DHA can modulate transcription factor activation and, 
subsequently, gene expression patterns (Gottlicher et al. 1992; Novak et al. 2003; 
Clarke 2004; Deckelbaumet al. 2006; Jump 2008; Calder 2012). Effects of ω-3 
LCPUFAs on transcription factor activation and gene expression are central to their 
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role in controlling inflammation, fatty acid and triacylglycerol metabolism, and 
adipocyte differentiation (Calder 2012; Calder 2014) Calder 2015a). The replacement 
of cell membrane AA by EPA and DHA influences the pattern of lipid mediators 
produced (Calder 2015a). As a result, EPA and DHA can influence inflammation, 
immune function, and blood clotting, vasoconstriction, and bone turnover, among 
other processes. EPA and DHA may also affect cell function by mechanisms that do 
not involve their incorporation into cell membranes. For example, non-esterified (NE) 
EPA and DHA can act directly via G protein-coupled receptors (GPRs) that exhibit 
some specificity for ω-3 LCPUFAs over other fatty acids as ligands. In particular, 
GPR120, which is highly expressed on inflammatory macrophages and adipocytes, 
was shown in cell culture experiments to play a central role in mediating the anti-
inflammatory effects of DHA on macrophages and the insulin-sensitizing effects of 
DHA on adipocytes (Oh et al. 2010). 
1.2.8.2.1 Effects on pregnancy and early childhood 
In the context of pregnancy and child development, LCPUFAs, specifically 
DHA, has a vital role in neural, visual and behavioral development (Simopoulos 2002; 
Himmelfarb et al. 2007; Calder 2008). DHA is found in very high levels in the central 
nervous system and retina, especially in the grey matter and photoreceptors and 
believed to be essential for optimal development of these regions (Innis 2003; 
Arterburn et al. 2006; Bradbury 2011). DHA is preferentially transported to the infant 
during the 3rd trimester of gestation in humans and coincides with the later stages of 
the brain and retinal maturation (Carlson 2001; Innis 2005; Carlson 2009). It has been 
estimated that 67-75 mg/day of DHA is accumulated in-utero during the last trimester 
of gestation (Clandinin et al. 1980; Innis 2005; Henriksen et al. 2008). More recent 
studies in animals have suggested that early DHA exposure influences neural 
differentiation, neurotransmitter target finding and synaptogenesis during gestation 
(Innis and Owens 2001; McNamara and Carlson 2006). Several studies have evaluated 
the efficacy of maternal supplementation on infant’s neurodevelopment (Lauritzen et 
al. 2004; Dunstan et al. 2007; Meldrum et al. 2012). It has been demonstrated that 
infant feeds which include DHA (and usually also AA) improve visual development in 
preterm infants and perhaps also improve visual and cognitive outcomes in term 
infants (Calder 2014). A recent meta-analysis has indicated an increase in mean 
gestational age and birth weight, and a decrease in the number of infants born before 
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37 weeks’ gestation in mothers receiving n-3 LCPUFAs supplementation during 
pregnancy (Salvig and Lamont 2011).   
LCPUFAs are the structural components of cell membranes. The retinal 
membrane phospholipids are comprised of over 47% DHA. Also, approximately 14% 
of brain DHA is present in grey matter (Diau et al. 2005; Heird and Lapillonne 2005). 
The availability of particular fatty acids during development is considered to be 
important in neurocognitive functions (Hadders-Algra et al. 2007; Bazan et al. 2011). 
High levels of LCPUFAs found in the basal ganglia, pre- and post- central cortices, 
hippocampus, and thalamus in neonatal baboons and rats suggesting that they affect 
sensorimotor integration and memory (Favreliere et al. 1998; Diau et al. 2005). It is 
now thought that EPA and DHA have important roles in the brain beyond infancy and 
may be important for brain function throughout the life course. Benefits of EPA and 
DHA have been shown in childhood attention, learning, or behavioral disorders 
(Richardson and Puri 2002; Stevens et al. 2003; Gustafsson et al. 2010; Milte et al. 
2012; Perera et al. 2012; Yui et al. 2012) depression (Su et al. 2003), bipolar manic 
depression (Stoll et al. 1999), unipolar depressive disorder (Nemets et al. 2002), 
schizophrenia (Peet et al. 2001; Peet and Horrobin 2002) and aggression (Hamazaki et 
al. 2002). 
1.2.8.2.2 Effects on blood lipid concentrations  
Like other fatty acids, long chain ω-3 PUFAs affect blood lipid concentrations; 
EPA and DHA are particularly effective at lowering blood triacylglycerol 
concentrations.  One important mechanism underlying this effect is reduced hepatic 
assembly and secretion of VLDLs, which are the main triacylglycerol- carrying 
lipoproteins in the fasting state. Hence, hepatic output of VLDL is decreased by EPA 
and DHA. There is also some evidence that EPA and DHA upregulate the expression 
of lipoprotein lipase in adipose tissue; an effect that would promote triacylglycerol 
clearance from the bloodstream. The triacylglycerol- lowering effect of EPA and DHA 
also probably involves decreased release of non-esterified fatty acids (NEFA) from 
adipose tissue, thereby reducing supply of substrate to the liver for triacylglycerol 
synthesis, and increased β-oxidation in skeletal and cardiac muscle thereby drawing 
circulating NEFAs away from the liver (Shearer et al. 2012). Acting through one or 
more, or perhaps all, of these mechanisms, EPA and DHA lower blood triacylglycerol 
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concentrations. EPA and DHA also influence the concentrations of cholesterol-
carrying lipoproteins. They typically cause a small increase in both LDL and HDL 
cholesterol concentrations (Harris 1997; Woodman et al. 2002; Balk et al. 2006). EPA 
and DHA also increase LDL particle size, rendering LDL less atherogenic (Suzukawa 
et al. 1995; Woodman et al. 2003; Mori et al. 2000; Neff et al. 2011). 
1.2.8.2.3 Antihypertensive effect 
EPA and DHA affect many processes related to blood pressure, including the 
production of eicosanoids with vasoactive effects, the secretion of aldosterone, the 
generation of nitric oxide by the endothelium, vascular reactivity, and cardiac 
hemodynamics. Consequently, EPA and DHA lower blood pressure (both systolic and 
diastolic), as confirmed through several studies (Bao et al. 1998; Geleijnse et al. 2002; 
Balk et al. 2004; Hartweg et al. 2007; Miller et al. 2014). A study revealed that n-3 
LCPUFAs consumption is related to the reduced risk of pre-eclampsia (Qui et al. 
2006). The study conducted on patients with hypertension and diabetes revealed that 
increased level of DHA in blood led to the significant decrease in diastolic blood 
pressure and increased heart rate as compared to the control group which had low 
DHA level in their blood platelet membranes (Christensen et al. 2001).  
1.2.8.2.4 Anti-inflammatory effect  
EPA and DHA reduce inflammation. A key aspect of this anti-inflammatory 
action is the reduced production of eicosanoids from arachidonic acid and the 
increased production of proresolving mediators (resolvins and protectins) from EPA 
and DHA (Stulnig 2003; Calder 2015a). Many cohort studies report inverse 
associations between dietary intake or blood concentrations of EPA and DHA and the 
concentrations of a range of inflammatory markers, including cytokines, adhesion 
molecules, and acute phase proteins (Yli-Jama et al. 2002; Pischon et al. 2003; 
Ferrucci et al. 2006; Forouhi et al. 2014). Intervention studies with EPA and DHA 
have shown lowered concentrations of various cytokines, adhesion molecules, and 
acute phase proteins (Calder et al. 2011). EPA and DHA have also been shown to 
target inflammation in adipose tissue in humans (Itariu et al. 2012; Spencer et al. 
2013). A placebo-controlled trial of n-3 supplementation in patients with exercise-
induced bronchoconstriction had a significant improvement in symptoms and a 
reduction in the synthesis of inflammatory mediators (Mickleborough et al. 2003). 
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EPA and DHA are effective in some chronic inflammatory diseases such as 
rheumatoid arthritis (Volker et al. 2000; Cleland et al. 2003; James et al. 2003; 
Covington 2004; Miles and Calder 2012). Interestingly, other potential symptomatic 
benefits of n-3 fatty acids have also been observed in other inflammatory diseases, 
such as; osteoarthritis (Curtis et al. 2002), rheumatoid arthritis, inflammatory bowel 
diseases (Crohn and ulcerative colitis), (Belluzzi et al. 1996; Belluzzi 2002), some 
nephropathies (immunoglobulin A [IgA]), (Goumenos and Brown 2004) and 
infectious diseases such as hepatitis (Leu et al. 2004). EPA and DHA may play a role 
in reducing risk of childhood allergic diseases (Miles and Calder 2014). Related to 
their effects on inflammation, EPA and DHA can influence immune functions and 
defense against infections. However, effects of EPA and DHA on immune functions, 
apart from those related to inflammation, have not been consistently seen in humans. 
Nevertheless, some RCTs in children providing EPA + DHA, either added into milk 
(Thienprasert et al. 2009) or as supplements (Malan et al. 2015), have reported 
decreased illness resulting from respiratory infections. 
1.2.8.2.5 Cardioprotective effect 
Through effects on blood lipids and lipoproteins, vascular function, blood 
pressure and blood flow and inflammation, EPA and DHA lower risk of coronary 
vascular disease (CVD) and may also be used to treat existing CVD (Hu and Willett 
2002; He et al. 2004; Von Schacky and Harris 2004). Substantial evidence from many 
studies has now accumulated, indicating that consumption of EPA and DHA reduces 
the risk of CVD outcomes in Western populations (London et al. 2007; Saravanan et 
al. 2010; De Caterina 2011). Chowdhury et al. (2014) reported a lowered risk of 
coronary outcomes in individuals consuming high compared with low amounts of EPA 
and DHA. Furthermore, individuals with high compared with low circulating 
concentrations of EPA, and DHA had lowered risk of coronary outcomes (Chowdhury 
et al. 2014). Thus, it seems likely that by establishing a better risk factor profile, EPA 
and DHA reduce the likelihood of atherosclerosis and so lower the risk of CVD. There 
has also been much interest in treating existing CVD with EPA and DHA. A number 
of studies published reported lower rates of death in patients with CVD who received 
supplemental EPA plus DHA, (Marchioli et al. 2002; Yokoyama et al. 2007; Gissi-HF 
et al. 2008). Three important mechanisms have been proposed to contribute to the 
therapeutic effect of EPA + DHA. The first is altered cardiac electrophysiology seen as 
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lower heart rate (Harris et al. 2008), increased heart rate variability (Xin et al. 2013), 
and fewer arrhythmias (Leaf and Xiao 2001). The second is an antithrombotic action 
resulting from the altered pattern of production of eicosanoid mediators that control 
platelet aggregation from AA and from EPA (von Schacky et al. 1985). The third 
mechanism is the well-documented anti-inflammatory effect of EPA (E-series 
resolvins, Rv) and DHA (D-series resolvins and neuroprotectin D1), which would 
serve to stabilize atherosclerotic plaques, preventing their rupture (Calder 2008; 
Serhan and Chiang 2008; Cawood et al. 2010). 
1.2.8.2.6 Anticancerous effects 
EPA and DHA exert a range of biological activities that may influence tumour 
cell proliferation and viability; for example, DHA can promote tumour cell apoptosis 
possibly through inducing oxidative stress (Gleissman et al. 2010; Merendino et al. 
2013). EPA and DHA also reduce production of mediators such as prostaglandin E 2 
that drive tumour cell proliferation and tumour growth (Wang and Dubois 2010; 
Vaughan et al. 2013).  Anti-thrombotic effect of n-3 LCPUFAs was initially associated 
to EPA because of its competition with AA in cyclooxygenase (COX) and 
lipoxygenase (LOX) pathways. n-3 LCPUFAs (particularly EPA) obstruct the 
cyclooxygenase activity and its inhibition leads to the low level of prostaglandins and 
activates the lipoxygenase enzymes. The increased activity of lipoxygenases results in 
increased formation of hydroxyeicosatrienoic acids (HETE) and leukotriene B4 
(LTB4), which are responsible for reducing the intensity of inflammation and pain and 
slow down the process of cancerous cells surpassing a tissue (Nomura et al. 2003). 
Through these effects, EPA and DHA can directly influence cancer cells and the 
tumour environment, and they can influence the host response to tumour bearing. Anti-
inflammatory actions of EPA and DHA may also be important in preventing or 
slowing some steps in tumour initiation, particularly in some cancers such as colorectal 
cancer. Recent reviews provide in-depth analysis of the mechanisms by which EPA 
and DHA affect tumour cell proliferation, invasion, and metastasis (Gleissman et al. 
2010; Merendino et al. 2013) and the ability of EPA and DHA to enhance the 
effectiveness of anticancer treatments (Merendino et al. 2013; Vaughan et al. 2013).  
Both DHA and EPA help in providing protection against tumor growths But, some 
human and animal studies conclude that DHA is the more effective anti-aggregatory 
agent than EPA in preventing transcription factor activator protein 1 (AP-1), which is 
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associated with the progress of cancerous growth (Liu et al. 2001; Woodman et al. 
2003; Cottin et al. 2011) 
1.2.8.2.7 Effects on insulin resistance and diabetes 
Insulin resistance plays an important role in various chronic diseases including 
metabolic syndrome and type II diabetes. A growing body of evidence suggested that 
there is an inverse association between n-3 LCPUFAs and insulin resistance (IR). 
Anti-diabetic effects of PUFAs have been observed, including increased basal 
metabolic rate and fat oxidation (Jones and Schoeller 1988; Couet et al. 1997); 
however, some of these findings were resulted from studies comparing 
polyunsaturated: saturated fatty acid intake. Studies involving fish oil effects on the 
composition of human body and IR vary depending on the health of the subjects and 
the type of the study. Consequently, it has been hard to determine the effects of EPA 
and DHA on diabetes-related parameters during human trials (Anderson and David 
2009). Animal studies involving EPA, DHA and IR likely to be more consistent and 
support an anti-diabetic effect. Numerous rodent studies revealed that EPA improves 
IR in numerous models of obesity and diabetes (Mori et al. 1997; Mori et al. 1999; 
Nobukata et al. 2000) and elevates systemic concentrations of insulin-sensitizing 
adiponectin (Flachs et al. 2006). An improved response to a glucose load was also 
reported in mice fed high-fat diets enriched in EPA and DHA (Ikemoto et al. 1996). 
Several studies evaluated fish oil feeding in sucrose-fed rats and noticed reduced 
peripheral IR, hyperglycemia and fat pad mass (Soria et al. 2002; Pighin et al. 2003) as 
well as increased insulin-stimulated glucose transport in supplemented animals 
(Peyron-Caso et al. 2002). EPA and DHA also observed to prevent alloxan-induced 
diabetes and restored the antioxidant status of various tissues to normal range in rats 
(Suresh and Das 2003). Both have shown to be more efficient than ALA at lowering 
plasma glucose plus insulin levels and improving insulin sensitivity (Andersen et al. 
2008). 
n-3 LCPUFAs are proposed to decrease the risk of insulin resistance by 
multiple means, few of which seem to be distinctively affected by n-3 fatty acids. EPA 
and DHA are favorably incorporated into cell membranes, hence increasing membrane 
fluidity. Which, in order, has been shown to raise the number of insulin receptors at the 
cell membrane and their affinity to insulin (Das 2005). Up-regulation of insulin 
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receptors decreases the insulin resistance and favorably modifies an individual's 
glycemic response, an effect that could potentially prevent or delay the onset of type II 
diabetes. Transcription factors are also involved in IR. Nuclear factor-kB (NF-kB) 
activation of endothelial cells was exhibited in response to hyperglycemia, though, 
EPA and DHA were exhibited to down-regulate NF- kB (Morigi et al. 1998). This 
could potentially mediate several vascular complications that result from chronically 
raised glucose levels seen in diabetics. Additionally, peroxisome proliferator-activated 
receptor gamma (PPARγ) is linked with the etiology of IR, as it raised the expression 
and translocation of glucose transporters (GLUT-1 and GLUT-4), thus, facilitating 
glucose uptake in adipocytes and the muscle cells (Kramer et al. 2001). EPA and DHA 
appear as ligands for PPARs and so, may have an anti-diabetic role. Furthermore, 
stimulation of PPARγ inhibits the expression of IR-promoting cytokines and 
simultaneously triggering an increase in the plasma concentrations of adiponectin 
(Gross and Staels 2007). This resulted in decreased blood glucose levels by improving 
insulin sensitivity and reducing liver glucose production (Yamauchi et al. 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
  31 
1.3 Diabetes mellitus 
Diabetes mellitus (simply diabetes, DM) is characterised by different metabolic 
disorders in which an individual has high blood glucose levels, either because of the 
pancreas that does not produce sufficient insulin or due to the cells, which do not 
respond to the insulin produced. As a result, typical manifestations of diabetes; 
polyuria (frequent micturition), polydipsia (increased thirst) and polyphagia (increased 
hunger) are produced (Shoback 2011). Diabetes has different types, however, the long-
term negative effects of chronic hyperglycemia on various organs; for example, 
kidneys (nephropathy), blood vessels (angiopathy), eyes (retinopathy), nerves 
(neuropathy) and heart remain similar (ADA 2012). 
1.3.1  Gestational diabetes mellitus  
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance 
that begins or is first recognised during pregnancy and generally resolving shortly after 
delivery. This definition acknowledges the prospect that patients may have 
undiagnosed diabetes mellitus previously or might have developed diabetes as a 
coincidence with pregnancy. (ACOG 2001; ADA 2004; Diabetes Care 2008; NICE 
2015). A woman is said to have GDM when the glucose intolerance continues beyond 
24-28 weeks of gestation. GDM, depending upon the populace studied, influences 1-
14% of all pregnant females (ADA 2012). GDM is frequently more common in 
populaces with a high occurrence of type II diabetes, for example, India and China 
(Hunt and Schuller 2007). It is acknowledged that GDM women have a significant risk 
of advancing to type II in later life (Kim et al. 2002).   
Although, it is an eminent cause of pregnancy complications, but its 
epidemiology has not been studied systematically. An important problem is the 
distinction of GDM, as now defined, from pre-existing but un-diagnosed diabetes, so 
that the degree of clinical surveillance may have a major impact on the estimated 
prevalence of GDM in a given population. This is especially true in high-risk 
populations in which the onset of type II diabetes occurs at an early age. Furthermore, 
investigators use different screening programs and diagnostic criteria for GDM, 
making comparisons among studies difficult (King 1998; ACOG 2001; Hunt and 
Schuller 2007). Almost 700,000 women give birth in the UK each year, and up to 5% 
of them have either pre-existing diabetes or GDM. Of females who have diabetes 
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during pregnancy, it is estimated that around 87.5% have GDM (that may or may not 
resolve after pregnancy), 7.5% have type I diabetes, and the remaining 5% have type II 
diabetes. The prevalence of type I diabetes, and especially type II diabetes, has 
increased in recent years. The incidence of GDM is also increasing as a result of the 
high prevalence of obesity in the general population as well as more pregnancies in 
older women (NICE 2015). 
As compared to Caucasians the frequency of GDM is two and four times 
greater in females of African and Asian origin, respectively (Toms et al. 1992; 
Koukkou et al. 1995). The impact of ethnic origin on the occurrence of GDM was 
assessed during a study in the UK, where the females were screened for GDM. 
Females from ethnic origins other than White had a higher incidence of GDM than 
White ones (2.9% vs. 0.4%). The relative risk of GDM in other ethnic groups 
compared to white females was: South East Asian 7.6, Black 3.1, Indian 11.3 and 
miscellaneous 5.9 (Dornhorst 1992). 
1.3.1.1   Risk factors for GDM 
Various maternal risk factors for the development of GDM have been 
described.  The traditional and most often reported risk factors for GDM are increased 
maternal age, weight, and high parity, previous delivery of a macrosomic infant and a 
family history of diabetes (Table 1.1). These and other reported risk factors are 
described below. 
1.3.1.1.1 Maternal risk factors 
1.3.1.1.1.1 Older age has consistently been reported as a risk factor for GDM 
(Egeland et al. 2000; Jimenez-Moleon et al. 2000; Jolly et al. 2000; Bo et al. 2001; Lao 
et al. 2001; Xiong et al. 2001; Ben-Haroush et al. 2004; Kieffer et al. 2006; Silva et al. 
2006; Berg et al. 2007). 
1.3.1.1.1.2 Ethnicity has an influence on the occurrence of GDM. It differs 
considerably among ethnic groups in the USA: 9.7% in Asians, 7% in Latinas, 4.3% in 
African-Americans and 4.1% in Caucasians (Esakoff et al. 2005).  Asian females 
residing in the USA have the high occurrence of GDM. Among them, the increased 
risk of GDM has been identified in females from Bangladesh with a risk ratio of 7.1 in 
comparison with non-Hispanic whites (Savitz et al. 2008). A study carried out in 
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London revealed that pregnant females with GDM from Bengali-Asians origin residing 
in an east London health district were more aged and of higher parity than the 
Caucasians and required insulin therapy more frequently. Persistence of abnormal 
glucose tolerance was shown by 20% of Bengali people as compared to the Caucasian 
group who presented no abnormalities (Toms et al. 1992).  
1.3.1.1.1.3 Higher parity has also been stated as maternal risk factors for GDM. 
Grand multiparas (i.e. females with ≥ 5 deliveries) had more frequently an insulin-
dependent GDM as compared to multiparas with 2-4 deliveries (Roman et al. 2004). 
The risk of GDM in grand multiparas was two-folds higher in comparison to females 
with 2-3 deliveries (Nassar et al. 2006).  
1.3.1.1.1.4 Pre-pregnancy body weight is another reported risk factor of GDM. Well-
known risk factors of GDM include overweight and obesity. Body mass index (BMI) 
of 25.0-29.9 kg/m2 doubles the risk of GDM, and it becomes 6-folds higher at BMI ≥ 
30 kg/m2 when compared to women having normal BMI (Cnattingius and Lambe 
2002). According to another study, obese pregnant women have more than doubled the 
risk of developing GDM, and it increases to four-folds with BMI ≥ 35 kg/m2 as 
compared to women with BMI less than 30 kg/m2 (Weiss et al. 2004). Another study 
has also identified the high BMI as a GDM risk factor (Kousta et al. 2000b). 
1.3.1.1.1.5 Polycystic ovarian syndrome (PCOS) is more prevalent in GDM women 
(Kousta et al. 2000b; Koivunen et al. 2001; Mikola et al. 2001; Haver et al. 2003).  
1.3.1.1.1.6 Short stature is another maternal risk factor described in some studies (Bo 
et al. 2001). The incidence of GDM was higher in Korean women shorter than 157cm 
(Jang et al. 1998). In Brazil, women shorter than 151cm demonstrated a 60% increase 
in GDM than women of 160cm height or above (Branchtein et al. 2000). Additionally, 
in Australia, GDM women were considerably shorter and have a lower leg-to-height 
percentage (Moses and Mackay 2004). South Asian and European women with 
previous GDM were shorter than control women from the same ethnic groups (Kousta 
et al. 2000a). 
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1.3.1.1.2 Genetic risk factors 
There are at least ten genes where certain polymorphisms are linked with a 
high risk of GDM, most significantly TCF7L2 (Zhang et al. 2013).  
 
Table 1.1. Maternal determinants, generally referred as" traditional risk 
factors for GDM (adopted from Ben-Haroush et al. 2004). 
 
Risk Factors for the development of GDM 
1. Prior GDM 
2. Pre-pregnancy obesity 
3. High risk ethnic group- South Asian, Aborginal, Hispanic 
4. Prior macrosomic infant (Birth weight > 4.5 kg) 
5. Maternal age > 35 years 
6. Polycystic ovarian syndrome 
7. Family history of T2DM in a first degree relative 
8. Multiple gestation 
9. Previous history of impaired fasting glucose or impaired glucose tolerance 
 
1.3.1.1.3 Family history  
 Family history of diabetes mellitus is considered as another risk factor for 
GDM (Jimenez-Moleon et al. 2000; Ben-Haroush et al. 2004; Cypryk 2008). The first-
degree heredity of type II DM was more prevalent in previous GDM than the control 
group (Holte et al. 1998). A family history of maternal type II diabetes mellitus is 
considerably more common among GDM women than a paternal family history 
(Egeland et al. 2000). Also, type II diabetes was significantly observed more in the 
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maternal-grand maternal line among GDM women compared to the paternal-grand 
paternal line (Harder et al. 2001).  
1.3.1.1.4 Previous obstetric outcomes 
Certain outcomes of previous pregnancies are also observed as risk factors for 
GDM in the consecutive pregnancies, for example, giving birth to a baby with 
macrosomia and previous GDM (Jimenez-Moleon et al. 2000). Though, previous 
macrosomia as a risk element for GDM has been argued recently as macrosomia may 
have some other causes, for example, obesity, multiparity, unnecessary weight gain in 
pregnancy and hereditary factors (Grassi and Giuliano 2000; Magenheim et al. 2007). 
However, it has been shown that pregnant women with the history of still birth and C-
section have a high incidence of GDM (Xiong et al. 2001). Some studies show that the 
GDM women are more likely to have the recurrence of the disease in their subsequent 
pregnancies (Major et al. 1998; Spong et al. 1998; MacNeill et al. 2001). 
1.3.1.1.5 Pregnancy factors 
Some other risk factors for GDM have been recognised as raised blood 
pressure during pregnancy (Ma and Lao 2001), multiple pregnancies (Wein et al. 1992; 
Schwartz et al. 1999; Sivan et al. 2002) and elevated iron stores (Lao et al. 2001). 
Accelerated foetal development (Langer et al. 1991; Nordin et al. 2006) and 
polyhydramnios (Nobile de Santis et al. 2004; Nordin et al. 2006) may also raise the 
risk of GDM. 
Added risk factors for GDM which are modifiable, include less physical 
activity, increased intake of dietary fat and life style habits (e.g. smoking and some 
drugs use), all badly influence insulin resistance. Wang et al. studied the aspect of 
increased body weight and polyunsaturated fat intake (Wang et al. 2000). They 
determined that both had an independent relationship with concentrations of glucose, 
such as increased body weight and reduced intake of polyunsaturated fat, both were 
predictive of the incidence of GDM. 
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1.3.1.2 Pathogenesis of gestational diabetes 
The incidence of GDM has doubled over the last few years and is paralleling 
the obesity epidemic. GDM causes long-term implications for the subsequent 
development of type II diabetes in the mother and high risk for obesity and glucose 
intolerance in the children. As pregnancy advances, the increasing tissue resistance to 
insulin creates a demand for more insulin, and, if resistance becomes dominant due to 
impaired insulin secretion, hyperglycaemia develops. In the majority of such cases, it 
develops in the latter half of gestation, with insulin resistance progressively increases 
until delivery, when, in most cases, it disappears rapidly (Barbour et al. 2007).  
It has been convincingly established that GDM arises as a result of a 
combination of insulin resistance and reduced insulin secretion. As per the definition 
of GDM, there are two important points for the discussion. First, pregnancy is 
normally attended by progressive insulin resistance that begins near mid-pregnancy 
and progresses through the third trimester till delivery. The insulin resistance develops 
from a combination of increased maternal adiposity and insulin-desensitizing effects of 
hormonal products of the placenta. The fact that insulin resistance rapidly decreases 
following delivery suggests that one of the contributors to this state of resistance are 
placental hormones. The second point is that pancreatic beta cells normally increase 
their insulin secretion to compensate for the insulin resistance of pregnancy. 
Consequently, the changes in blood glucose levels over the period of pregnancy are 
quite small as compared to the large changes in insulin sensitivity (Moshe Hod et al. 
2008), (Figure 1.11). 
1.3.1.2.1 Insulin resistance  
The development of resistance to the glucose-lowering effects of insulin is a 
normal phenomenon of pregnancy. This physiological insulin resistance also appears 
in women with GDM. Though, it occurs on a background of chronic insulin resistance 
and to that the insulin resistance of pregnancy is partially additive. Thus, GDM 
pregnant women tend to have even greater insulin resistance than healthy pregnant 
women. In addition to that, insulin secretion is inadequate to compensate for the 
insulin resistance, leading to hyperglycaemia that is detected by routine glucose 
screening in pregnancy. Thus, chronic insulin resistance is a central component of the 
pathophysiology of GDM (Barbour et al. 2007). 
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Human pregnancy is characterised by a sequence of metabolic changes that 
enhance adipose tissue accretion in early pregnancy, followed by insulin resistance and 
facilitated lipolysis in later pregnancy. At the beginning of pregnancy, the insulin 
secretion increases, while insulin sensitivity is unchanged, decreased, or may even 
increase (Catalano et al. 1993; Catalano et al. 1999). However, in late pregnancy, 
maternal adipose tissue depots decline, while postprandial FFAs levels increase and 
insulin-mediated glucose disposal worsens by 40-60% as compared to pre-pregnancy 
(Catalano et al. 1999). The ability of insulin to suppress whole-body lipolysis is also 
reduced during late gestation (Homko et al. 1999). This insulin ability is further 
reduced in GDM women (Catalano et al. 2002), contributing to greater postprandial 
increases in FFA levels, increased hepatic glucose production, and high insulin 
resistance (Metzger et al. 1993; Buchanan et al. 1999; Catalano et al. 1999; Friedman 
et al. 1999). Catalano et al. (1991) determined an approximate decrease of 21% in 
insulin sensitivity appearing to 12-14 weeks of gestation and 56% decrease in insulin 
sensitivity appearing to 34-36 weeks. Others have shown similar results (Xiang et al. 
1999; Buchanan et al. 2000; Buchanan et al. 2001). 
Although many placental hormones have been suggested to reorganise 
maternal physiology to meet the foetal needs, the cellular mechanisms behind this 
complex transition remain unclear (Handwerger and Freemark 2000). Much effort has 
been invested in identifying the tissues that contribute to the insulin resistance of 
pregnancy. Findings in animal models indicate a 40% reduction in insulin-mediated 
glucose utilisation by skeletal muscle and a similar effect in cardiac muscle and fat 
cells (Leturque et al. 1986; Hauguel et al. 1988).  
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1.3.1.2.2 Hormonal effects 
Pregnancy is accompanied by profound hormonal changes, which have a direct 
effect on carbohydrate tolerance. Reproductive hormones tend to increase during 
pregnancy, most of them contribute to insulin resistance and altered beta-cell function. 
In early gestation, both progesterone and oestrogen rise but their effects on insulin 
activity are counterbalanced. Progesterone causes insulin resistance whereas oestrogen 
is protective (Ryan and Ennes 1988; Gonzalez et al. 2000). Cortisol levels increase as 
pregnancy progresses and by the end of pregnancy concentrations are three-folds 
higher than in the non-pregnant state (Gibson and Tulchinski 1980). High levels of 
Cortisol are linked with increased hepatic glucose production, decreased 
phosphorylation of the insulin-receptor and profound insulin resistance (Rizza et al. 
1982). During pregnancy, maternal prolactin levels increase 7-10 folds. Although, 
raised prolactin levels are not of pathophysiological importance in the development of 
GDM (Skouby et al. 1986). The levels of human placental lactogen (hPL) rise at the 
beginning of the 2nd trimester, causing a decrease in phosphorylation of insulin 
receptor substrate (IRS)-1 and severe insulin resistance (Ryan and Ennes 1988). 
Adiponectin is a key insulin-sensitizing hormone produced by the adipose 
tissue. It is considerably lower in women with the history of GDM and declines further 
with advancing pregnancy, suggesting its likely involvement in the transition to insulin 
resistance (Ranheim et al. 2004; William et al. 2004; Winzer et al. 2004; Heitritter et 
al. 2005; Thyfault et al. 2005; Ategbo et al. 2006). In adipose tissue, the lipogenic 
transcription factor and PPAR-δ decreases in obese pregnant women that could shift 
genes in metabolic pathways to support increased lipolysis, hence accelerating adipose 
tissue insulin resistance (Bruun et al. 2003; Fasshauer et al. 2003).  This transition to 
insulin resistance adds on to greater postprandial increases in the circulating FFAs and 
increased hepatic glucose production, which results in greater fuel availability to the 
foetus of the GDM women. Thus, like a perfect storm, the placental hormones, less 
adiponectin secretion, and excess lipolysis collaborate to cause profound insulin 
resistance in muscle, liver, and adipose tissue in GDM women. 
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1.3.1.2.3 Pancreatic beta-cell function  
Insulin is a hormone that controls blood glucose concentration. Fasting plasma 
insulin increases gradually during pregnancy, and by the 3rd trimester, levels are 2-
folds higher than before pregnancy. Women with GDM have fasting insulin levels 
equal to or higher than those of women with healthy pregnancies, with the highest 
levels occurring in obese GDM women. During normal pregnancy, oral and 
intravenous glucose tolerance deteriorates only slightly, despite the reduction in insulin 
sensitivity (Buchanan et al. 1990). The mechanism accountable for increase insulin 
secretion during gestation is not well understood. A chief contributing factor is an 
increase in the beta cell mass, a combination of hyperplasia and hypertrophy (Van 
Assche et al. 1987). The increased beta cell mass can contribute to the increased 
fasting insulin concentration despite normal or lowered fasting glucose concentrations 
in late gestation, and the enhanced insulin response to glucose during gestation (2-3 
folds above non-pregnant levels). In most women, pancreatic insulin secretion rises to 
meet this need (to overcome insulin resistance), but in those with underlying beta cell 
defects, hyperglycaemia ensues (Swinn et al. 1995). GDM tends to be milder in 
subjects with a normal beta cell response, and they are at relatively low risk for 
developing diabetes in later life (Kjos et al. 1995). 
1.3.1.2.4 Genetics, immunology and gestational diabetes mellitus 
Increased plasma levels of TNF-α have also been linked to insulin resistance. 
The mechanism involved is probably related to a decrease in the insulin receptors 
(Hotamisligil et al. 1994; Kirwan et al. 2002). Some GDM women manifest evidence 
for autoimmunity towards beta cells (insulin auto-antibodies and anti-islet cell 
antibodies); though, the prevalence of such autoimmunity has been stated to be 
extremely low (< 10%), (Catalano et al. 1990; Damm et al. 1994). The parallel 
frequencies of HLA-DR2, -DR3 and -DR4 antigens in well pregnant women and GDM 
women, and the low incidence of markers for autoimmune destruction of the beta cells 
in GDM may exclude the possibility that GDM has an autoimmune origin (Ober et al. 
1989; Vambergue et al. 1997). 
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1.3.1.2.5 Insulin signalling system in normal pregnancy and GDM 
When insulin binds to the insulin receptor (IR), the activation of the tyrosine 
kinase (TK) enzyme on the beta subunit leads to increased phosphorylation of the 
cellular substrates. Insulin receptor substrate-1 (IRS-1) is a cytosolic protein that binds 
to the phosphorylated intracellular substrates and transmits the insulin signal 
downstream. The dispersal of the IRS proteins tends to be tissue specific. IRS-2 is 
more abundant in the liver and pancreas, while both IRS-1 and IRS-2 are widely 
spread in skeletal muscle. Insulin triggers the activation and binding of the lipid kinase 
enzyme, phosphatidylinositol (PI)-3-kinase, and its binding to IRS-1. The formation of 
PI is crucial for insulin action on the glucose transport. In GDM women, the skeletal 
muscle contains lower levels of IRS-1 protein and considerably less insulin-stimulated 
IRS-1 tyrosine phosphorylation, whereas the levels of IRS-2 protein are increased. 
These findings propose that the insulin resistance of GDM can be exerted through a 
reduction in insulin resistance cascade at the level of IRS proteins. The higher IRS-2 
level may be a compensation for the reduced IRS-1 level (Shao et al. 2000). 
The latest research suggests that the post-receptor mechanisms that contribute 
to insulin resistance of pregnancy are multifactorial, but are exerted at the beta subunit 
of the IR and the level of IRS-1. The resistance to insulin-mediated glucose transport 
appears to be greater in skeletal muscle of GDM women than from pregnancy alone 
(Garvey et al. 1993). IR tyrosine phosphorylation has also been reported to be 
impaired in muscle from obese GDM women (Garvey et al. 1992). Besides, 
overexpression of membrane plasma cell differentiation factor-1 (PC-1) may play a 
role in developing insulin resistance by inhibiting the TK activity of the IR (Garvey et 
al. 1993). In GDM women, PC-1 levels were significantly higher in skeletal muscle 
compared to healthy pregnant women (Goldfine et al. 1998; Shao et al. 2000). 
GDM is a predictor of DM (mainly type II) later in life. Also, GDM is a 
predictor or even an early manifestation of the metabolic syndrome (insulin 
resistance). GDM is a risk factor for cardiovascular diseases and affected women 
should be screened to avert late complications. 
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1.3.1.3 Management of gestational diabetes mellitus  
In most pregnant women, GDM doesn't manifest itself. Most cases are only 
diagnosed when the blood sugar level is tested for the screening of GDM. In some 
women, the symptoms may appear when their blood glucose level gets too high 
(hyperglycaemia), such as polydipsia, polyuria, a dry mouth and tiredness. Although, 
some of these symptoms are common in pregnancy anyway and aren't necessarily a 
sign of a problem. 
1.3.1.3.1 Screening  
 The National Institute for Clinical Excellence (NICE) recommends that 
screening should be offered at booking appointment to the healthy pregnant women 
with the following risk factors for GDM (Table 1.2).  
   
 
Table 1.2.   Current recommendations for screening (NICE Clinical Guidelines 
2015). 
Screening criteria according to NICE guidelines 
1. BMI > 30/m2 
2. Previous macrosomic baby weighing ≥ 4.5 kg   
3. Previous GDM 
4. First degree relative with diabetes (family history of diabetes) 
5. Family origin with a high incidence of diabetes (South Asian, dark 
Caribbean and Middle Eastern)  
  
 Offer women with any one of the above-mentioned risk factors testing for GDM. 
The use of 2-hour 75gm oral glucose tolerance test (OGTT) at 24-28 weeks is 
recommended to test for GDM in the women with risk factors.   
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 Women with the history of GDM should be offered early days self-monitoring of 
blood glucose or a 2 hour 75gm oral glucose tolerance test (OGTT) as early as possible 
after booking i.e.; 16-18 weeks, followed by another OGTT (2 hour 75gm) at 24-28 
weeks when the result of the 1st test is normal. 
 Beware of glycosuria ≥ 2+ one-time or ≥ 1+ two or more times detected by 
reagent strip testing during the routine antenatal care. It may indicate undiagnosed 
GDM. If this happens, consider further testing to exclude GDM (NICE Clinical 
Guideline 2015). 
 Ruling out the risk factor is controversial. Many experts (IADPSG) advise 
universal screening for all pregnant women (Metzger et al. 2010). Oral glucose 
tolerance test (OGTT) is extensively adopted throughout the world for the diagnosis of 
GDM because of its highest test performance, high sensitivity, high specificity and 
low false positive rates as compared to the other tests. After an overnight fast between 
8 to 14 hours, OGTT is performed in the morning. The test is carried out to measure 
the glucose level by taking a blood sample at the beginning and 2-hour interval 
subsequently after drinking a solution that contains 75gm of glucose (NICE Clinical 
Guideline 2015). 
1.3.1.3.2 Diagnosis 
At least six types of different criteria have been practised globally for the 
diagnosis of GDM. The differences among the diagnostic tests are basically about the 
glucose load to be given, the timings and the type of blood sample (Agarwal et al. 
2005; Agarwal et al. 2015). NICE recommends a 2-hour 75gm OGTT for the diagnosis 
of GDM (NICE Clinical Guideline 2015).  
As per NICE guidelines, GDM diagnosed if the woman has either fasting 
plasma glucose level ≥ 5.6 mmol/l or a 2-hour 75gm OGTT plasma glucose level ≥ 7.8 
mmol/l. 
1.3.1.3.3 Management of GDM 
Self-care is a very important component of the management of GDM. Both 
medical and nutrition treatments are required to be started once the GDM is diagnosed. 
The management regime suggested for GDM women includes dietary therapy, self-
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monitoring of blood glucose levels and healthy lifestyle measures postpartum. The 
involvement of a dietician and the diabetes educator experienced in the care of GDM 
women facilitate these areas of management. All of the recommendations are 
described below.   
1.3.1.3.3.1 Dietary therapy  
  It is generally accepted that the dietary therapy is a cornerstone of treatment of 
GDM. So, all the women with GDM should receive counselling from a specialist 
dietitian. Recommendations are individualised after a dietary assessment of each 
patient. The aim is to achieve normoglycaemia while providing the required nutrients 
for normal foetal growth and maternal health. Another aim (secondary) is to prevent 
excessive maternal weight gain, especially in women who are overweight/obese or 
have gained excess weight during pregnancy. Few trials have examined the efficacy of 
dietary therapy for GDM. Among those, a study has provided support for Medical 
Nutrition Therapy (MNT) for GDM as per the recommendations of American Diabetes 
Association (ADA). In this study, 215 GDM women were randomised to deliver either 
MNT or standard care. Only 24.6% of subjects in the MNT group required insulin 
(Reader 2007). The ADA proposes that all women should receive individualised 
counselling to provide sufficient calories and nutrients to meet the needs of gestation 
and consistency in the blood glucose goals. For obese women, a 30-33% calorie 
restriction to around 25 kcal/kg actual weight/day is recommended. Carbohydrate 
intake should be restricted to 35-40% of calories.  
  There are also data to support low carbohydrate diets in pregnancy, and for the 
carbohydrate to be of low glycemic index (GI). In a non-randomised study, GDM 
women on a diet comprising < 42% carbohydrates, had lower post-prandial blood 
glucose levels, were less likely to have need for insulin, and had a low incidence of 
large for gestational age (Major et al. 1998). A small study which randomised pregnant 
women to low GI or high GI diets found that the low GI group resulted in lower blood 
glucose levels, a blunting of the pregnancy allied rise in insulin resistance, and low 
birthweight (Clapp 2002). In another study of GI, women assigned to a low GI diet 
during pregnancy gave birth to infants who were lighter (3408 ± 78g vs. 3644 ± 90g) 
and had a low incidence of large for gestational age, as compared to the women given 
a high GI diet (Moses et al. 2006). GDM diagnosed women assigned to a low-
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glycemic index diet regimen were observed to be considerably less likely to meet the 
criteria of insulin therapy. In the group of women with GDM allocated to a traditional 
high fibre and higher glycemic index diet, nearly half of the women who reached the 
criteria for insulin treatment avoided the treatment after shifting to the low-glycemic 
index diet (Moses et al. 2009).  
 As per above mention studies, it would be appropriate to recommend low GI 
carbohydrate diet to GDM women. Additional dietary measures are generally based 
upon the general recommendations for DM. A reduced intake of simple carbohydrates 
and fat are advisable. It is emphasised that the dietary intake should be spread over six 
meals daily including three main meals and three snacks, to avoid large carbohydrate 
loads at any time. Except for saccharin, which can cross the placenta and is therefore 
not recommended, other non-caloric sweeteners may be used in moderation (Cheung 
2009). 
1.3.1.3.3.2 Blood glucose monitoring  
Women with GDM should perform self-monitoring of blood glucose (SMBG). 
Blood glucose levels are usually measured in the fasting state and 1-2 hours after 
meals. Management of post-prandial targets leads to superior pregnancy outcomes as 
compared to pre-prandial targets (de Veciana et al. 1995). Women performing SMBG 
showed 10% improvement in self-efficacy from baseline (Homko et al. 2002). 
According to a research study, pregnancy outcomes can be improved by meal based 
SMBG, and that available clinical evidence favours testing at 4-times a day in diet-
treated GDM; e.g. before breakfast and 1 hour after each meal throughout the day 
(Jovanovic 2008).  
The recommended treatment targets vary from country to country (Table 1.3). 
These are mostly consensus-based since the risk of complications is continuous and 
there are no clear thresholds above which the risk significantly increases. The initial 
intervention usually entails dietary advice, individualised if possible, and 
recommended by a dietitian. Lifestyle measures can deliver adequate control in the 
majority of subjects. If the blood glucose targets are not effectively met by lifestyle 
measures, and possibly a review of dietary intake, then pharmacotherapy should be 
considered. This generally means the commencement of insulin. Instead of basing the 
need for insulin on glycemic parameters only, some have supported the combined 
  46 
usage of ultrasound assessment of foetal abdominal circumference together with blood 
glucose levels (Kjos et al. 2001).  This practice allowed more women to avoid insulin 
therapy. 
 
Table 1.3. Recommended glucose targets (Cheung 2009). 
 Fasting 
(mmol/l) 
1 hr postprandial 
(mmol/l) 
2 hr postprandial 
(mmol/l) 
NICE 5.3 7.8 6.4 
ADA 5.8 8.6 7.2 
ADIPS 5.5 8.0 7.0 
CDA 5.3 7.8 6.7 
 
 
1.3.1.3.3.3 Physical activity  
In people with type II diabetes, there is sufficient evidence that regular physical 
activity enhances their insulin sensitivity, facilitates weight loss, and thus improves 
glucose control. Various small studies have tested whether regular exercise is also 
helpful in the management of GDM. In a study, 19 GDM women were randomised to 
either a regime of diet alone or diet with 20-minutes of supervised aerobic training 
three days/ week for six-weeks (Jovanovic-Peterson et al. 1989). The results of this 
modest amount of physical activity were reduced fasting glucose levels, low glucose 
response to a glucose challenge, and a lower HbA1c. In another study, 29 GDM 
women were randomised either to 30-minutes of exercise at 70% estimated maximal 
heart rate, 3-4 times/ week, or control (Avery et al. 1997). There was a trend to 
improved glucose levels in those who exercised, which did not reach significance. 
There were no differences in neonatal outcomes. Measures of cardiorespiratory fitness, 
however, improved. A study of 32 women randomised to circuit-type exercise 3-times 
a week or control, demonstrated that resistance training led to lower postprandial 
glucose levels along with a delay in the requirement of insulin (Brankston et al. 2004). 
  47 
Amongst women with a pre-pregnancy BMI 25, those who exercised regularly were 
less likely to require insulin. Thereby, it appears quite reasonable to recommend that 
the GDM women with no medical or obstetric contraindication should maintain a 
practicable level of low and moderate intensity exercise throughout the pregnancy. The 
above-mentioned studies corroborate that moderate intensity physical activities such 
as; walking for 20-30 minutes each day, and presence at antenatal exercise classes can 
be safely encouraged, and that modest improvements in the glycemic control may be 
achieved. 
1.3.1.3.3.4 Insulin therapy for gestational diabetes  
When treatment targets are not attained by dietary means, at that time insulin is 
required. Prandial fast-acting insulin is given to control post-prandial hyperglycaemia, 
and bed-time basal insulin is administered if there is fasting hyperglycaemia. In some 
GDM women, an extra morning injection of basal insulin might further improve 
glycemic control. As the levels of insulin resistance vary between subjects, it is a 
common practice to administer small doses of insulin at the beginning, and after that to 
increase the doses at frequent intervals until target blood glucose levels are achieved. 
The required dose of insulin increases progressively over the last trimester of 
pregnancy. Frequent review and titration of the insulin dosage are recommended. 
Dissimilar to the situation of women with pre-existing type I diabetes, though, 
significant hypoglycaemia is uncommon in insulin-treated GDM women. 
Nevertheless, the women should be advised on appropriate hypoglycaemia prevention 
and management measures (Cheung 2009).  
For long-time, fast-acting (regular) insulin, and intermediate-acting (isophane) 
insulin have been the most preferred insulins for the treatment of GDM. Human insulin 
does not usually cross the placenta, however; antibody bound animal insulin has been 
reported to do so (Menon et al. 1990). However, it has been shown by Jovanovic that it 
is maternal glucose control, rather than maternal anti-insulin antibody levels which 
influence birthweight (Jovanovic et al. 1992). Human insulin is considered safe in 
gestation as many years of experience have not suggested an increase in foetal 
complications as an outcome of its use. Nowadays, there is increasing evidence that 
the newer rapid-acting insulin analogues lispro and aspart are also safe during 
pregnancy, and therefore, they are commonly used. No increase in pregnancy 
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complications has been found in observational studies where lispro was used, in either 
woman with GDM or pre-existing diabetes (Bhattacharyya et al. 2001; Persson et al. 
2002; Aydin et al. 2008). 
There is a report regarding the use of aspart in pregnancy suggesting that aspart 
is as safe and effective as human insulin (Hod et al. 2008). With respect to GDM, there 
have been several small randomised studies comparing the use of rapid-acting insulin 
analogues with the regular insulin. They all have demonstrated that the rapid-acting 
analogues are as efficacious as regular insulin in the treatment of GDM, with parallel, 
if not favourable outcomes (Cheung 2009). Data regarding the long-acting insulin 
analogues are less clear than for rapid-acting analogues. Concerns have been stated 
about the usage of glargine in pregnancy, as of its potential effect on mitogenesis 
(Hirsch 2005; Jovanovic and Pettitt 2007). 
NICE recommends offering immediate treatment with insulin (with or without 
metformin), along with changes in diet and exercise to GDM women with fasting 
plasma glucose level of 7.0 mmol/l or above at the time of diagnosis (NICE Clinical 
Guideline 2015). 
1.3.1.3.3.5 Oral antidiabetic agents in GDM  
There is a controversy regarding the use of oral hypoglycemic agents in 
pregnancy. Many government drug-agencies have not validated their use during 
pregnancy, and major specialty diabetes organisations suggest that oral agents be 
stopped if the woman had been taking them pre-pregnancy (McElduff et al. 2005; 
Canadian Diabetes Association 2008; Kitzmiller et al. 2008).  
Though, insulin is considered as the gold standard for the treatment of 
hyperglycaemia in pregnancy when dietary and lifestyle modifications cannot achieve 
the recommended glucose targets. However, recent studies have shown that certain 
oral antidiabetic drugs may be safe and acceptable alternatives (Kalra et al. 2015; 
Singh and Singh 2015). NICE recommends offering metformin to women with GDM 
(fasting plasma glucose < 7.0 mmol/l at diagnosis) not meeting blood glucose targets 
with diet and exercise within one to two weeks. The GDM women in whom blood 
glucose targets are not achieved with metformin but who decline insulin treatment or 
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who cannot tolerate metformin can be considered for glibenclamide (NICE Clinical 
Guideline 2015). 
1.3.1.4 Future risks of GDM 
1.3.1.4.1 Increased maternal risks 
Pre-eclampsia and the gestational hypertension are apparently more common in 
women with GDM (Dukler et al. 2001; Innes et al. 2001; Xiong et al. 2001). 
Preeclampsia increases the incidence of (3-fold increased) preterm delivery (Vatten 
and Skjaerven 2004). Caesarian section is likely to be carried out in females with 
GDM and labour is required to be induced (Aberg et al. 2001; Brody et al. 2003; Berg 
et al. 2007). Preeclampsia is particularly developed more in pregnant obese females 
with insulin-treated GDM having poor glycemic control in comparison to pregnant 
obese females with well-controlled insulin-treated GDM. Chronic hypertension is two 
to three folds more prevalent in overweight and obese GDM females irrespective of 
the treatment or glycemic control level (Langer et al. 2005).   
The increased risk of developing DM later in life for GDM women is well 
known. It has been also recognised that GDM women have up to 8-fold higher risk of 
developing metabolic syndrome (MS). This syndrome is linked to a high rate of type II 
diabetes and cardiovascular complications (Peters et al. 1996; Kim et al. 2002). The 
collective incidence of type II ranges from 2.6% to above 70% at six weeks to 28 years 
post-partum in females with prior GDM (Kim et al. 2002).  
1.3.1.4.2 Increased child risks  
GDM during pregnancy possibly affects the outcome of the progenies. A 
higher percentage of children are born premature, macrosomic and have dystocia, 
(Jensen et al. 2000; Yang et al. 2002; Ostlund et al. 2003), even when the GDM is 
being treated (Bartha et al. 2003). Hypoglycaemia affects newborn babies more 
frequently, and they require care in neonatal intensive care units (NICU) to a greater 
degree (Simmons et al. 2000; Svare et al. 2001). It is revealed that if GDM is 
diagnosed in the third trimester, the risks of congenital anomalies are reduced (Savona-
Ventura and Gatt 2004). Some specific anomalies are reported more frequently 
amongst GDM affected pregnancies, for example, certain cardiac defects, spinal 
deformations and oesophageal /intestinal atresia (Aberg et al. 2001).  
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It has become progressively clear over the past decades that many foetal 
stresses may lead to foetal programming and alteration in the normal developmental 
gene expression pattern. Current research indicates that the children of the diabetic 
mother remain at high risk for a variety of developmental disturbances: obesity 
(Dabelea and Pettitt 2001; Brody et al. 2003; Gillman et al. 2003), impaired glucose 
tolerance or diabetes (Silverman et al. 1995; Brody et al. 2003) and diminished 
neurobehavioral capacities (Rizzo et al. 1991; Sells et al. 1994; Lincoln et al. 1996). It 
is also observed that LGA offspring of GDM mothers had a higher than a 3-fold risk 
for symptoms associated with metabolic syndrome, at 11 years of age (Boney et al. 
2005). Females with previous GDM reported that their children to be less healthy as 
compared to the controls 3 to 5 years after childbirth (Feig et al. 1998). Also, children 
of the mothers who had DM or GDM during pregnancy reported lower marks in school 
(Dahlquist and Kallen 2007). Thus, it would be sensible to speculate that the process 
whereby a stimulus or insult (glucose toxicity and other metabolic fuels) acting at a 
critical stage of development in early and during late intrauterine life, may alter gene 
expression patterns for life. 
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1.4 Pregnancy, oxidative stress and micronutrients 
1.4.1 Overview 
The significance of appropriate nutrition consumed prior and during pregnancy 
on optimising the health status of mother and infant is known for long (Fawzi et al. 
2007; Allen et al. 2009). “Micronutrients” is a term used collectively for minerals and 
vitamins. These dietary components are required in traces for the maintenance of 
normal physiological functions of human body. They are essential dietary elements, as 
the body cannot synthesise them and their inadequacy results in specific metabolic 
deformities especially in children, pregnant and lactating women. High Systemic 
oxidative stress occurs late in pregnancy because of increased metabolic demand, 
which leads to decreased availability of antioxidants during pregnancy. Therefore, the 
content of these micronutrients should be increased in the diet in order to compensate 
their substantial loss (Bedaiwy et al. 2003; Oyawoye et al. 2003; Berchieri et al. 2011). 
Insufficient supplies of micronutrients throughout pregnancy can have unfavourable 
impacts on the mother, for example, anaemia, hypertension, labour complications or 
even death. The foetus can also be affected, such as stillbirth, preterm delivery, 
intrauterine growth retardation, congenital malformations, reduced immunity and 
organ abnormalities. Hence, attention should be paid to maintain adequate levels of 
micronutrients throughout the gestation (King 2000; Owens and Fall 2008). 
1.4.2  Oxidative stress  
Oxidative stress is explained as an imbalance between the production of 
reactive oxygen species and antioxidant defences, characterised by increased 
concentration of oxygen and non-oxygen-derived products that stimulate critical and 
sometimes irreversible cell injury (Caimi et al. 2003). These reactive species are 
generated as by-products of metabolism, physiological mediators and signalling 
molecules (Evans and Halliwell 2001). These reactive species include reactive oxygen 
species (ROS), reactive nitrogen species (RNS) and reactive chloride species (RCS). 
These reactive oxygen species are produced endogenously under both physiologic 
(pregnancy) and pathologic conditions (Cotovio et al. 2001). They are also known as 
free radicals (highly reactive molecules that damage cells throughout the body). They 
are believed to be responsible for cardiovascular diseases, cancer, neurological 
disorders, cataract, arthritis, ageing, fatigue, and muscle damage (Food and Nutrition 
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Board 2000; Fang et al. 2002). During pregnancy, the generation of lipoperoxides 
exceeds their decomposition rate creating oxidative stress. These lipoperoxides also 
increase in the foetus as it grows but to a lesser degree than of mother (Sobki et al. 
2004). This increased oxidative stress causes lipid and protein peroxidation, which 
impairs endothelial cell function (Serdar et al. 2003). It can affect the foetal skeletal 
formation, and it can also cause spontaneous abortion, recurrent pregnancy loss and 
preeclampsia in pregnancy (Prater et al. 2008; Agarwal et al. 2012). 
1.4.3      Antioxidants 
Defence system of the human body against free radicals is a system of 
antioxidant molecules that interact rapidly with free radicals and stop the chain 
reaction before it can destroy vital macromolecules (proteins, nucleic acids, starches 
and lipids). Antioxidant defence system includes both enzymatic (SOD, catalase, GSH 
peroxidase and GSH reductase) and non-enzymatic components (mainly vitamin E, A, 
C and β-carotene), (Cho and Choi 1994).  
Vitamin E, A and β-carotene are low molecular antioxidant compounds. They 
absorb into the blood by the lymphatic system and then reach the liver and fatty tissues 
by the blood where they are stored for their required actions (Grzelinska et al. 2007). 
Vitamin E is the main liposoluble antioxidant in human body which scavenges peroxyl 
radicals produced during lipid peroxidation by transferring its phenolic hydrogen to a 
peroxyl free radical of a peroxidized polyunsaturated fat (PUFA), thus breaking the 
radical chain reaction and preventing the peroxidation of PUFA in cellular and 
subcellular membrane phospholipids (Oostenbrug et al. 1997; Grissa et al. 2007). This 
lipid soluble property permits it to diffuse into various tissues rapidly. Vitamin A is 
another non-enzymatic antioxidant capable of reacting directly with free radicals while 
β-carotene is reported to scavenge singlet molecular oxygen effectively (Baydas et al. 
2002).  
1.4.3.1 Vitamin A, β-carotene and vitamin E 
 Vitamin A is a generic term applied to a large number of closely related 
compounds. Chemically, it is a poly-isoprenoid compound with a fat-soluble property 
and also serves as a precursor for the synthesis of some hormones. There are two 
active and major forms of vitamin A; retinol (vitamin A1) and 3-dehydroretinol 
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(vitamin A2). A chemically diverse group of plant carotenoids forms provitamin A 
through which vitamin A is synthesised enzymatically in the walls of the small 
intestine and liver. β-carotene is the most active carotene among over 50 carotenoids, 
and it is responsible for the biological action of vitamin A, directly or after its 
transformation into two molecules of this vitamin (Cikot et al. 2001). 
Vitamin E is another vital fat-soluble vitamin that occurs naturally. It is a 
collective name for a family of eight antioxidants; four tocopherols (α β, γ and δ) and 
four tocotrienols (α β, γ and δ), which perform similar activities (Nelson and Cox 
2005; Traber 2007). Out of the four types, α-tocopherol (5,7,8-trimethyl tocol) is the 
most vital type of vitamin E. Its levels are maintained actively in the body; hence, it is 
the type of vitamin E present excessively in the blood and tissues (Figure 1.12a, b, c), 
(Ogbodo et al. 2012).  
 
 
 
 
Figure 1.12a. Structure of retinol (adopted from (Ogbodo et al. 2012). 
 
  
 
 
 
 
Figure 1.12b. Structure of β-carotene (adopted from 
http://www.thecollapsedwavefunction.com). 
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Figure 1.12c. Structure of alpha-tocopherol (adopted from (Ogbodo et al. 2012). 
1.4.3.1.1 Sources  
Animal products, vegetables and yellow-pigmented plant products are the 
various sources of vitamin A. Fish liver oil, liver, eggs, milk and butter are major 
animal sources while the yellow pigmented items including carrots, sweet potatoes and 
other yellow vegetables contain β-carotene (Nelson and Cox 2005). Vitamin E was 
initially isolated from wheat germ oil where it is found in abundance. It is also found 
in cottonseed oil, rice, eggs and vegetable oils (Cohn 1975). 
1.4.3.1.2 Functions 
Vitamin A and β-carotene are vital for normal vision, tissue growth, building 
up epithelium and skin, and stabilization of epithelial cells (Maden 2000; Smith and 
Steinemann 2000), maintenance of normal neural shields, synthesis of adrenal cortex 
hormones, immune reactions, thyroid thyroxine secretion, synthesis of erythrocytes 
and defense against cancer development (Sies and Stahl 1995). Vitamin E averts 
oxidative damage to cellular structures and tissues by breaking chain reaction of free 
radicals so participating in the maintenance of an appropriate cell membrane structure, 
inhibiting the generation of micro-clots and thus blocking the production of 
nitrosamines (Malila et al. 2002; Feskanich et al. 2003, Osganian et al. 2003; Knekt et 
al. 2004). Vitamin E is the most significant micronutrient involved in the protection of 
LDL from oxidation and increasing mean HDL level while decreasing LDL level 
(Kagan et al. 1992; Paolisso et al. 1993). Numerous studies indicate that adequate 
plasma concentrations of vitamin E and β-carotene inhibit oxidation of low-density 
lipo-proteins, thus decreasing the risk for the development of atherosclerosis, 
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cardiovascular diseases, cancers and age-related macular degeneration (Pryor 2000; De 
Wart et al. 2001; Rao 2002). 
1.4.3.1.3 Requirements 
 The latest recommended dietary allowance (RDA) is based on the amount 
needed to ensure adequate stores of the vitamin in the body to support reproductive, 
immune function, gene expression and vision (Table 1.4). A tabular presentation of 
RDA is given below. 
 
 
Table 1.4. RDA for vitamin A and E (adopted from Food and Nutrition Board 2000; 
2001). 
 
 
 
Group Age RDA of vitamin A 
RDA of vitamin 
E 
Infants 
0-6 months 400 µg/day 4 mg/day 
7-12 months 500 µg/day 5 mg/day 
Adults 
14 years and above 
(vitamin RDA) 
900 µg/day (male) 
----------- 700 µg/day 
(female) 
19 years and above 
(vitamin E RDA) 
---------- 15 mg/day 
Pregnancy 
18 years and below 750 µg/day 15 mg/day (for 
pregnancy all 
ages) 19 years and above 770 µg/day 
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1.4.4 Antioxidant status during normal pregnancy    
There is a less number of studies dealing with the status of vitamin E, A and β-
carotene in both cord and maternal blood during normal pregnancy. Baydas et al. 
(2002) have clearly demonstrated that vitamin E levels in cord blood were lower than 
in maternal blood. This finding corroborates previous reports (Chen et al. 1996; Chan 
et al. 1999; Kiely et al. 1999). A positive correlation between the cord and maternal 
serum levels of vitamin E as determined in this study was also verified by other 
investigators (Vobecky et al. 1982; Shah et al. 1987). It is obvious that neonatal 
vitamin E concentration is dependent on maternal vitamin E levels and it is well 
recognised that placental transfer of vitamin E is limited (Specker et al. 1992). 
Nonetheless, the mechanism of transportation is still unclear.   
Vitamin E concentrations during pregnancy progressively increased compared 
with preconception values. This finding is following previous reports (Mooij et al. 
1993). The increase in vitamin E might have a compensatory effect on the increase in 
oxygen radical formation as gestation progresses (Wang et al. 1991). The elevation of 
vitamin E seems to correspond with the increase in products of membrane damage 
during late gestation. The concentration of retinol minor decreased during pregnancy. 
In contrast, the concentration of α-tocopherol showed a progressive increased or 
showed only minor changes during pregnancy, when compared with preconception 
values. Most obvious vitamin changes occur gradually during pregnancy, but its 
mechanism is not completely understood yet. It may be due to increase renal excretion, 
hormonal influences and haemodilution occurring during gestation. Another reason for 
decreased levels of vitamins may be the increasing requirement of vitamins during 
pregnancy both for mother and foetus (Cikot et al. 2001).   
1.4.5  Antioxidant status during GDM 
Along with several other complications, GDM mothers and their foetus are also 
exposed to oxidative stress associated with down-regulation of antioxidant status, 
resulting in the production of highly reactive oxygen free radicals. These free radicals 
are highly toxic to the cells, particularly in the plasma membranes where they interact 
with the lipid bilayer (Cederberg et al. 2001; Damasceno et al. 2002; White et al. 2002; 
Prasenjit et al. 2008). GDM is the most frequent metabolic disorder of pregnancy 
occurring in 1-10% of all pregnancies with increased susceptibility to oxidative stress 
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(Dey et al. 2008), affecting even the foetuses and can put the foetus at the risk of 
developing congenital malformations, premature birth or other serious complications 
(Sobki et al. 2004). The reason for developing oxidative stress is established as down 
regulation of antioxidant status and disturbance in free radical scavenging system in 
DM (Chen and Scholl 2005; Grissa et al. 2007). Another reason for this elevated 
oxidative stress was found to be impaired SOD activities and enhanced levels of 
thiobarbituric acid-reactive substances (TBARSs) during GDM. In animal models, 
experimental diabetes disrupts maternal and foetal lipid metabolism. It was also found 
that there was a significant decrease in plasma arachidonic acid and an increase in 
linoleic acid levels in diabetic pregnant rats. This may be because of impaired action of 
desaturases enzymes. This diabetes-induced low concentration of plasma AA has a 
critical role in maintaining the appropriate mass and function of beta cells especially 
by affecting rates of cell proliferation and insulin secretion (Yessoufou and Moutairou 
2011).  
In another study, a significant depletion of vitamin E in cord plasma of GDM 
patients was found which is in concurrence with other studies and is suggestive of 
raised oxidative stress. A slight reduction in vitamin E levels in maternal plasma of 
GDM patient is also supported by findings of another study (Kharb 2000), but it is in 
contrast to the study of Bates et al. (1997) who has shown an increase in serum vitamin 
E levels in diabetic pregnant women. This decrease of vitamin E levels in the cord 
blood may be due to the progressive utilisation of this vitamin during excessive lipid 
peroxidation. Alternatively, these lower cord vitamin E levels in GDM patients may be 
due to its preferential mobilisation toward the tissues with the maximum requirement. 
Another study revealed that novel alpha-tocopherol binding protein in the human 
placenta may control the movement of tocopherols between the foetus and mother. It 
was further observed that tocopherol ratios in the cord or maternal plasma of control 
group were significantly higher than that of the GDM patients regardless of the 
treatment they received. However, this ratio was always higher in maternal plasma 
than cord plasma (Sobki et al. 2004). Some other researchers found that GDM women 
exhibit decreased levels of vitamin E without any changes in vitamin A (Yessoufou 
and Moutairou 2011). Investigations by the researchers also support above-mentioned 
findings (Peuchant et al. 2004; Grissa et al. 2007). 
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 Specific Aims: 
 The aims of this study are to investigate if;  
• Diabetes in pregnancy compromises plasma omega-3 and omega-6 fatty acid 
status of pregnant women at diagnosis. 
• Babies born to diabetic women have reduced levels of plasma omega-3 and 
omega-6  fatty acids at birth.  
• High pre-pregnancy body mass index alters the plasma fatty acid profile in GDM 
women. 
• Supplementation with the omega-3 fatty acid, docosahexaenoic, enhances the 
level of the aforementioned fatty acid in plasma of gestational diabetic mothers 
and their neonates at delivery.  
• Docosahexaenoic acid supplementation improves the plasma antioxidant status 
of gestational diabetic women and their neonates at birth.   
 Null Hypothesis: 
• Diabetes in pregnancy does not compromise plasma omega-3 and omega-6 fatty 
acid status of women affected with the condition at diagnosis. 
• Babies born to diabetic mothers do not have reduced levels of plasma omega-3 
and omega-6 fatty acids at birth.  
• High pre-pregnancy body mass index does not alter the plasma fatty acid profile 
in GDM women. 
• Supplementation with docosahexaenoic acid during pregnancy does not enhance 
the level of the fatty acid in plasma of pregnant women affected with diabetes 
and their neonates at birth. 
• Docosahexaenoic acid supplementation of pregnant women with diabetes does 
not improve the plasma antioxidant status of mothers and their neonates at 
delivery.   
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2.1 Subjects and recruitment criteria 
 A total of 170 women (between ages 17 - 45 years) with single pregnancy 
(healthy/non-diabetic n = 28 and gestational diabetic women, GDM n = 142) were 
recruited (17th - 34th weeks of gestation) during their visit to the antenatal or diabetic 
clinics at Newham University Hospital, London, UK. The following NICE criterion 
was adopted for the screening of gestational diabetes. 
2.1.1 Diagnosis of gestational diabetes mellitus 
    After an overnight fast, high risk identified women undergone a 75gm oral 
glucose tolerance test (OGTT) and their blood glucose level were monitored at 0 and 
120 minutes. GDM is diagnosed when the blood plasma glucose concentration at 0 
min (fasting) ≥ 5.6mmol/l and/or 120 min (non-fasting) ≥ 7.8mmol/l (NICE Clinical 
Guidelines 2008; NICE Clinical Guidelines 2015). 
2.1.2 Exclusion criteria 
 Women who had been taking omega-3 supplements during the period of time 
leading to their current pregnancy were excluded. Those who were on or planning to 
receive tocolytic or corticosteroid therapy were also excluded.  
Women with chronic medical conditions such as; HIV/AIDS, kidney disease, 
congenital heart disease, autoimmune disease (e.g. lupus or anti-phospholipid 
syndrome), and haematological disease (e.g. sickle cell disease or other 
hemoglobinopathies) were also excluded.  
2.1.3 Ethical approval and consent 
Ethical approval for the study was obtained from the East London and The City 
HA Local Research Ethics Committee 3 (REC Reference Number; 06/Q0605/89) and 
registered with ISRCTN Register (registration no. ISRCTN68997518). A written 
informed consent was taken from all the participants of the study. All the investigators, 
midwives and participants were blinded to the allocation of the intervention till the 
completion of the analysis and the data recording.  
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2.1.4   Study design and treatment 
   The study was a randomised, double-blind, placebo-controlled trial. After 
recruitment, the healthy pregnant and GDM women were randomly assigned to the  
active treatment group (ω-3 enriched supplement) or placebo group. The active 
treatment group (n = 82) received two omega-3 capsules daily and the placebo group 
(n = 88) received two placebo capsules daily, until delivery. Each omega-3 capsule 
provided 300mg of DHA, 42mg of EPA and 8.4mg of AA. Whereas, placebo capsule 
contained high oleic acid sunflower seed oil (721mg of oleic acid). 8µg of α-
tocopherol (vitamin E) was added as an antioxidant in both supplements. These two 
supplements were filled in identical soft gelatin, oblong shaped capsules (750mg in 
size). Randomization was done using a random code generated by the supplement 
supplier (Equazen/Vifor Pharma Ltd., Switzerland). 
2.1.5 Sample size 
  Sample size was calculated based on previous case control study conducted by 
our research group. A difference of 35% was found in DHA between neonates of 
healthy pregnant women (5.4%) and GDM women (4.0%). It was ssumed that 
supplementation of GDM women with DHA-enriched formula will increase the level  
of the fatty acid in the neonates of the GDM to that of the neonates of healthy pregnant 
women. The result of this calcualtion indicated that 80 women (40 in each arm of the 
study) will be required to detect changes in the level of the fatty acid with 80% power 
at 5% significance level. The sample size was calcualted using G*Power 3 (Faul et al. 
2007) and based on two independent groups, two-tailed t-test with an alpha of 0.05. 
2.1.6 Demographic and obstetric information  
The details of demographic, clinical and obtetric data were collected from the 
hospital medical records.  
2.1.7  Neonatal anthropometric measurement 
  Weight and length of the neonates were recorded at delivery. It was taken by 
the midwife who attended the delivery as a part of routine practice. Head, shoulder, 
mid-arm and abdominal circumferences were measured by research midwives (JH and 
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IN), using Seca 210 portable measuring mat and Seca 201 ergonomic circumference 
measuring tape (Seca UK, Birmingham, UK). 
2.1.8 Biological specimen 
A volume of about 5-10ml of non-fasting venous blood was obtained from both 
the placebo and active-treatment groups. Blood samples were collected at 2-time 
points, first at recruitment (from mum) and second at delivery (from both mum and 
cord), for analysis of fatty acids and antioxidant vitamins. At delivery, venous blood 
was taken from the placental side of clamped cord. 
2.1.9 Sample collection and preparation of plasma 
The whole blood was collected into the vacutainer tubes containing an 
anticoagulant, ethylenediaminetetraacetic acid (EDTA, K2 (spray-dried), BD 
Company) at Newham General Hospital. The blood samples collected during the day 
were immediately transported to Lipidomics and Nutrition Research Centre (LNRC) 
laboratory, London Metropolitan University. Where these samples were instantly 
separated into plasma and red cells by cold centrifugation at 3000 rpm for 15 minutes. 
After centrifugation, the top plasma layer was removed into clearly labelled eppendorf 
tube, closed tightly under a stream of oxygen-free nitrogen (OFN) and stored at -70oC 
until further analysis. Subsequently, the bottom erythrocytes pellet was recovered by 
aspiring the supernatant and made the volume up to 10ml with PBS (physiological 
saline, 0.85% NaCl). These tubes were then vortex and inverted gently to re-suspend 
the cells and centrifuged at 3000rpm for 5 minutes. The supernatant was discarded, 
and the same procedure was repeated again (total 2 washings with PBS, vortex, 
centrifuge and aspiration of supernatant) to remove traces of plasma and buffy coat. 
Finally, the erythrocytes were transferred into clearly labelled eppendorf tube, closed 
tightly under a stream of OFN. The blood samples collected at night time or over the 
weekend were processed at pathology laboratory, Newham General Hospital and then 
subsequently sent to the LNRC, London Metropolitan University on next working day. 
All the samples were stored at -70oC until further analysis (Figure 2.1). 
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Figure 2.1. Diagrammatic representation of separation of blood cells (adopted 
from https://en.wikipedia.org/wiki/File:Blood-centrifugation-scheme.png). 
 
2.2  Plasma fatty acids analysis 
2.2.1 Extraction of plasma total lipids 
 Plasma total lipids were extracted based on the method of Folch et al. (1957) 
by homogenising the samples in chloroform and methanol, (C/M, 2:1, v/v). 1ml of 
defrosted plasma was homogenised with 45ml of C/M (chloroform/methanol, 
30+15ml, + BHT 0.01% w/v) in a 100ml extraction tube. Homogenization was done 
by vortex the sample with solvents thoroughly for two to three minutes and then 
flushed with oxygen-free nitrogen (OFN) approximately for one minute by bubbling 
gas throughout the sample (to displace any dissolved oxygen). The extraction tube was 
capped instantly and stored at 4oC in a refrigerator for 24 hours. All the solvents used, 
contained butylated hydroxyl toluene (BHT) as an antioxidant to prevent potential 
oxidation (possible damage to the extract due to oxygen caused by free radicals) of 
unsaturated fatty acids. Also, all the samples were handled under OFN (Folch et al. 
1957). The used chemicals and their sources are enlisted in detail in Appendix 2.  
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2.2.2  Separation of non-lipid impurities from lipids "Partitioning" 
 The tubes containing extracted plasma samples were removed from the 
refrigerator and allowed to stand under dim light, at room temperature, for 30 minutes 
in order to prevent condensation. The extracted samples were then filtered into 100ml 
separating funnels, through the conical metal funnels lined by Grade 1 filter papers 
(Whatman International Ltd. England). The residue in the extraction vessel and the 
filter paper (lining the conical metal funnels) was washed with 10ml + 5ml of C/M 
(2:1 v/v, + BHT) just to ensure almost complete transfer of whole lipid contents 
(Figure 2.2). 
 After complete filtration, the filter funnels along with filter papers were 
removed and a volume of 15ml of saline (85% w/v of NaCl, equivalent to 25% v/v of 
the total filtrate volume) was added to the filtrate (in separating funnels) for the 
purpose of complete phase separation. The samples were then flushed thoroughly by 
bubbling OFN and stored at 4oC in a refrigerator overnight. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Separating funnels used for partitioning (picture taken at LNRC lab). 
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2.2.3 Rotary evaporation 
 On the next day, the separating funnels were removed from the refrigerator 
and allowed to stand under dim light, at room temperature for 30 minutes to attain 
equilibrium. The lower organic layer containing purified lipids (organic) was then 
drained into a 100ml round bottom flask. Afterwards, the solvent was removed by the 
rotary evaporator (vacuum pump V-700, Buchi, Switzerland) under reduced pressure 
in a water bath at 37oC. The lipid residue-containing flask was rinsed twice with 2ml 
of methanol just to ensure the complete removal of any residual water in the sample. 
After absolute drying, the whole lipid extract was transferred to a 10ml glass vial by 
washing thrice with 2ml of C/M (2:1 v/v + 0.01% BHT w/v). This total 6ml volume of 
the recovered lipids was then reduced to 1ml under a stream of OFN at 37oC, flushed 
carefully and stored at -20oC until required for thin-layer chromatography (TLC), 
(Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Recovery of total lipids by rotary evaporator (picture taken at LNRC 
lab). 
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2.2.4     Thin-layer chromatography (TLC)  
2.2.4.1  Preparation and activation of TLC plates 
  For consistent results, commercially available 20×20 cm, pre-coated silica gel 
glass plates (0.25 mm thickness) were used for analysis (Merck KGa, Germany); 
however, TLC plates can be prepared manually in the laboratory. For analytical 
purposes, layers of adsorbent 0.25mm thick or less give maximum resolution. Glass is 
by far the most commonly used support for the adsorbent in the TLC of lipids. It is 
resistant to acid and alkalis used in developing solvents or detection sprays (Hinrichsen 
and Nas 2006). TLC plates were scored about 2.5cm from the top (to prevent solvent 
over-elution) and 0.5 cm from each side. Each plate was scored from right to left into 
three equal channels (6×6×6), by scraping the narrow lines of adsorbent. So, there 
were three compartments (for each sample) on each plate. The purpose of channelling 
was to ensure the sample’s application at defined regular distance to prevent the spread 
of one sample into another. For good separation by silica gel, the water content of gel 
must be carefully controlled. Therefore, after complete scoring, the TLC plates were 
conditioned for 1 hour at 110-120oC in an oven just to ensure its dryness (due to 
reduced activity of adsorbent in the presence of water) and stored in a desiccator until 
the time of the sample application (Appendix 2). 
2.2.4.2 Solvent system 
  The solvent mixture/ mobile phases; chloroform: methanol: methylamine 
(C:M:M, 65:35:15 v/v/v + 0.01% BHT w/v), and petroleum spirit: ether: formic acid: 
methanol (P:E:F:M, 85:15:2.5:1 v/v + 0.01% BHT w/v) were prepared freshly to 
separate the phospholipids (choline phosphoglycerides, CPG) and neutral lipid 
(cholesterol ester, CE and Triglyceride, TG) fractions respectively.  Each mobile phase 
was mixed thoroughly. The total neutral lipids were further fractionated with later 
mobile phase after recovery from the TLC plate containing polar and non-polar lipids 
separately (Appendix 2). 
2.2.4.3 Developing chambers 
 For the development of 20×20 plates, rectangular glass chambers of 
10×21×21cm approximate dimensions are commonly used. In addition to being inert 
to the developing solvents, glass is transparent and allows the progress of the 
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ascending solvents to be monitored. Classical chambers have flat bottoms and sides 
and allow a maximum of two plates to be developed simultaneously.  
 A freshly prepared 150ml of mobile phase (C:M:M for phospholipids and 
P:E:F:M for neutral lipids) was poured into the TLC tank lined with filter papers. The 
tank was lined with filter paper and capped immediately with a well-fitted heavy glass 
lid to seal the environment inside and helped to saturate the atmosphere with solvent 
vapour that speeds up the analysis. The developing tank was closed for almost 30 
minutes to achieve equilibrium before use. 
2.2.4.4   Application of samples on TLC plates 
 The quality of lipids analysis by TLC depends greatly on the careful 
application of the sample mixture to the adsorbent. Care was taken not to damage the 
adsorbent layer during sample application and TLC plates were only handled by the 
edges, to avoid contamination from fingers. The activated plate was kept smoothly on 
a balanced surface lined with filter paper, in dim light. A led pencil was used lightly to 
draw a narrow line almost 2cm from the bottom edge. This application line was used 
as a locator on which the sample was loaded. The sample was dried under OFN and 
total lipid extract was re-dissolved thrice with 10, 8 and 6 drops of C/M (2:1 v/v 
+0.01% BHT w/v) respectively, for its complete and uniform application on TLC 
plate. The sample was applied as a narrow uniform streak along the application line 
using a disposable capillary tube (75µl micro-haematocrit). A maximum number of 
three samples were loaded on each plate. Samples were identified by their allocated 
numbers written by a soft pencil at the top of the plate (before each sample), (Figure 
2.4). 
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Figure 2.4. Application of total lipid extract on a TLC plate by micro-haematocrit 
tube (picture taken at LNRC lab). 
 
2.2.4.5   Development of TLC plates 
 With least disturbance of atmospheric equilibrium inside, the two plates were 
transferred quickly (facing each other) to the developing tank containing mobile phase. 
The tank was covered with a lid instantly by ensuring a good seal. The solvent moved 
up the plate by the capillary action taking the various components with it at different 
rates, according to the extent to which they were held by the adsorbent. When the 
solvent front was travelled across the plates and touched the line scored at the top of 
the plates, the plates were kept further inside the tank for 5-10 minutes to improve the 
definition of bands. The time taken for a TLC plate to develop depends on the solvent 
system employed. For instance, a TLC plate takes much longer time to develop in a 
polar mobile phase as compared to be in non-polar. Phospholipids plates took nearly 
90 minutes to develop while the neutral lipids plates took about 30 minutes.  
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2.2.4.6 Visualization of TLC plates 
 After removal from the tank, the developed plates were air-dried to remove 
the solvent and sprayed with a reagent (methanolic solution of 2, 7-
dichlorofluorescein, 0.1%, w/v) until each plate was coated lightly and uniformly. 
Since lipids are generally colourless, the separated lipid components have to be 
rendered visible by chemical reagents. The chemical reagent spray can be specific for 
certain types of lipid or certain functional groups, or it may be a non-specific reagent 
for all lipids. Therefore, a methanolic solution of 2, 7-dichlorofluorescein is most 
frequently used spray that renders all lipids visible and causes lipids to show up as 
bright yellow spots/bands on a yellow/green background under UV light (Vinson and 
Hooyman 1977).  
 After spray, the plates were air-dried again for few minutes to reduce the 
background staining on view. The entire procedure was carried out in a dark fume 
cupboard. Successively, the phospholipids (CPG on phospholipid’s plate) and neutral 
lipid’s bands (CE and TG on neutral lipid plate) were visualized under ultraviolet light 
(UV, 533nm, a non-destructive visualization method). These lipid fractions were 
appeared as lines of discrete bands. Each band was then marked carefully with a soft 
pencil and identified by using commercially available authentic standards 
(Appendices 5, 6, Figure 2.5). 
 
 
 
 
 
 
 
 
Figure 2.5. TLC spray cabinet and UV light source used for staining and 
visualization of the TLC plates (picture taken at LNRC lab). 
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2.2.4.7 Scraping of lipid bands 
 The required bands (plasma CPG and neutral lipids) were recovered after 
detaching by an appropriate non-destructive method. A blunt spatula was used to 
detach the adsorbent band onto a filter paper, from both the plasma phospholipids and 
neutral lipids containing plates and transferred the flakes and dust to their labelled 
methylating tubes (16×160 mm Pyrex tube fitted with a PTFE lined screw top, Fisher 
Scientific, UK).  
2.2.5 Separation /recovery of neutral lipids 
 Lipids mostly recover by repeatedly mixing the adsorbent with the solvent in 
a test tube, centrifuging and decanting the supernatant liquid. The non-polar neutral 
lipids (NL) travel in the polar solvent system collectively as one band rather than 
separating into different fractions. After elution, the NL bands were reached at the top 
of the TLC plates, scraped by the scraper and transferred to a labelled centrifuge tube. 
Flakes and dust were suspended in 5ml petroleum spirit: diethyl ether (P: E, 50:50 v/v, 
0.01% BHT w/v) shook well and centrifuged at 3000 rpm for 5 minutes. The 
supernatant containing the neutral lipids was transferred to a labelled glass vial of 
10ml. The whole step was repeated again. In the end, each glass vial had a 10ml 
volume of supernatant in total. These recovered NLs were concentrated under a stream 
of OFN and loaded on a TLC plate in the same manner as described above, by 
dissolving in 1ml of C/M (2:1 v/v +0.01% BHT w/v). A mixture of petroleum spirit: 
ether: formic acid: methanol (P:E:F:M, 85:15:2.5:1 v/v + 0.01% BHT w/v) was used 
as mobile phase. Two bands (TG and CE) were scraped off into the methylating tubes. 
The rest of the procedure was same as described above in TLC protocol.  
2.2.6  Preparation of fatty acid methyl ester “FAME” 
 Before the fatty acid composition of a lipid can be determined by gas 
chromatography, it is necessary to prepare the comparatively volatile methyl ester 
derivatives of the fatty acid components. This must be by far the most common 
chemical reaction performed by lipid analysts. 
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2.2.6.1 “Trans-methylation” (acid-catalysed trans-esterification) 
 Fatty acid components require to be converted into fatty acid methyl esters so 
as to improve their volatility and hence to ensure better gas chromatographic peak 
shape (Meier et al. 2006; Peterson and Cummings 2006). A standard method of an 
acid-catalysed trans esterification reaction was used to form fatty acid methyl esters 
(FAME) by heating the lipid fractions (for a recommended time) with an excess of 
anhydrous methanol in the presence of an acidic catalyst. The reaction is referred to as 
“trans-esterification” in general and “trans-methylation” or simply “methylation”.  
 The methylating reagent (15% acetyl chloride in 100ml anhydrous methanol) 
was prepared freshly by adding acetyl chloride very slowly to cold and dry methanol. 
4ml of methylating reagent was transferred to the different lipid fractions (CPG, CE 
and TG bands) containing methylating tubes and flushed thoroughly with OFN. 
Immediately after flushing, the methylating tubes were closed tightly and kept for 
heating in an oven at 70oC for 3 hours. The tubes were removed from the oven at 60, 
and 120 minutes respectively, vortexed and checked for leakage (indicated by reduced 
volume than original). If necessary, then made up the volume by adding more 
methylating reagent, re-flushed and vortexed the sample before putting them back in 
the oven. 
2.2.6.2 Extraction of fatty acids methyl esters 
 After 3 hours, the methylating tubes were removed from the oven and cooled 
in dimmed light, at room temperature. 4ml of sodium chloride solution (5% w/v) and 
2ml of petroleum ether + BHT (0.01% w/v) was added to each methylating tube 
(reffered as tube 1). The methylating tubes were closed tightly and shaken well to 
ensure complete transfer of FAMEs into petroleum ether. Methylating tubes were 
allowed to settle till two phases formed. 3-5 drops of methanol were added to each 
tube to break emulsions resulted from vigorously shaking of tubes. The upper FAME 
containing petrol layer from each methylating tube was transferred to another tube 
containing 2 ml of (2% w/v) potassium bicarbonate (reffered as tube 2) to neutralize 
any acid if transferred. 1ml of petroleum ether was again added to the original 
methylating tube (tube 1), capped and shook vigorously. 2-3 drops of methanol were 
added again to break the emulsion. The upper FAMEs containing layer of petroleum 
ether was transferred to the same tube that contained potassium bicarbonate (tube 2). 
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This entire step is repeated again. In total, FAMEs were extracted with 4ml of 
petroleum ether (2+1+1ml, 3 times addition). 
 The tube 2 (FAMEs containing layer of petroleum ether + potassium 
bicarbonate) was vortexed and two layers formed. The upper FAMEs containing layer 
of petrol was transferred to a test tube (reffered as tube 3) containing 100-200gm of 
anhydrous granular sodium sulphate, to ensure removal of any residual water. From 
tube 3, the FAMEs solution was transferred to a properly labelled 3ml glass vial. 
Petroleum ether was evaporated under a stream of OFN at 37oC and the sample was 
taken in 1ml of heptane + BHT (0.01% w/v). The resulting FAMEs were flushed with 
OFN and stored at -20oC until analysed by gas liquid chromatography. 
2.2.7 Analysis of fatty acid methyl esters by gas-liquid chromatography  
 After extraction of methyl esters, FAMEs were separated by a capillary gas 
chromatograph (HRGC MEGA 2 series, Fisons Instruments, Italy) fitted with a BPX-
70 capillary column (60m × 0.32mm ID, 0.25µm film, SGE Europe Ltd, UK), split 
injector, and FID. Operating conditions were; hydrogen to column 110Kpa, hydrogen 
to detector 50Kpa and air to column 70 Kpa. Hydrogen was used as a carrier gas at 2 
ml/min and the injector, oven and detector temperatures were 250, 230 and 280oC 
respectively. The oven temperature was initially at 135oC, held for one minute and 
then rose at the rate of 2oC/minute. Once reached 180oC, it was sustained here again 
for 1 minute, followed by a further increase at a rate of 0.7oC/minute. After attaining 
190oC, it was maintained for 2 minutes, led to further increase to 230oC at the rate of 
15oC/minute and maintained here for 2 minutes. The total run time per sample was 42 
minutes. Specifications for instrumentation of gas chromatography are enlisted in 
Appendix 1 (Figure 2.6, 2.7).  
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Figure 2.6. GLC system used for the analysis of fatty acids methyl esters (picture 
taken at LNRC lab). 
 
 10µl of FAME sample solution (CPG, CE and TG) was prepared and injected. 
The eluting FAMEs were detected by FID and peak areas were calculated with 
chromatography data system (Scientific Software Inc., San Ramon, CA). Fatty acids 
were identified by the comparison of retention times with authentic standards (FAME 
standard mixture from Supelco® 37 component FAME Mix. U47885-U, Sigma-
Aldrich, Dorset, UK and GC-MS authenticated FAMEs) prepared from lipid extracts 
of olive oils (contain alpha-linolenic acid, gamma-linolenic and stearidonic acids). 
Peak areas were quantified by a computer chromatography data system (EZChrom 
Chromatography Data System, Scientific Software Inc., San Ramon, CA), 
(Ghebremeskel et al. 2000; Min et al. 2004), (Appendices 3, 7, 8). The area of each 
peak was expressed as the percentage of total identified peaks.  
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Figure 2.7. A chromatogram of fatty acid methyl esters (adopted from 
http://lipidlibrary.aocs.org/Analysis/). 
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2.3 Analysis of plasma alpha-tocopherol, retinol and beta-carotene by high-
performance liquid chromatography (HPLC). 
2.3.1 Extraction of plasma α-tocopherol, retinol and β-carotene 
 A volume of 100µl of plasma sample was transferred into a 3ml vial, 
deproteinized with 500µl of absolute ethanol (with BHT 0.01% w/v) by Vortex. After 
that, 1ml of hexane (with BHT 0.01% w/v) was added, vortexed thoroughly again for 5 
minutes and centrifuged at 3000rpm for 8 minutes. The supernatant was transferred to 
another well-labeled 3ml glass vial. The sample was extracted again with 1ml hexane 
as described previously to ensure complete transfer of vitamins into hexane. The whole 
extract was evaporated under a stream of OFN (at 37oC) and took up into 100µl of a 
mixture of methanol+ dichloromethane (80:20, with BHT 0.01% w/v). A volume of 
25µl of extracted sample was injected through the injector into the column. As 
mentioned earlier, all extraction procedures were carried out in dim light. The 
chemicals used and their sources are enlisted in detail in Appendix 2.  
2.3.2 Separation and identification 
 Separation and identification of plasma α-tocopherol, retinol and β-carotene 
were carried out by Agilent 1100 series HPLC (Agilent Technologies Deutschland 
GmbH, Waldbronn, Germany). The HPLC was connected to an auto sampler, diode-
array detector and fitted with a reverse phase column (C18 reverse phase, 5micron, 
250 × 4.6nm, Thermo Scientific). Methanol (98% HPLC grade mobile phase) was 
used as a mobile phase at a flow rate of 1ml/min. The column temperature was 
maintained at 20oC. α-tocopherol, retinol and β-carotene were detected at their 
maximum absorption wavelengths of 292, 325 and 453nm respectively. According to 
the authentic standards, the retention times for α-tocopherol, retinol and β-carotene 
were 6.4, 4 and 13.8 respectively. The total run-time per sample was 15 minutes. Pure 
standards of the vitamins were used for authentication (Appendix 4). Specifications 
for instrumentation of HPLC are enlisted in Appendix 1 (Figure 2.8, 2.9).  
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Figure 2.8. A diagramatic representation of HPLC system (adopted from 
http://web.nmsu.edu/~kburke/Instrumentation/Waters_HPLCSystem.gif). 
 
 
 
 
 
 
 
 
 
Figure 2.9. A chromatogram showing retention times of retinol, α-tocopherol, and 
β-carotene, respectively (picture taken at LNRC lab). 
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2.3.3 Quantification 
 Standard stock solutions of α-tocopherol (30mg/dl), retinol (600µg/dl) and β-
carotene (120µg/dl) were prepared by dissolving the authentic standards into a mixture 
of methanol and dichloromethane (with BHT, 0.01% w/v, HPLC grade). Working 
standards for α-tocopherol, retinol and β-carotene were prepared from the stock 
solutions by serial dilution and used to plot the linear regression lines of concentration 
versus peak areas. The correlation coefficients (r) of the regression lines were α-
tocopherol (r =0.999), retinol (r=0.999) and β-carotene (r=0.999). The concentrations 
of the vitamins in the samples were calculated by using their respective standard 
curves (regression line equation obtained from the serial dilution of standard stock 
solution). Agilent ChemStation (computer software, Agilent Technologies, Germany) 
was used to compute the peak areas and concentrations of the vitamins. Results are 
expressed in mg/dl for α-tocopherol while µg/dl for both retinol and β-carotene 
(Figure 2.10, 2.11 and 2.12). 
  
 
 
 
 
 
 
 
 
 
Figure 2.10. Standard curve of α-tocopherol with equation of regression line and 
correlation coefficient (picture taken at LNRC lab). 
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Figure 2.11. Standard curve of retinol with equation of regression line and 
correlation coefficient (picture taken at LNRC lab). 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Standard curve of β-carotene with equation of regression line and 
correlation coefficient (picture taken at LNRC lab). 
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2.4 Data analysis 
 The data are expressed as mean ± standard deviation (SD), median (range) 
and n (%), as appropriate. The assumptions of outliers, normality of distribution 
(Shapiro-Wilk test) and homogeneity of variance (Levene test) for all the data sets 
were assessed for each statistical test. Depending on the normality of data distribution, 
parametric (normal distribution) or non-parametric (non-normal distribution) statistical 
tests were used. The details of each statistical test used to assess significant differences 
between the groups are discussed in the relevant chapters. Statistical significance was 
assumed when “P” value < 0.05, unless otherwise stated. The statistical analyses were 
carried out with IBM SPSS Statistics version 24 (IBM Corporation, USA).  
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CHAPTER 3 
 
The fatty acid status of gestational diabetic women before 
and after intervention with omega-3 fatty acid specifically 
docosahexaenoic acid-----------------------------------------(80-99) 
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3.1 Introduction 
 Insulin resistance together with perturbations in general lipid metabolism in 
GDM may affect EFAs metabolism and may ultimately alter placental transfer and 
foetal LCPUFAs accretion (Clark et al. 1997; Brenner et al. 2000). Other studies 
(Holman et al. 1983; Poisson and Cunnane 1991) also showed that diabetes impairs the 
synthesis of long chain ω6 and ω3 PUFAs. Furthermore, the women or/and their 
offspring having type I, II (Tilvis and Meittinen 1985; Lakin et al. 1998; 
Ghebremeskel et al. 2004; Min et al. 2005b), or GDM have reduced levels of 
membrane AA and DHA (Wijendran et al. 2000; Min et al. 2004; Min et al. 2005a; 
Pagan et al. 2013).  
 DHA is a long-chain polyunsaturated n-3 fatty acid with bioactive properties, 
and it is a key nutrient for optimal foetal neurovisual development. Furthermore, it is 
thought to be an effective anti-adiposity agent (Ruzickova et al. 2004). A growing 
body of evidence suggested that there is an inverse association between n-3 LCPUFAs 
and insulin resistance (IR), (Soria et al. 2002; Pighin et al. 2003). n-3 supplementation 
has also increased insulin-stimulated glucose transport in supplemented animals 
(Peyron-Caso et al. 2002). n-3 LCPUFAs are proposed to decrease the risk of insulin 
resistance by multiple means, few of which seem to be distinctively affected by n-3 
fatty acids. DHA and EPA are favorably incorporated into cell membranes, hence 
increasing membrane fluidity, up-regulating insulin receptors, decrease insulin 
resistance and favorably modify an individual's glycemic response, an effect that could 
possibly delay or avert the onset of type II diabetes mellitus (Das 2005). 
 Since diabetes impairs the synthesis of long-chain ω3 PUFAs, it is plausible 
that the increased dietary intake of ω3-LCPUFAs during pregnancy associated with 
GDM may rectify the required maternal and foetal LCPUFAs levels. A number of  
studies have investigated the beneficial effects of ω-3 fatty acid supplementation in the 
enhancement of maternal and neonatal fatty acids status in normal pregnancy (Dunstan 
et al. 2004; Escolano-Margarit et al. 2013). To the best of our knowledge, no clinical 
study has been conducted to evaluate the effect of dietary ω3 supplementation on 
LCPUFAs status (particularly DHA) of GDM mothers and their neonates. Hence, we 
carried out a double-blind, randomized, placebo-controlled trial to investigate if ω3-
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enriched fish oil supplementation enhances the plasma fatty acids status, particularly 
DHA, in women with GDM.  
3.2 Subjects and methods 
The details of subjects and methods are described in Chapter 2.  
3.3  Statistical analysis 
 The data are expressed as mean ± standard deviation (SD), n (%) and median 
(range) as appropriate. Statistical significance was assumed at P < 0.05 unless 
otherwise stated. Independent samples t-test (for equal variances) or Welch t-test (for 
unequal variances) was run to explore the significant differences in the plasma fatty 
acid levels between healthy pregnant and GDM women, at baseline. One-way analysis 
of variance (ANOVA) was used to compare the differences in; 
• Demographic and obstetric data of healthy pregnant and GDM women (placebo and 
active-treatment groups). 
• Plasma fatty acids composition between healthy pregnant and GDM women 
(placebo and active-treatment groups), at delivery.  
 A pairwise comparison was performed using Tukey’s honest significant 
difference (HSD, for equal variance) and Games-Howell (for unequal variance) tests 
for each dependent variable separately when the F-ratio was significant (P < 0.05). All 
statistical analyses were carried out with IBM SPSS Statistics version 24 (IBM 
Corporation, USA).  
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3.4 Results 
3.4.1 Clinical and demographic characteristics of the participants 
 170 women in total, of which 142 with GDM and 28 with healthy pregnancy  
were randomized to either placebo or ω-3 enriched active treatment group (Figure 
3.1). 117 women with GDM (active group, n = 61; placebo group, n = 56) and 23 
healthy pregnant women (active group, n = 9; placebo group, n = 14) completed the 
trial. The detailed characteristics of the participants are given in Table 3.1. 
 Although the differences were not significant, the BMI were higher in GDM 
women (active and placebo groups) as compared to healthy pregnant women. GDM 
women (active-treatment and placebo groups) also had higher blood glucose 
concentrations as compared to both healthy pregnant active- and placebo-groups, at 0 
(P < 0.0001) and 120min (P < 0.0001) after the oral glucose tolerance test (OGTT). 
The majority of the subjects were of Asian (55.9%) and African/Afro-Caribbean 
(28.2%) origin. 23.6% of the GDM women from active-group and 28.6% from 
placebo-group had gestational diabetes in their previous pregnancy. Over 60% of 
GDM women were treated with oral hypoglycemic agents (active-group 33.3%; 
placebo-group 32.9%), insulin (active-group 25.0%; Placebo-group 20.0%) or oral 
hypoglycaemic agents + insulin (active-group 2.8%; Placebo-group 8.6%).  
 There was a wide variation in the duration of supplementation. This was 
because of a number of women being diagnosed with GDM either early or late stage of 
pregnancy. 6 GDM women (4 in active- and 2 in placebo-group) and 1 healthy 
pregnant woman (placebo) claimed to have occasionally taken omega-3 supplement 
purchased from health shops during the course of the study. However, their DHA and 
EPA levels were not different from the mean values of their respective groups. 
Compliance was monitored by regular home visits by the research midwives and 
telephone contact (including out of office hour), and by counting unused capsules 
which the women were asked to bring with them before dispensing the next batch of 
supplements.  
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Figure 3.1. Flowchart of clinical trial showing 170 women (142 with GDM and 28 
with normal pregnancy), randomized to either dietary omega-3 supplementation 
or placebo. 
 
Randomized  
GDM women       Healthy pregnant women 
     (n = 142)                (n = 28) 
Enrolled 
 
GDM women       Healthy pregnant women 
     (n = 151)               (n = 32) 
11 GDM and 4 healthy pregnant 
women excluded due to not meeting 
inclusion criteria or declined 
Active 
treatment 
(n = 72) 
 
Placebo 
(n = 70) 
 
Active 
treatment 
(n = 10) 
 
Placebo 
(n = 18) 
 
6 = n----------Dropout-----------n = 8 
0 = n---------Miscarriage--------n = 1 
5 = n----Moved out of area-----n = 4 
0 = n----------Stillbirth-----------n = 1 
0 = n--------Termination--------n = 0 
 
1 = n----------Dropout-----------n = 3 
0 = n---------Miscarriage--------n = 0 
0 = n----Moved out of area-----n = 1 
0 = n----------Stillbirth-----------n = 0 
0 = n--------Termination--------n = 0 
 
Delivery  
(n = 61) 
• 12 deliveries 
were missed (no 
maternal and 
cord samples 
available) 
• 5 cord samples 
were unavailable 
Delivery  
(n = 56) 
• 15 deliveries 
were missed (no 
maternal and 
cord samples 
available) 
• 1 maternal 
sample was 
unavailable 
•  
Delivery  
(n = 9) 
• 2 deliveries were 
missed (no 
maternal and 
cord samples 
available 
• 1 cord sample 
was unavailable 
Delivery  
(n = 14) 
• Maternal and 
cord sample 
received (n = 14) 
• Unavailable due 
to missed 
delivery (n = 0) 
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Table 3.1. Demographic and obstetric variables of the participants. 
 
GDM women Healthy pregnant women 
Active-group Placebo-group Active-group Placebo-group 
Number of participants (n)a 72 70 10 18 
Gestation at recruitment 
(weeks)b 
28.0 (17.0-34.0) 27.5 (17.0-32.0) 27.0 (23.0-31.0) 27.0 (17.0-29.0) 
Age (years)b 30.0 (20.0-44.0) 32.0 (19.0-43.0) 31.0 (21.0-40.0) 31.0 (17.0-39.0) 
Height (m)c 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 
Pre-pregnancy weight (kg)c 74.1±15.8 72.9±15.7 69.5±17.5 68.1±12.3 
Pre-pregnancy BMI (kg/m2)c 29.0±5.5 29.3±5.7 27.2±4.8 25.7±4.5 
≤ 25.0 (n)d 
19 (26.4) 25 (35.7) 04 (40.0) 10 (55.6) 
25.1-30.0 (n)d 27 (37.5) 20 (28.6) 03 (30.0) 06 (33.3) 
> 30.0 (n)d 26 (36.1) 25 (35.7) 03 (30.0) 02 (11.1) 
Racial Origin (n)d, e 
Asian 44 (61.1) 42 (60.0) 4 (40.0) 5 (27.8) 
African/Afro-Caribbean 18 (25.0) 18 (25.7) 5 (50.0) 7 (38.9) 
Caucasian 6 (8.3) 6 (8.6) 0 (0.0) 6 (33.3) 
Others 
4 (5.6) 4 (5.7) 1 (10.0) 0 (0.0) 
Smoker (n)d 
2 (2.8) 0 (0.0) 0 (0.0) 2 (11.1) 
Planned pregnancy (n)d 
43 (59.7) 35 (50.0) 3 (30.0) 12 (66.7) 
Parity (n)d 
0 33 (45.8) 22 (31.4) 3 (30.0) 10 (55.6) 
1-2 24 (33.3) 34 (48.6) 5 (50.0) 6 (33.3) 
≥ 3 15 (20.8) 14 (20.0) 2 (20.0) 2 (11.1) 
GDM in previous pregnancy 
(n)d 17 (23.6) 20 (28.6) 0 (0.0) 0 (0.0) 
Folic acid use (n)d 41 (56.9) 40 (57.1) 7 (70.0) 9 (50.0) 
Family history of diabetes (n)d, f 41 (56.9) 38 (54.3) 0 (0.0) 8 (44.4) 
Glucose tolerance test 
Gestation (weeks)b 19.5 (12.0-31.0) 20.0 (12.0-31.0) 28.0 (27.0-31.0) 28.0 (17.0-32.0) 
Glucose at 0 min (mmol)c 5.6±1.6***+++ 5.5±1.5***+++ 4.2±0.5 4.2±0.4 
Glucose at 120 min (mmol)c 9.4±2.1***+++ 9.2±1.6***+++ 5.4±1.1 5.3±1.0 
Diabetes treatment (n)d 
Diet only 28 (38.9) 27 (38.6) 0 (0.0) 0 (0.0) 
Oral hypoglycemic agents 24 (33.3) 23 (32.9) 0 (0.0) 0 (0.0) 
Insulin 18 (25.0) 14 (20.0) 0 (0.0) 0 (0.0) 
Oral hypoglycemic + insulin 2 (2.8) 6 (8.6) 0 (0.0) 0 (0.0) 
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a This number included all the subjects who enrolled at the beginning of this trial regardless of the 
dropout later. 
b Data are expressed as median (mininum - maximum) 
c Data are expressed as mean ± SD 
d Data are expressed as number of subjects (%) 
e We classified individuals according to the UK Home Office’s classification for an individual’s 
ethnicity which is based on person’s self-defination (African/Afro-Caribbean: Afro-Caribbean, Black 
African, Black British, Caribbean; Asian: Bangladesh, Bengali, Indian, Pakistani, Sri Lankan; 
Caucasian: English, European, Irish, Polish; Others: Arab, Filipino, Latin American, North African, 
mixed race).  
f Information was not available from five women with GDM (1 active-group, 4 placebo-group).  
Healthy active versus GDM active group and GDM placebo group: *P < 0.05, **P < 0.01, ***P < 0.001 
Healthy placebo versus GDM active group and GDM placebo group: +P < 0.05, ++P < 0.01, +++P < 0.001 
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3.4.2  Maternal plasma fatty acid composition at baseline  
 This result reports plasma choline phosphoglycerides, cholesterol esters, and 
triglycerides fatty acids of the GDM (n = 142) and healthy pregnant women (n = 28) at 
diagnosis, matched for the gestational period.  
3.4.2.1 Plasma choline phosphoglycerides (CPG) 
 Fatty acid composition of plasma CPG at baseline is presented in Table 3.2. 
Compared with healthy pregnant women, the GDM women had lower levels of 22:5n-
3 (docosapentaenoic acid; P < 0.01). The levels of other fatty acids were comparable 
between the healthy pregnant and GDM women (P > 0.05). 
3.4.2.2 Plasma cholesterol esters (CE) 
 Fatty acid composition of plasma CE at baseline is presented in Table 3.3. 
Compared with healthy pregnant women, the GDM women had lower levels of 18:1n-
9 (oleic acid) and Σ monounsaturates (P < 0.05). The levels of other fatty acids were 
comparable between the healthy pregnant and GDM women (P > 0.05). 
3.4.2.3 Plasma triglycerides (TG) 
 Fatty acid composition of plasma TG at baseline is presented in Table 3.4. 
Compared with healthy pregnant women, the GDM women had lower levels of 14:0 
(myristic acid; P < 0.05). The levels of other fatty acids were comparable between the 
healthy pregnant and GDM women (P > 0.05). 
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Table 3.2. Mean (±SD) percent fatty acid composition of plasma choline 
phosphoglycerides of healthy pregnant and GDM women at baseline. 
 
          
Healthy pregnant women versus GDM women: *P < 0.05, **P < 0.01 
 
 
 
Fatty acids 
Healthy pregnant women 
(n = 28) 
GDM women (n = 142) 
14:0  0.2 ± 0.1 0.2 ± 0.1 
16:0  29.7 ± 3.5 30.2 ± 3.3 
18:0  10.5 ± 1.3 10.1 ± 1.3 
20:0  0.04 ± 0.01 0.04 ± 0.02 
22:0  0.1 ± 0.1 0.1 ± 0.1 
24:0  0.1 ± 0.03 0.1 ± 0.02 
Σ Saturates 41.1 ± 2.7 41.4 ± 2.8 
16:1n-7  0.4 ± 0.3 0.4 ± 0.2 
18:1n-7  1.4 ± 0.3 1.4 ± 0.4 
18:1n-9  9.8 ± 2.3 9.5 ± 2.7 
24:1n-9  0.04 ± 0.02 0.05 ± 0.03 
Σ Monoenes 12.0 ± 2.5 11.5 ± 3.1 
18:2n-6  24.2 ± 3.1 24.8 ± 3.2 
18:3n-6  0.1 ± 0.04 0.1 ± 0.1 
20:2n-6  0.5 ± 0.1 0.4 ± 0.1 
20:3n-6  3.9 ± 1.0 3.6 ± 0.9 
20:4n-6  10.0 ± 1.9 10.6 ± 2.1 
22:4n-6  0.3 ± 0.1 0.3 ± 0.2 
22:5n-6  0.4 ± 0.2 0.4 ± 0.3 
Σ n-6 39.3 ± 3.7 40.3 ± 3.4 
18:3n-3  0.3 ± 0.1 0.3 ± 0.1 
20:5n-3  0.8 ± 0.5 0.7 ± 0.6 
22:5n-3  0.7 ± 0.2** 0.5 ± 0.2 
22:6n-3  4.9 ± 1.7 4.4 ± 1.1 
Σ n-3 6.8 ± 2.2 6.0 ± 1.7 
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Table 3.3. Mean (±SD) percent fatty acid composition of plasma cholesterol esters 
of healthy pregnant and GDM women at baseline. 
 
Fatty acids 
Healthy pregnant women 
(n = 28) 
GDM women (n = 142) 
14:0  0.3 ± 0.2 0.3 ± 0.2 
16:0  9.5 ± 1.7 9.5 ± 1.8 
18:0  0.5 ± 0.1 0.5 ± 0.1 
20:0  0.05 ± 0.02 0.04 ± 0.02 
22:0  0.03 ± 0.03 0.03 ± 0.02 
24:0  tr tr 
Σ Saturates 11.6 ± 2.6 12.1 ± 3.1 
16:1n-7  1.9 ± 1.3 1.6 ± 1.0 
18:1n-7  1.1 ± 0.2 1.0 ± 0.2 
18:1n-9  17.4 ± 3.6* 15.8 ± 2.8 
24:1n-9  0.8 ± 0.5 0.7 ± 0.4 
Σ Monoenes 21.2 ± 4.3* 19.1 ± 3.4 
18:2n-6  54.9 ± 5.1 55.5 ± 5.4 
18:3n-6  0.6 ± 0.3 0.5 ± 0.2 
20:2n-6  0.1 ± 0.02 0.1 ± 0.02 
20:3n-6  0.9 ± 0.2 0.9 ± 0.2 
20:4n-6  8.0 ± 1.7 8.6 ± 2.0 
22:4n-6  0.1 ± 0.04 0.1 ± 0.1 
22:5n-6  0.1 ± 0.1 0.1 ± 0.1 
Σ n-6 64.7 ± 5.1 65.8 ± 5.4 
18:3n-3  0.7 ± 0.3 0.7 ± 0.3 
20:5n-3  0.8 ± 0.5 0.7 ± 0.6 
22:5n-3  0.1 ± 0.02 0.1 ± 0.1 
22:6n-3  0.9 ± 0.4 0.9 ± 0.3 
Σ n-3 2.6 ± 0.9 2.4 ± 0.9 
 
tr - trace  
Healthy pregnant women versus GDM women: *P < 0.05 
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Table 3.4. Mean (±SD) percent fatty acid composition of plasma triglycerides of 
healthy pregnant and GDM women at baseline. 
 
Fatty acids 
Healthy pregnant women (n 
= 28) 
GDM women (n = 142) 
14:0  1.6 ± 0.8* 1.2 ± 0.7 
16:0  28.4 ± 4.8 26.6 ± 4.0 
18:0  3.0 ± 0.5 3.0 ± 0.6 
20:0  0.1 ± 0.02 0.1 ± 0.04 
22:0  0.1 ± 0.1 0.04 ± 0.03 
24:0  tr tr 
Σ Saturates 34.2 ± 5.5 32.1 ± 4.7 
16:1n-7  2.4 ± 1.4 1.9 ± 0.8 
18:1n-7  2.0 ± 0.4 2.1 ± 0.4 
18:1n-9  33.3 ± 5.5 33.5 ± 5.0 
24:1n-9  0.04 ± 0.03 0.03 ± 0.02 
Σ Monoenes 38.3 ± 5.4 38.0 ± 5.2 
18:2n-6  21.1 ± 6.2 23.3 ± 5.7 
18:3n-6  0.3 ± 0.2 0.3 ± 0.1 
20:2n-6  0.3 ± 0.1 0.3 ± 0.1 
20:3n-6  0.4 ± 0.1 0.4 ± 0.1 
20:4n-6 1.5 ± 0.6 1.4 ± 0.4 
22:4n-6  0.2 ± 0.1 0.2 ± 0.1 
22:5n-6  0.3 ± 0.2 0.3 ± 0.1 
Σ n-6 24.1 ± 6.7 26.2 ± 6.1 
18:3n-3  1.1 ± 0.4 1.3 ± 0.6 
20:5n-3  0.2 ± 0.1 0.2 ± 0.2 
22:5n-3  0.2 ± 0.1 0.2 ± 0.1 
22:6n-3  0.9 ± 0.4 0.9 ± 0.6 
Σ n-3 2.6 ± 0.8 2.8 ± 1.1 
 
tr – trace 
Healthy pregnant women versus GDM women: *P < 0.05 
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3.4.3 Maternal plasma fatty acid composition at delivery  
3.4.3.1 Plasma choline phosphoglycerides (CPG) 
  Fatty acid composition of plasma CPG is given in Table 3.5. The healthy 
placebo-group had higher levels of 16:1n-7 (palmitoleic acid; P < 0.05), 18:1n-9 (oleic 
acid; P < 0.05), Σ monoenes (P < 0.05) and 20:3n-6 (dihomo-γ-linolenic acid; P < 
0.01) compared with healthy active-treatment group. In comparison with healthy 
placebo, GDM placebo-group had lower levels of 16:1n-7 (palmitoleic acid; P < 0.01), 
18:1n-7 (vaccenic acid; P < 0.05), 18:1n-9 (oleic acid; P < 0.05), Σ monoenes (P < 
0.01) and 20:3n-6 (dihomo-γ-linolenic acid; P < 0.05) but high Σ n-6 fatty acids (P < 
0.05). GDM active-treatment group in comparison with healthy placebo-group, had 
lower levels of 16:1n-7 (palmitoleic acid; P < 0.001), 18:1n-7 (vaccenic acid; P < 
0.05), 18:1n-9 (oleic acid; P < 0.01), Σ monoenes (P < 0.001) and 20:3n-6 (dihomo-γ-
linolenic acid; P < 0.05) but high 18:2n-6 (linoleic acid; P < 0.01) and Σ n-6 fatty acids 
(P < 0.01). DHA (22:6n-3; P < 0.05) was increased in GDM active-treatment group 
compared with GDM placebo. Although not significantly, but DHA (22:6n-3) was 
high in healthy active-treatment group as compared to the healthy-placebo.  
3.4.3.2 Plasma cholesterol esters (CE) 
 Table 3.6 shows plasma CE fatty acid levels of all four groups. 16:1n-7 
(palmitoleic acid; P < 0.01) was elevated in healthy placebo-group than in healthy 
active-treatment group. GDM placebo compared to healthy placebo-group had lower 
levels of 16:1n-7 (palmitoleic acid; P < 0.001), 18:1n-9 (oleic acid; P < 0.001) and Σ 
monoenes (P < 0.05) but higher Σ n-6 fatty acids (P < 0.001). In comparison with 
healthy placebo-group, GDM active-treatment group also had lower levels of 16:1n-7 
(palmitoleic acid; P < 0.001), 18:1n-9 (oleic acid; P < 0.001) and Σ monoenes (P < 
0.05) but higher Σ n-6 fatty acids (P < 0.001). DHA (22:6n-3) was elevated in both 
GDM active (P < 0.01) and healthy active-treatment (not significantly) groups than 
their placebo-treated counterparts (GDM-placebo and healthy-placebo).  
3.4.3.3  Plasma triglycerides (TG) 
     Mean fatty acids of the plasma TG is presented in Table 3.7. The healthy 
placebo-group compared with the healthy active-treatment group had reduced 18:2n-6 
(linoleic acid; P < 0.01), Σ n-6 (P < 0.01) and increased 16:1n-7 (palmitoleic acid; P < 
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0.01) and Σ monoenes (P < 0.05). GDM placebo compared with healthy placebo-group 
had lower 16:1n-7 (palmitoleic acid; P < 0.001) but higher 18:2n-6 (linoleic acid; P < 
0.01) and Σ n-6 fatty acids (P < 0.01). GDM active-treatment group compared with 
healthy-placebo had lower 16:1n-7 (palmitoleic acid; P < 0.001) and Σ monoenes (P < 
0.01) but higher 18:2n-6 (linoleic acid; P < 0.001) and Σ n-6 fatty acids (P < 0.01). 
DHA (22:6n-3; P < 0.05) was elevated in GDM active-treatment group compared with 
GDM placebo. Although it did not reach the level of a statistical significance, the mean 
percentage of DHA (22:6n-3) was also higher in the healthy active-treatment group as 
compared to healthy placebo. 
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Table 3.5. Mean (±SD) percent fatty acid composition of maternal plasma choline 
phosphoglycerides at delivery. 
 
Fatty acids 
Healthy pregnant women          
(n = 21) 
GDM women (n = 89) 
Placebo group 
(n = 14)  
Active group 
(n = 7) 
Placebo group 
(n = 40)  
Active group 
(n = 49) 
14:0  0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
16:0  31.7 ± 3.7 31.8 ± 1.3 32.7 ± 2.4 32.2 ± 2.2 
18:0  9.1 ± 2.4 10.1 ± 1.9 8.9 ± 1.2 9.0 ± 1.1 
20:0  0.05 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
22:0  0.2 ± 0.1 0.1 ± 0.03 0.1 ± 0.03 0.1 ± 0.03 
24:0  tr tr tr tr 
Σ Saturates 41.9 ± 1.8 42.9 ± 2.3 42.7 ± 2.3 42.3 ± 2.0 
16:1n-7  1.0 ± 0.3* 0.6 ± 0.4 0.7 ± 0.3++ 0.6 ± 0.3××× 
18:1n-7  1.7 ± 0.4 1.5 ± 0.3 1.4 ± 0.2+ 1.4 ± 0.3× 
18:1n-9  14.0 ± 1.8* 11.0 ± 1.2 11.9 ± 2.5+ 11.6 ± 2.1×× 
24:1n-9  0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 
Σ Monoenes 16.9 ± 2.0* 13.4 ± 1.4 14.2 ± 2.8++ 13.8 ± 2.4××× 
18:2n-6  20.1 ± 3.7 21.8 ± 4.1 22.7 ± 3.7 23.8 ± 3.1×× 
18:3n-6  0.1 ± 0.03 0.1 ± 0.03 0.1 ± 0.03 0.1 ± 0.04 
20:2n-6  0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 
20:3n-6  3.9 ± 1.2** 2.7 ± 0.7 3.2 ± 0.8+ 3.2 ± 0.8× 
20:4n-6  9.5 ± 3.0 10.4 ± 3.0 10.0 ± 2.3 9.2 ± 1.7 
22:4n-6  0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
22:5n-6  0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.1 
Σ n-6 34.8 ± 1.8 35.8 ± 2.6 37.0 ± 4.1+ 37.2 ± 3.0×× 
18:3n-3  0.5 ± 0.2 0.3 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 
20:5n-3  0.7 ± 0.5 1.5 ± 1.4 0.6 ± 0.5 0.7 ± 0.4 
22:5n-3  0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.1 
22:6n-3  3.8 ± 1.5 4.8 ± 1.3 3.7 ± 1.1 4.4 ± 1.1≠ 
Σ n-3 5.6 ± 1.9 7.3 ± 2.8 5.3 ± 1.6 6.0 ± 1.4 
 
tr - trace 
Healthy placebo versus healthy active group: *P < 0.05, **P < 0.01 
Healthy placebo versus GDM placebo group: +P < 0.05, ++P < 0.01 
Healthy placebo versus GDM active group: ×P < 0.05, ××P < 0.01, ×××P < 0.001 
GDM Placebo versus GDM active group: ≠P < 0.05 
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Table 3.6. Mean (±SD) percent fatty acid composition of maternal plasma 
cholesterol esters at delivery. 
 
 
tr - trace 
Healthy placebo versus healthy active group: *P < 0.05, **P < 0.01 
Healthy placebo versus GDM placebo group: +P < 0.05, ++P < 0.01, +++P < 0.001 
Healthy placebo versus GDM active group: ×P < 0.05, ××P < 0.01, ×××P < 0.001 
GDM Placebo versus GDM active group: ≠P < 0.05, ≠≠P < 0.01 
 
 
 
 
Fatty acids 
Healthy  pregnant women        (n 
= 21) 
GDM women (n = 89) 
Placebo group 
(n = 14)  
Active group 
(n = 7) 
Placebo group 
(n = 40)  
Active group 
(n = 49) 
14:0  0.3 ± 0.2  0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
16:0  11.0 ± 1.8 10.3 ± 2.4 9.6 ± 1.6 9.5 ± 1.8 
18:0  0.7 ± 0.7 0.9 ± 1.0 0.6 ± 0.9 0.5 ± 0.1 
20:0  0.1 ± 0.03 0.04 ± 0.03 0.1 ± 0.1 0.1 ± 0.1 
22:0  0.1 ± 0.04 0.04 ± 0.02 0.1 ± 0.1 0.1 ± 0.1 
24:0  tr tr tr tr 
Σ Saturates 13.5 ± 3.0 12.7 ± 3.3 11.8 ± 2.7 11.5 ± 2.1 
16:1n-7  4.5 ± 1.8** 2.2 ± 1.5 1.9 ± 1.1+++ 1.7 ± 1.0××× 
18:1n-7  1.5 ± 1.0 1.4 ± 0.8 1.0 ± 0.2 1.0 ± 0.2 
18:1n-9  22.9 ± 4.6 19.0 ± 5.4 17.1 ± 2.4+++ 16.8 ± 3.0××× 
24:1n-9  0.2 ± 0.2 0.3 ± 0.3 0.4 ± 0.2 0.4 ± 0.2 
Σ Monoenes 29.2 ± 5.8 22.9 ± 6.7 20.4 ± 3.0+ 20.0 ± 3.5× 
18:2n-6  44.2 ± 10.8 49.8 ± 11.8 54.5 ± 4.8 55.4 ± 4.4 
18:3n-6  0.8 ± 0.3 0.5 ± 0.2 0.6 ± 0.3 0.6 ± 0.3 
20:2n-6  0.05 ± 0.03 0.04 ± 0.02 0.1 ± 0.1 0.1 ± 0.1 
20:3n-6  1.1 ± 0.4 0.8 ± 0.3 0.9 ± 0.2 0.9 ± 0.3 
20:4n-6  7.7 ± 2.8 9.1 ± 3.5 8.7 ± 2.3 8.1 ± 2.0 
22:4n-6  0.1 ± 0.1 0.1 ± 0.02 0.1 ± 0.1 0.1 ± 0.1 
22:5n-6  0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.2 
Σ n-6 54.1 ± 7.6 60.5 ± 9.3 65.0 ± 4.9+++ 65.3 ± 4.3××× 
18:3n-3  0.9 ± 0.5 0.5 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 
20:5n-3  0.6 ± 0.4 1.4 ± 1.3 0.7 ± 0.6 0.7 ± 0.4 
22:5n-3  0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 
22:6n-3  0.8 ± 0.3 1.2 ± 0.3 0.9 ± 0.3 1.1 ± 0.3≠≠ 
Σ n-3 2.5 ± 0.9 3.4 ± 1.7 2.4 ± 0.9 2.8 ± 0.8 
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Table 3.7. Mean (±SD) percent fatty acid composition of maternal plasma 
triglycerides at delivery. 
 
Fatty acids 
Healthy pregnant women (n = 21) GDM women (n = 89) 
Placebo group 
(n = 14)  
Active group 
(n = 7) 
Placebo group 
(n = 40)  
Active group 
(n = 49) 
14:0  0.7 ± 0.3 0.8 ± 0.7 0.6 ± 0.3 0.7 ± 0.3 
16:0  29.0 ± 3.1 25.6 ± 3.0 26.8 ± 3.3 27.4 ± 2.5 
18:0  2.9 ± 0.9 3.1 ± 1.0 2.6 ± 0.5 2.7 ± 0.6 
20:0  0.1 ± 0.04 0.04 ± 0.02 0.04 ± 0.01 0.04 ± 0.04 
22:0  0.04 ± 0.01 0.05 ± 0.04 0.1 ± 0.2 0.05 ± 0.1 
24:0  tr tr tr tr 
Σ Saturates 33.7 ± 2.7 30.4 ± 3.7 31.0 ± 3.5 31.7 ± 2.6 
16:1n-7  3.1 ± 1.1** 1.8 ± 1.0 1.9 ± 0.8+++ 1.8 ± 0.7××× 
18:1n-7  2.8 ± 0.7 2.1 ± 0.4 2.3 ± 0.3 2.1 ± 0.4 
18:1n-9  38.2 ± 3.4 33.8 ± 2.2 36.7 ± 3.5 34.9 ± 4.3 
24:1n-9  0.02 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.1 
Σ Monoenes 44.6 ± 3.4* 38.1 ± 2.0 41.3 ± 3.8 39.1 ± 4.7×× 
18:2n-6  15.0 ± 2.8** 22.9 ± 2.2 21.6 ± 4.9++ 22.6 ± 4.5××× 
18:3n-6  0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 
20:2n-6  0.2 ± 0.04 0.3 ± 0.1 0.3 ± 01 0.3 ± 0.1 
20:3n-6  0.4 ± 0.3 0.4 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 
20:4n-6  1.5 ± 0.6 1.9 ± 0.9 1.4 ± 0.4 1.4 ± 0.5 
22:4n-6  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 01 
22:5n-6  0.3 ± 0.3 0.3 ± 0.3 0.3 ± 01 0.2 ± 0.1 
Σ n-6 18.0 ± 2.8** 26.3 ± 2.8 24.3 ± 5.3++ 25.2 ± 4.8×× 
18:3n-3  0.8 ± 0.4 0.8 ± 0.4 0.9 ± 0.3 0.9 ± 0.3 
20:5n-3  0.2 ± 0.1 0.6 ± 0.6 0.2 ± 0.1 0.2 ± 0.2 
22:5n-3  0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 
22:6n-3  0.9 ± 0.6 1.7 ± 1.0 0.8 ± 0.4 1.2 ± 0.8≠ 
Σ n-3 2.5 ± 1.2 3.7 ± 1.9 2.4 ± 0.7 2.8 ± 1.1 
 
tr - trace 
Healthy placebo versus healthy active group: *P < 0.05, **P < 0.01 
Healthy placebo versus GDM placebo group: +P < 0.05, ++P < 0.01, +++P < 0.001 
Healthy placebo versus GDM active group: ×P < 0.05, ××P < 0.01, ×××P < 0.001 
GDM Placebo versus GDM active group: ≠P < 0.05, ≠≠P < 0.01 
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3.5 Discussion and conclusion 
 This study shows that the GDM women were heavier (BMI ≥ 29) and of higher 
parity (parity ≥ 3) as compared to non-diabetic pregnant women. These findings 
corroborate earlier reports, demonstrating a BMI ≥ 29 kg/m2 (Ramos and Caughey 
2005; Chu et al. 2007; Shah et al. 2011; Khan et al. 2013) and high parity (Al-Rowaily 
and Abolfotouh 2010; Khan et al. 2013) are important risk factors for gestational 
diabetes. The GDM women in our study did not show significant difference in age 
when compared to the healthy pregnant women. However, on further evaluating the 
demographic data, 40 GDM women were ≥ 35 years old as compared to only 7 healthy 
pregnant women in this age category, although the sample size of latter group was 
small. The relationship between parity and diabetes is strongly associated to obesity 
and age. Women with higher parity tend to be older and obese. However, age is a 
confounding factor in the association between parity and GDM. Hence, while 
evaluating parity the control for age cannot be ignored. The strength of this 
association, on the other hand could diminish when the adjustments for BMI are made. 
The association between high parity and the risk of developing GDM could be better 
studied through a hierarchical model (Dode and dos Santos 2009).  
 A vast majority of GDM women were of Asian (approximately 60%, mainly 
Bangladeshi) and African/Afro-Caribbean (approximately 25%) origin. Although, 
Newham Borough (the resident population area) has one of the highest ethnic minority 
populations among all the districts in the country, but with no particular ethnic group 
dominating. Also, the subjects were recruited at random. This disproportionate 
representation of women of Asian and African/Afro-Caribbean origin in the GDM 
group proposes that they may have higher chances of developing GDM. It has been 
considered for long that some ethnicities of women are at high risk of developing 
GDM (Yuen and Wong 2015). For example, Africans and South-Indians women were 
at higher risk of developing GDM regardless of BMI (Makgoba et al. 2012). Another 
study has shown that South Asian women were at higher risk (7.1%) of developing 
GDM than Caucasian women (Savitz et al. 2008). It is plausible that genetic 
predisposition, lifestyle and dietary habits including less physical activity and a high 
intake of saturated fat promoting obesity may be partially responsible for the 
disproportionate prevalence of the GDM among the Asian and Afro-Caribbean/African 
women in the current study.  
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 In pregnancies complicated by GDM, some studies have shown comparable 
levels of LCPUFAs particularly DHA and AA (to their controls) in maternal plasma 
phospholipids (Wijendran et al. 1999) and triglycerides (Min et al. 2005a). Even higher 
levels of DHA and AA have also been reported in maternal plasma phospholipids 
(Ghebremeskel et al. 1998; Thomas et al. 2004) and neutral lipids (Thomas et al. 
2004). In corroboration to the studies mentioned above, this study has also shown that 
the GDM women compared with their healthy control, have apparently normal DHA 
and AA levels in plasma CPG, CE and TG lipid fractions. There is no clear 
explanation for this relatively equivalent DHA and AA status in the three plasma lipid 
fractions (CPG, CE, TG) of the GDM women. Though, it could be due to higher 
intake, mobilisation or insulin-induced increased synthesis. Since the blood samples 
were collected at diagnosis before the start of any medical treatment, insulin therapy or 
diet could not have been a factor. Raised plasma fatty acids are a common sign of 
insulin resistance (Unger and Foster 1998; Nelson et al. 2010; Karpe et al. 2011). 
Thus, it is possible that a persistently high concentration of glucose might have led to 
the mobilisation of fatty acids, including ALA, LA, DHA and AA from adipose tissue 
and the liver. It would lead to an upsurge in plasma levels of the less oxidisable AA 
and DHA (Leyton et al. l987) but not of readily oxidisable fatty acids, LA and ALA 
(Cunnane l996).  
  Recent study has revealed that activity of the delta-5 desaturase enzyme is 
enhanced in type II diabetes (Imamura et al. 2014). Up to now, there is no evidence 
that the activities of delta-6 and delta-5 desaturase enzymes are impaired in gestational 
diabetes. These enzymes are vital for the synthesis of the n-3 and n-6 LCPUFAs (Garg 
et al. 2017) and their impairment is often revealed by an increase in ALA and LA, and 
an associated decrease in their respective major metabolites DHA and AA. The data 
from this study do not provide support for the evidence of the impairment of either 
delta-6 or/and delta-5 desaturase in gestational diabetics. The GDM women had non-
significantly higher AA in CPG and CE, and comparable AA (in plasma TG) and 
DHA in plasma CPG, CE and TG lipid fractions. Indeed, the higher AA/LA in plasma 
CPG and CE suggest that they might have had enhanced desaturase activity. These 
findings are in persistence with the previous studies that have reported enhanced AA 
and DHA status in plasma CPG of women with gestational diabetes (Ghebremeskel et 
al. 1998; Min et al. 2004; Min et al. 2006).  
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 Contrary to the findings in plasma, the red cells of the GDM women 
(irrespective of their ethnic origin and dietary background) had significantly lower 
levels of DHA (Min et al. 2004; Min et al. 2005a; Min et al. 2006). We are uncertain as 
to why gestational diabetes had different effects on DHA levels in plasma and red cell. 
It is plausible that GDM reduces the incorporation of the fatty acid into red cells and 
other tissues. Mature red blood cells have a limited ability of synthesizing 
phospholipids de novo and the renewal/remodelling of red blood cell membrane 
phospholipids, which occurs continuously, is reliant on plasma lipid pool (Shohet 
1971; Lubin 1989). Therefore, it is evident that the fatty acid moieties of red blood cell 
phospholipids have their origin in plasma lipids (Kleinfeld et al. 1998), in healthy 
individuals. In the light of these findings, our research group postulated that the 
incorporation of DHA from plasma into red blood cells is compromised in GDM 
women due to hyperglycaemia. Additionally, we postulated that the rigorous 
glycaemic control could improve this impairment. Based on these postulations, our 
research group conducted studies on GDM women supplemented with DHA-enriched 
formula and whose blood glucose levels were well-controlled using diet, oral 
hypoglycaemic agents or/and insulin. It was found that DHA level in their red blood 
cells phospholipids (Min et al. 2016), plasma phospholipids and neutral lipids (this 
study) was enhanced.  
 The loss of maternal plasma and red cell DHA level at the end of pregnancy has 
been considered as a physiological response to pregnancy. However, this phenomenon 
was not observed in healthy pregnant women supplemented with fish or fish oil (Miles 
2011; Escolano-Margarit et al. 2013), and women from high fish and seafood-
consuming communities (Luxwolda et al. 2012). Consistent with these findings, in the 
current study, the plasma DHA level did not decline at the end of pregnancy in the 
gestational diabetic women Thus, it appears that the decline of DHA level in 
pregnancy could be a reflection of an imbalance between maternal status and materno-
foetal requirement rather than a physiological response to pregnancy.  
 In this study, the GDM women, who were supplemented with the placebo, had 
comparable DHA levels to their healthy counterparts. This may be attributable to 
vitamin E, which was incorporated in the placebo supplement to prevent peroxidation. 
Indeed, supporting evidence comes from a study by Ota (Ota et al. 2004), who 
reported an improvement in red cell membrane omega-6 and omega-3 fatty acid levels 
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after 500 mg/day of vitamin E supplementation in patients with the hepatitis C virus. 
However, it is worth noting that the dose that the women in our study would have 
consumed is minute (approximately 8 mg/d) compared with that which Ota et al. used 
(500mg/day). 
 In summary, the results of the present study show that the plasma DHA and 
AA levels are not compromised by gestational diabetes in pregnant women. It may be 
that the unaffected plasma DHA and AA levels observed in the GDM pregnant women 
is linked with a failure to incorporate these fatty acids into the phospholipids of the red 
cell membrane and impaired placental transport. Also, a considerable number of 
samples were collected at diagnosis, and it is plausible that the duration of the diabetes 
was very short to produce an obvious adverse effect on the plasma DHA and AA 
levels.    
 This study also demonstrates that DHA-enriched supplementation is effective 
in enhancing the maternal DHA status in pregnant women with gestational diabetes. 
Moreover, it shows that the decline in maternal DHA, which occurs in the final stages 
of gestation and was thought to be a physiological response to pregnancy, can be 
halted by supplementation. We suggest that the provision of a DHA supplement should 
be integrated with the antenatal care of pregnant women with gestational diabetes to 
optimize foetal development and avert maternal DHA depletion in pregnancy. 
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CHAPTER 4 
 
Effect of dietary docosahexaenoic acid-enriched 
supplementation on plasma fatty acids profile of neonates 
born to the women with gestational diabetes: A randomized 
double-blinded placebo-controlled trial----------------(100-112) 
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4.1  Introduction  
The importance of DHA and AA in foetal life has been extensively 
documented (Uauy et al. 2000; Koletzko et al. 2001). They are marked as essential for 
optimum foetal growth and development. AA influences the foetal growth (Carlson et 
al. 1993; Innis 2005). DHA, a chief component of the developing CNS, is essential for 
visual and cognitive functions (Innis 1994; Hibbeln et al. 2007; Oken and Bellinger 
2008; Makrides et al. 2010). Also, based on animal models of obesity and cell culture 
studies, it is postulated that DHA might be a potent anti-adiposity agent (Ruzickova et 
al. 2004) and enhance glucose utilization by modulating insulin secretion and action 
(Ramanadham et al. 2002; Gonzalez-Periz et al. 2009).  
Of these two LCFUFAs, DHA is considered to be the most limiting nutrient in 
pregnancy and lactation, because it is scarce or absent in land animal and plant food 
sources. Moreover, the synthesis of DHA from the parent compound α-linolenic acid is 
inefficient. In a normal pregnancy, DHA is preferentially transferred by placental 
selection from maternal to placental circulation. However, recent studies have reported 
that the placental uptake and transfer of DHA is impaired in pregnancy complicated by 
GDM (Araujo et al. 2013; Pagan et al. 2013). Studies also show that lower values of 
DHA and other LCPUFAs were observed in the cord blood of neonates born to GDM 
mothers (Min et al. 2005a; Thomas et al. 2005). There is no published data whether or 
not the impact of this impairment could be ameliorated by DHA supplementation. This 
chapter presents the findings of a randomized, double-blinded, placebo-controlled trial 
in which the pregnant women with GDM were supplemented with DHA-enriched 
formula or high oleic acid sunflower seed oil. We aimed to measure the plasma 
phospholipids and neutral lipids DHA levels in the cord blood of neonates born to 
GDM women.  
4.2  Subjects and methods 
 Subjects and methods are given in detail in Chapter 2.  
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4.3  Statistical analysis 
 The data are expressed as mean ± standard deviation (SD), median (range) and 
number of occurrence, n (%) as appropriate. Statistical significance was assumed at P 
< 0.05 unless otherwise stated. One way ANOVA was used to compare the difference 
in; 
• Anthropometric measurements between babies born to healthy pregnant and GDM 
women (placebo and active-treatment groups) 
• Plasma fatty acids composition of cord blood of the babies born to healthy pregnant 
and GDM women (placebo and active-treatment groups) 
 A pairwise comparison was performed using Tukey’s honest significant 
difference (HSD, for equal variance) and Games-Howell (for unequal variance) tests 
for each dependent variable separately when the F-ratio was significant (P < 0.05). All 
statistical analysis were carried out with IBM SPSS Statistics version 24 (IBM 
Corporation, USA).  
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4.4 Results 
4.4.1 Clinical characteristics of the neonates 
 The neonatal anthropometric data were obtained from babies born to 85 GDM 
(active-treatment group n = 44 and placebo-group n = 41) and 20 healthy pregnant 
(active-treatment group n = 6 and placebo-group n = 14) women. The detailed 
anthropometric data and pregnancy out comes of the neonates are given in Table 4.1. 
Of the two GDM women in placebo group, one delivered a stillborn baby and the other 
one had miscarriage. One baby was born with cleft lip and palate in GDM active-
treatment group. There was no difference in the mean gestational age and the 
anthropometric measurements between the active-treatment and placebo groups 
(healthy and GDM). Although the differences were not satistically significant, but the 
number of babies born with low birth weight and at preterm were higher in GDM 
active-treatment group. 
4.4.2 Plasma fatty acid composition of cord blood 
 This result reports the plasma choline phosphoglycerides, cholesterol esters, 
and triglycerides fatty acids composition of the neonatal cord blood from GDM 
(active-treatment group n = 44, placebo group n = 41) and healthy pregnant women 
(active-treatment group, n = 6; placebo group, n = 14), at delivery.  
4.4.2.1 Plasma choline phosphoglycerides (CPG) 
  Percentages of the major fatty acids of plasma CPG are presented in Table 
4.2. All the groups (GDM placebo-, active-treatment and healthy placebo-, active-
treatment) had comparable levels of saturated and monounsaturated fatty acids. The 
cord blood plasma of GDM active-treatment group had low levels of AA (20:4n-6; P < 
0.01) compared to the cord blood plasma of healthy placebo-group. Σ n-3 levels were 
high in healthy active-treatment group when compared to GDM placebo and GDM 
active-treatment groups (P < 0.05). Although it did not reach the level of a statistical 
significance, the mean percentage of DHA (22:6n-3) was also high in the healthy 
active-treatment group when compared to GDM placebo and GDM active-treatment 
groups. 
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4.4.2.2 Plasma cholesterol esters (CE) 
 Mean fatty acid composition of the cord plasma CE is presented in Table 4.3. 
All the groups (GDM placebo-, active-treatment and healthy placebo-, active-
treatment) had comparable levels of saturated and monounsaturated fatty acids. Similar 
to the CPG fraction, the cord blood plasma of GDM active-treatment group had low 
levels of AA (20:4n-6; P < 0.01) compared to the cord blood plasma of healthy 
placebo-group. DHA (22:6n-3) and Σ n-3 levels were high in healthy active-treatment 
group as compared to GDM active-treatment group (P < 0.05).  
4.4.2.3 Plasma triglycerides (TG) 
 Fatty acid composition of the cord plasma TG is given in Table 4.4. The 
levels of saturated and monounsaturated fatty acids were comparable between all the 
groups. Like CPG and CE fractions, although not significantly, the cord blood plasma 
of GDM active-treatment group had low levels of AA (20:4n-6; P > 0.05) compared to 
the cord blood plasma of healthy placebo-group. The cord blood plasma of GDM 
active-treatment group had low levels of adrenic acid (22:4n-6; P < 0.05) compared to 
the cord blood plasma of healthy placebo-group.  
 EPA (20:5n-3) was high in healthy active-treatment group when compared to 
GDM placebo (P < 0.05). The mean percentages of DHA (22:6n-3) and Σ n-3 fatty 
acids were also high in the healthy active-treatment group compared to GDM placebo 
and GDM active-treatment groups, though it did not reach the level of significance. 
 Within the GDM active supplemented group, the DHA levels in plasma CPG, 
CE and TG of neonates whose mothers had less than 10 weeks (on average) of 
supplementation did not differ significantly from those supplemented for a longer 
period.  
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Table 4.1.  Pregnancy outcomes and anthropometric data of neonates*.  
 
GDM women Healthy pregnant women 
Active- group Placebo-groupa Active- group Placebo-group 
Live births (n)b 61 56 9 14 
Gestation at delivery (weeks)c 38.0 (33.0-41.0) 38.0 (34.0-40.0) 39.0 (34.0-41.0) 38.0 (35.0-42.0) 
Supplementation duration 
(weeks)c 
10 (4.0-22.0) 10.0 (4.0-22.0) 11.0 (9.0-21.0) 12.0 (8.0-24.0) 
Gender of neonates (n)d   
Male  30 (49.2) 32 (57.1) 6 (66.7) 8 (57.1) 
Female 31 (50.8) 24 (42.9) 3 (33.3) 6 (42.9) 
Delivery method (n)d   
Vaginal  
Spontaneous 16 (26.2) 13 (23.2) 6 (66.7) 5 (35.7) 
Assisted  2 (3.3) 0 (0.0) 0 (0.0) 1 (7.1) 
Induced  11 (18.0) 15 (26.8) 0 (0.0) 1 (7.1) 
Caesarean 
section 
Elective  10 (16.4) 11 (19.6) 1 (11.1) 2 (14.3) 
Emergency  22 (36.1) 17 (30.4) 2 (22.2) 5 (35.7) 
Preterm birth (n)d e 12 (19.7) 6 (10.7) 1 (11.1) 1 (7.1) 
Late preterm birth (n)d f 11 (18.0) 6 (10.7) 1 (11.1) 1 (7.1) 
Low birth weight (n)e g 7 (11.5) 3 (5.4) 2 (22.2) 2 (14.3) 
Macrosomia (n)d h 3 (4.9) 2 (3.6) 1 (11.1) 0 (0.0) 
Congenital defect (n)d i 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 
Neonatal hypoglycemia (n)d 2 (3.3) 2 (3.6) 0 (0.0) 0 (0.0) 
Anthropometric measurementj   
Weight (kg) 3.2 ± 0.6 3.1 ± 0.4 3.1 ± 0.7 3.0 ± 0.5 
Length (cm) 49.2 ± 7.7 50.1 ± 5.6 50.0 ± 4.7 49.5 ± 3.4 
Head circumference (cm) 33.8 ± 1.7 33.7 ± 2.4 33.8 ± 0.8 33.8 ± 1.3 
Shoulder circumference (cm) 36.3 ± 5.4 35.9 ± 5.5 37.1 ± 1.3 36.0 ± 1.2 
Mid-arm circumference (cm)  11.9 ± 2.1 11.5 ± 2.7 10.9 ± 0.7 11.0 ± 0.6 
Abdominal circumference 
(cm) 33.1 ± 4.0 33.0 ± 4.4 32.3 ± 1.1 32.3 ± 0.9 
 
* The pregnancy outcome and neonatal anthropometric measurement did not differ between the groups 
a There was one stillbirth and one miscarriage in the placebo-group (GDM women).  
b This number included all the subjects who completed the supplementation regardless of the availability 
of blood samples at delivery 
c Data are expressed as median (min-max) 
d Data expressed as number of subjects (%) 
e Preterm birth; born less than 37 weeks of gestation 
f Late-preterm birth; born between 34 0/7 weeks and 36 6/7 weeks of gestation. 
g Low birth weight; birth weight less than 2.5kg. 
h Macrosomia; body weight greater than 4kg. 
i One baby from the active-group (GDM women) was born with cleft lip and palate. 
j Data are expressed as mean ± SD. The measurement for one baby from the active-group (GDM women) 
was not obtained.  
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Table 4.2. Mean (±SD) percent fatty acid composition of cord plasma choline 
phosphoglycerides at delivery. 
 
Fatty acids 
Healthy (n = 20) GDM (n = 85) 
Placebo group 
(n = 14) 
Active group 
(n = 6) 
Placebo group 
(n = 41) 
Active group 
(n = 44) 
14:0   0.3 ± 0.1  0.4 ± 0.2 0.3 ± 0.2  0.3 ± 0.1 
16:0   28.7 ± 2.1 29.0 ± 2.5 30.2 ± 2.2 30.3 ± 2.2 
18:0  13.5 ± 2.2 13.9 ± 1.2 13.3 ± 1.4 13.3 ± 1.9 
20:0  0.1 ± 0.01 0.03 ± 0.01 0.03 ± 0.02 0.04 ± 0.01 
22:0  0.1 ± 0.1 0.1 ± 0.04 0.1 ± 0.1 0.1 ± 0.1 
24:0  tr tr tr tr 
Σ Saturates 43.2 ± 1.9 44.1 ± 2.4 44.5 ± 2.5 44.6 ± 2.3 
16:1n-7  0.8 ± 0.2 0.7 ± 0.2 0.9 ± 0.3 0.9 ± 0.4 
18:1n-7  2.7 ± 0.5 2.7 ± 0.4 2.7 ± 0.4 2.7 ± 0.5 
18:1n-9  8.4 ± 1.5 8.9 ± 1.5 9.0 ± 1.6 9.2 ± 1.7 
24:1n-9  0.05 ± 0.03 0.04 ± 0.01 0.05 ± 0.04 0.05 ± 0.04 
Σ Monoenes 11.8 ± 1.8 12.4 ± 1.5 12.7 ± 1.7 12.9 ± 2.2 
18:2n-6  8.7 ± 2.0 10.1 ± 2.4 10.0 ± 3.1 10.5 ± 3.0 
18:3n-6  0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
20:2n-6  0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.3 
20:3n-6  5.5 ± 1.0 4.6 ± 1.4 5.1 ± 1.3 5.3 ± 1.2 
20:4n-6  20.3 ± 2.5 17.4 ± 2.2 18.1 ± 3.2 16.8 ± 3.1×× 
22:4n-6  0.6 ± 0.1 0.6 ± 0.2 0.6 ± 0.2 0.5 ± 0.1 
22:5n-6  0.8 ± 0.3 0.6 ± 0.4 0.7 ± 0.3 0.6 ± 0.3 
Σ n-6 36.3 ± 2.6 33.7 ± 3.9 34.9 ± 3.3 34.2 ± 3.3 
18:3n-3  0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
20:5n-3  0.4 ± 0.3 0.8 ± 0.7 0.5 ± 0.4 0.5 ± 0.3 
22:5n-3  0.5 ± 0.2 0.8 ± 0.4 0.5 ± 0.2 0.4 ± 0.2 
22:6n-3  6.5 ± 1.9 7.4 ± 2.7 5.4 ± 1.6 5.8 ± 1.7 
Σ n-3 7.6 ± 2.2 9.4 ± 3.3=∞ 6.6 ± 1.9 6.9 ± 1.9 
 
tr - trace 
Healthy placebo versus GDM active group: ×P < 0.05, ××P < 0.01 
Healthy active versus GDM placebo group: =P < 0.05 
Healthy active versus GDM active group: ∞P < 0.05 
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Table 4.3. Mean (±SD) percent fatty acid composition of cord plasma cholesterol 
esters at delivery. 
 
Fatty acids 
Healthy (n = 20) GDM (n = 85) 
Placebo group  
(n = 14) 
Active group 
(n = 6) 
Placebo group 
(n = 41) 
Active group 
(n = 44) 
14:0   0.2 ± 0.1 0.5 ± 0.3  0.3 ± 0.2 0.3 ± 0.3  
16:0   14.6 ± 2.6 17.1 ± 2.8 16.7 ± 2.7 16.0 ± 2.6 
18:0  2.2 ± 0.6 2.6 ± 0.9 2.7 ± 0.9 3.0 ± 0.9 
20:0  0.04 ± 0.01 0.04 ± 0.02 0.03 ± 0.02 0.03 ± 0.03 
22:0  0.1 ± 0.02 0.1 ± 0.04 0.1 ± 0.04 0.1 ± 0.04 
24:0  tr tr tr tr 
Σ Saturates 18.5 ± 3.3 23.0 ± 4.1 21.3 ± 3.5 21.1 ± 3.6 
16:1n-7  4.3 ± 1.3 5.2 ± 1.8 5.7 ± 1.7 5.6 ± 2.0 
18:1n-7  3.6 ± 0.6 3.6 ± 0.7 3.4 ± 0.6 3.4 ± 0.8 
18:1n-9  27.1 ± 2.3 24.9 ± 3.4 28.5 ± 3.9 29.2 ± 5.5 
24:1n-9  0.3 ± 0.2 0.3 ± 0.3 0.2 ± 0.1 0.3 ± 0.2 
Σ Monoenes 35.2 ± 3.0 34.1 ± 2.6 37.9 ± 4.8 38.6 ± 7.3 
18:2n-6  23.6 ± 8.4 21.5 ± 2.8 21.7 ± 6.6 22.3 ± 8.6 
18:3n-6  0.7 ± 0.2 0.6 ± 0.2 0.8 ± 0.2 0.9 ± 0.5 
20:2n-6  0.1 ± 0.01 0.04 ± 0.01 0.1 ± 0.1 0.1 ± 0.05 
20:3n-6  1.7 ± 0.5 1.5 ± 0.2 1.4 ± 0.4 1.4 ± 0.4 
20:4n-6  16.4 ± 4.2 14.7 ± 1.4 13.3 ± 3.4 11.8 ± 3.5×× 
22:4n-6  0.1 ± 0.02 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
22:5n-6  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 
Σ n-6 42.9 ± 5.4 38.6 ± 3.3 37.6 ± 6.1 36.9 ± 9.0 
18:3n-3  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 0.2 ± 0.2 
20:5n-3  0.4 ± 0.3 0.7 ± 0.8 0.4 ± 0.3 0.3 ± 0.2 
22:5n-3  0.1 ± 0.02 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
22:6n-3  1.3 ± 0.6 1.7 ± 0.9∞ 1.1 ± 0.4 1.0 ± 0.6 
Σ n-3 2.0 ± 0.9 2.9 ± 1.5∞ 1.9 ± 0.8 1.7 ± 0.9 
 
tr - trace 
Healthy placebo versus GDM active group: ×P < 0.05, ××P < 0.01 
Healthy active versus GDM active group: ∞P < 0.05 
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Table 4.4. Mean (±SD) percent fatty acid composition of cord plasma 
triglycerides at delivery. 
 
Fatty acids 
Healthy (n = 20) GDM (n = 85) 
Placebo group 
(n = 14) 
Active group 
(n = 6) 
Placebo group 
(n = 41) 
Active group 
(n = 44) 
14:0   0.8 ± 0.3  0.6 ± 0.5 0.7 ± 0.5 0.7 ± 0.4 
16:0   25.1 ± 1.8 20.5 ± 5.8 24.4 ± 4.2 24.8 ± 3.4 
18:0  3.8 ± 0.7 5.2 ± 1.4 5.1 ± 2.7 4.7 ± 1.3 
20:0  0.1 ± 0.1 0.1 ± 0.02 0.1 ± 0.1 0.1 ± 0.2 
22:0  0.1 ± 0.1 0.3 ± 0.4 0.1 ± 0.1 0.1 ± 0.1 
24:0  tr tr tr tr 
Σ Saturates 31.0 ± 1.8 28.7 ± 6.4 31.6 ± 5.5 31.5 ± 3.8 
16:1n-7  4.5 ± 1.6 3.3 ± 1.4 4.6 ± 1.5 4.2 ± 1.5 
18:1n-7  3.5 ± 0.7 3.9 ± 1.2 4.0 ± 0.8 3.8 ± 0.9 
18:1n-9  32.8 ± 4.9 29.0 ± 4.7 32.5 ± 3.9 33.0 ± 4.6 
24:1n-9  0.03 ± 0.02 0.1 ± 0.2 0.05 ± 0.1 0.1 ± 0.1 
Σ Monoenes 40.9 ± 4.9 36.5 ± 3.7 41.4 ± 4.0 41.3 ± 5.1 
18:2n-6  13.1 ± 1.5 17.0 ± 3.8 13.2 ± 3.2 14.0 ± 4.5 
18:3n-6  0.5 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.4 ± 0.2 
20:2n-6  0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.5 0.3 ± 0.1 
20:3n-6  1.0 ± 0.3 1.0 ± 0.4 0.8 ± 0.3 0.8 ± 0.3 
20:4n-6  4.3 ± 1.5 4.9 ± 2.4 3.9 ± 1.8 3.3 ± 1.4 
22:4n-6  0.9 ± 0.3 0.7 ± 0.4 0.7 ± 0.3 0.5 ± 0.2× 
22:5n-6  1.2 ± 0.6 1.3 ± 1.1 1.2 ± 0.7 1.0 ± 0.5 
Σ n-6 21.4 ± 3.1 26.1 ± 6.3 20.8 ± 4.9 20.4 ± 4.6 
18:3n-3  0.6 ± 0.3 0.7 ± 0.5 0.6 ± 0.4 0.6 ± 0.3 
20:5n-3  0.3 ± 0.3 0.7 ± 0.5= 0.3 ± 0.2 0.4 ± 0.3 
22:5n-3  0.6 ± 0.4 0.9 ± 0.6 0.4 ± 0.2 0.4 ± 0.3 
22:6n-3  3.2 ± 1.9 4.5 ± 2.4 2.9 ± 1.4 3.3 ± 1.8 
Σ n-3 5.5 ± 2.7 7.6 ± 3.4 5.1 ± 1.7 5.6 ± 2.4 
 
tr - trace 
Healthy placebo versus GDM active group: ×P < 0.05 
Healthy active versus GDM placebo group: =P < 0.05 
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4.5  Discussion and conclusion 
 Although not statistically significant, this study indicates that the plasma n-3 
and n-6 LCPUFAs in neonates may be adversely affected by gestational diabetes. A 
trend of reduced levels of DHA and AA were consistently observed in the cord plasma 
(CPG, CE and TG) of the GDM women who were supplemented with placebo 
compared with their healthy counterparts who received the placebo. These findings are 
consistent with previous report showing reduced levels of the two fatty acids in foetal 
plasma phospholipids and neutral lipids (Min et al. 2005a; Thomas et al. 2005).  
 Moreover, in this study, the women with GDM, who were supplemented with 
the placebo, had relatively equivalent DHA and AA compared with their healthy 
counterparts who received the placebo (discussed in Chapter 3). To support this, there 
is evidence to indicate that DHA and AA levels are elevated or relatively equivalent to 
their control groups in plasma phospholipids (Ghebremeskel et al. 1998; Wijendran et 
al. 1999; Min et al; 2004; Thomas et al. 2004; Min et al. 2005a; Min et a. 2006) and 
neutral lipids (Thomas et al. 2004; Min et al. 2005a; Min et al. 2006) of gestational 
diabetic women. The reduction in DHA and AA in neonatal cord plasma of the 
gestational diabetic women was intriguing since the nutrients are preferentially 
transferred from the expectant mother to her foetus (Crawford 2000b; Vriese et al. 
2002; Gil-Sanchez et al. 2010). 
 The influx of n-3 and n-6 fatty acids from mother to the foetus is dependent on 
maternal status and placental efficiency. It is reported that dietary linoleic acid 
correlates with plasma or serum triglyceride linoleic acid concentrations (Moore et al. 
1977). In our study, the plasma triglyceride linoleic acid concentration was 
significantly higher in GDM placebo women than healthy placebo women (P < 0.01). 
This might be a reflection of a high intake of linoleic acid by the GDM placebo group. 
On the other hand, however, the AA and DHA levels in neonates of the GMD placebo 
group were lower than in the neonates of healthy placebo group. Hence, it appears that, 
in spite of enhanced maternal LA status, the reduced levels of AA and DHA in the 
neonates of the gestational diabetic women could be a reflection of the impaired 
placental transfer. However, the evaluation of dietary data of these two groups could 
have been helpful to explain this point.  
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 The uptake of LCPUFAs by the placenta is thought to be mediated by 
membrane bound cytosolic fatty acid binding proteins (FABPs) (Dutta-Roy 2000), and 
the rate of flux is primarily dependent on the abundance of the available binding sites 
(Haggarty 2002). It is conceivable that gestational diabetes may have an adverse effect 
on the binding capacity of FABPs. It is postulated that placental FABP polymorphisms 
may affect the processes involved in the selective transfer of LCPUFAs (Haggarty 
2002). The other possibility is that the two fatty acids may be taken up by the placenta 
and retained instead of being transferred to the foetus. A study showing enhanced 
levels of AA and DHA in the placenta of gestational diabetic women (Bitsanis et al. 
2004) seems to favour this proposition.  
 The data from the present study indicate that neonates born to the gestational 
diabetic women had a relative insufficiency of plasma DHA and AA, which are 
essential structural components of neuro, vascular and visual systems. This finding is 
significant since experimental and epidemiological evidence exhibits that intra uterine 
nutritional constraint is associated with impaired postnatal development and increased 
risk of chronic diseases in adulthood. It has been shown that a three-fold increase in 
DHA and AA occurs in human cerebrum and cerebellum during the third trimester. 
The lower levels of AA and DHA were found in neonates of low birth weight, small 
head circumference (Leaf et al. 1992b) and those who suffered from intrauterine 
growth restriction (Vilbergsson 1994). It has been shown that a higher intake of n-3 
fatty acids during pregnancy is associated with gestational length and cerebral 
maturation in the new-born (Helland et al. 2001). A positive effect of n-3 fatty acid 
particularly DHA, has been recognized in insulin sensitivity (Borkman et al. 1993; 
Storlien et al. 1996; Clore et al. 2000), obesity (Von Kries et al. 1999) and high blood 
pressure (Forsyth et al. 2003).  
 It has been found consistently that maternal supplementation with high DHA 
during normal pregnancy results in enhanced DHA status in neonates (Adriana et al. 
1995; Dunstan et al. 2004; Susanne et al. 2007). Recently, a report was published 
showing enrichment of cord blood DHA induced by maternal supplementation in 
pregnancy complicated by type II diabetes (Min et al. 2014). In current study, 
however, the neonates of the DHA-supplemented GDM women did not show the 
increased level of the nutrient. The exact reason behind this interesting finding is not 
clear since type II diabetes and GDM share many similar metabolic features and both 
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groups of women were supplemented daily with 600mg of DHA. However, impaired 
placental uptake (Araujo et al. 2013; Pagan et al. 2013), materno-foetal transfer of 
DHA (Pagan et al. 2013) and significant placental abnormalities have been reported 
more in pregnancies complicated by GDM than in type I and type II diabetes (Salge et 
al. 2012). Also, it is imperative to note that outcome of the current study could have 
been affected by the shorter supplementation duration (median 10 weeks) as compared 
to the study mentioned earlier (Min et al. 2014) on pregnant women with type II 
diabetes who were supplemented for longer duration (median 26 weeks).  
 Increased intake of long chain omega-3 fatty acids during pregnancy resulted in 
reduced number of preterm births by prolonging gestation period (Olsen et al. 1992; 
Olsen and Secher 2002; Klebanoff et al. 2011; Carlson et al. 2013). Likewise, the same 
has been observed in a small number of pregnant women with type II diabetes (Min et 
al. 2014). To the contrary, though statistically insignificant, the number of preterm 
births in the present study was higher in the women of GDM active-group. To look for 
the possible rationale for this finding, past obstetric histories of the women who 
delivered prematurely were examined. 8 out of 12 GDM women in the active-
supplemented group and 4 out of 6 from GDM placebo-group who delivered 
prematurely had obstetric complications such as pregnancy induced hypertension, 
gestational diabetes and miscarriages in their previous pregnancies. Therefore, the 
number of preterm births encountered in the GDM women of both groups might be 
explained by the predisposition of these women to a recurrent preterm delivery and 
due to genetic-environmental factors or clinical/subclinical medical conditions rather 
than the effect of supplementation. 
 It is suggested that the supplementation of DHA during pre- and postnatal 
periods promotes adiposity in infants (Groh-Wargo et al. 2005; Lucia et al. 2007) and 
pre-school children (Donahue et al. 2011; Pedersen et al. 2012). We have evaluated 
whether a similar effect was present in our study using shoulder, mid-arm and 
abdomen circumference measurements as indirect indicators of adiposity. No 
difference was observed in the values of aforementioned parameters between the 
neonates born to the GDM active and placebo groups of mothers. This finding was not 
a surprise for us because the maternal supplementation did not improve foetal DHA 
status.  
  112 
 The current investigation, consistent with the previous studies mentioned-
above, shows an abnormal LCPUFAs status in the healthy new-born babies of 
gestational diabetic women. Due to the importance of these nutrients, this abnormality 
may have untoward effects on foetal growth and development as well as health of an 
individual in adulthood. There are studies available providing evidence of speech and 
reading impairments, developmental concerns, and lower IQ in babies of pre-
gestational and gestational diabetic women (Rizzo et al. 1991; Rizzo et al. 1995; 
Silverman et al. 1998; Ornoy et al. 2001). It has also been proved that intrauterine 
exposure to diabetes is a positive predictive factor for the development of insulin 
resistance and early onset type II diabetes in the offspring (Dabelea et al. 2000; 
Sobngwi et al. 2003). 
 This double-blinded, placebo-controlled, randomized study has demonstrated 
that DHA supplementation is effective in enhancing maternal DHA status of GDM 
women but not their foetal DHA status. The failure in improving the foetal DHA status 
by supplementation is of some concern because the babies born to GDM women are 
with a lower level of the nutrient. This condition is considered to be link with a risk of 
neuro-developmental deficits. It is plausible that supplementing the mother with more 
than 600mg of DHA may trickle down to the foetus and compensate the deficiency or 
an increased duration of maternal supplementation may improve the foetal DHA 
status. Nevertheless, we can allude that babies of gestational diabetic women, 
particularly those not sucking mother’s milk, similar to the babies born prematurely 
would benefit from formula-milk fortified with a higher level of DHA. 
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CHAPTER 5 
 
Role of dietary omega-3 polyunsaturated fatty acids (chiefly 
DHA) in the modulation of plasma antioxidant vitamins 
status in GDM women and their offspring------------(113-125) 
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5.1  Introduction 
Oxidative stress refers to a disturbance in the balance between the production 
of reactive oxygen species (ROS) and antioxidant defenses that may lead to the tissue 
injury (Halliwell 1997). Oxidative stress due to elevated reactive oxygen species 
(ROS) has been clearly linked to type II diabetes mellitus (Baynes 1991; West 2000). 
However, inadequate and inconsistent research data are available on the involvement 
of oxidative stress in GDM, a disease of similar pathophysiology. Some studies have 
revealed the occurrence of high production of oxygen free radicals, supporting the 
postulation that gestational diabetes is associated with increased oxidative stress 
(Cederberg et al. 2001; Damasceno et al. 2002; White et al. 2002). However, there are 
still some loopholes in understanding about oxidative stress during gestational diabetic 
pregnancy and its reflection on neonates. GDM carries numerous risks for offspring 
including the high incidence of teratogenicity, as a result of cellular damage caused by 
the activity of free radicals (Surapaneni 2007).  
  It has been reported that oxidative system is impaired owing to both 
overproduction of free radicals and/or a defect in the antioxidant defense (Peuchant et 
al. 2004). The increased production of reactive oxygen species (ROS) has been 
attributed to protein glycation (Gillery et al. 1988; Baynes 1991) and glucose auto-
oxidation in a hyperglycemic environment (Hunt et al. 1990). Impaired radical 
scavenger function has been attributed to the decreased activity of enzymatic and non-
enzymatic scavengers. A study demonstrated an increase in biomarkers of oxidative 
stress and impaired antioxidant defense in diabetic patients (West 2000). 
The biological effects of free radicals are normally controlled in vivo by a wide 
range of antioxidants, such as vitamin A, C and E, glutathione (GSH), and anti-oxidant 
enzymes, such as catalase, superoxide dismutase (SOD), GSH peroxidase, and GSH 
reductase. Vitamin E, the main liposoluble antioxidant in human beings, scavenges 
peroxyl-radicals produced during lipid peroxidation (Therond et al. 2000). Vitamin E 
can transfer its phenolic hydrogen to a peroxyl free radical of a peroxidized 
polyunsaturated fatty acid (PUFA), thereby breaking the radical chain reaction and 
preventing the peroxidation of PUFA in cellular and subcellular membrane 
phospholipids. Vitamin A also has the ability to react directly with reactive oxygen 
species (Livrea and Tesoriere 1998; Gutteridge and Halliwell 2000; Debier and 
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Larondelle 2005; Bettencourt 2010). It plays an important role in cellular function, 
development and maintenance of normal visual acuity (Maden 2000; Smith and 
Steinemann 2000). Carotenoids also have antioxidant activity. β-Carotene is reported 
to quench singlet molecular oxygen effectively (Krinsky 1989). 
Treatment with antioxidants may prevent or reverse abnormalities associated 
with diabetes and its complications. Several studies have shown that dietary 
supplements containing vitamins and/or minerals prevent or, at least, mitigate the 
organic deterioration caused by increased oxidative stress in diabetics (Guerra 2001; 
Ylonen et al. 2003). There is a general notion that omega-3 PUFA might deteriorate 
antioxidant capacity. Nonetheless, no consensus has been reached on this subject as 
shown in Table 5.1. It has been argued that excessive intake of omega-3 PUFA may 
affect antioxidant status and enhance the susceptibility to oxidative damage (Cho and 
Choi 1994; Allard et al. 1997; Wander and Du 2000; Yilmaz et al. 2002; Grundt et al. 
2003). Some investigators could not find any changes in the antioxidant status in 
humans and rats treated with omega-3 fatty acid-rich diet (Hansen et al. 1998; Ando et 
al. 1998; Nordoy et al. 1998). However, other researchers have demonstrated that 
treating diabetic patients (Kesavulu et al. 2002) or gestational diabetic rats and their 
offspring (Yessoufou et al. 2006) with omega-3 fatty acids significantly improves their 
antioxidant status. Owing to the effects of omega-3 LCPUFA stated above, we tested 
the hypothesis whether supplementation with dietary omega-3 is implicated in 
prevention and protection against free radical production or oxidative stress associated 
with lipid peroxidation in GDM.   
To our knowledge, no research study has directly investigated the role of DHA-
enriched supplementation on plasma antioxidant vitamins status in gestational diabetic 
women and their neonates. Therefore, it was thought worthwhile to undertake the 
current study to evaluate the antioxidant status of gestational diabetic women (who had 
enhanced LCPUFAs status due to DHA-enriched supplementation) and their new-
borns. Maternal and cord plasma α-tocopherol, retinol and β-carotene levels were 
estimated to evaluate the natural antioxidant status. 
 
 
  116 
Table 5.1. Effects of omega-3 fatty acids on antioxidant status as reported by 
various investigators (adapted from Yessoufou et al. 2006). 
 
Omega-3 PUFA level 
in the diet 
Species 
Antioxidant 
status 
References 
10% of diet (considered as 
excessive) 
Diabetic rats Decreased Cho and Choi 1994 
EPA: 2.5 g/day; DHA: 1.8 
g/day 
Healthy humans Decreased Wander and Du 2000 
6.26 g/day for 6 weeks Healthy humans Decreased Allard et al. 1997 
850–882 mg/day (EPA + 
DHA) for 1 year 
Patients with myocardial 
infarction 
Decreased Grundt et al. 2003 
Fish oil Diabetic rats Decreased Yilmaz et al. 2002 
4 g/day (n-3) PUFA for 5 
weeks 
Healthy humans Unchanged Hansen et al. 1998 
n-3 fatty acid-rich diet (fish 
oil) 
Rats Unchanged Ando et al. 1998 
4 g/day (DHA or EPA) Hyperlipidemic patients Unchanged Nordøy et al. 1998 
EPA: 1.08 g/day; DHA: 0.72 
g/day for 2 months 
Diabetic humans Improvement Kesavulu et al. 2002 
2.1% of diet Diabetic rats Improvement Yessoufou et al. 2006a 
400mL/day of energy drink 
(DHA 320mg, EPA 72mg, 
vit. E 6mg, vit. C 36mg vit. 
D 3µg) for 7 months 
Normal pregnant women 
and their infants 
Improvement Kajarabille et al. 2017 
 
5.2 Subjects and methods  
Subjects and methods are described in detail in Chapter 2. 
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5.3 Statistical analysis 
 The data are expressed as mean ± standard deviation (SD), median and inter-
quartile range (IQR) as appropriate.  
At baseline;   
• Independent samples t-test was run to explore the significant differences in plasma 
alpha-tocopherol levels between; (a) healthy pregnant and GDM women (b) GDM 
placebo- and GDM active group.  
• Mann Whitney U test was run to explore the significant differences in plasma 
retinol and beta-carotene levels between; (a) healthy pregnant and GDM women (b) 
GDM placebo- and GDM active group. 
At delivery;  
• Independent samples t-test was used to explore the significant differences in the 
maternal and cord plasma alpha-tocopherol levels between GDM-placebo and 
GDM-active treatment group.  
• Mann Whitney U test was used to explore the significant differences in the maternal 
and cord plasma retinol and beta-carotene levels between GDM-placebo and GDM-
active treatment group.  
Within-group baseline and delivery comparison, the maternal plasma alpha-
tocopherol, retinol and beta-carotene levels were compared using Wilcoxon Signed 
Ranks test. Statistical significance was assumed at P < 0.05 unless otherwise stated. 
All statistical analysis were carried out with IBM SPSS Statistics version 24 (IBM 
Corporation, USA). 
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5.4  Results 
The antioxidant data was obtained from 85 GDM (active-treatment group n = 
44 and placebo-group n = 41) and 13 healthy pregnant (baseline data) women. The 
antioxidant status of the subjects was evaluated by estimation of the plasma α-
tocopherol (vitamins E), retinol (vitamin A) and β-carotene levels.  
5.4.1  Maternal and neonatal plasma antioxidant vitamins levels  
5.4.1.1 Plasma α-tocopherol levels 
 At baseline, plasma α-tocopherol levels were comparable between healthy 
pregnant and GDM women (Figure 5.1). Maternal plasma α-tocopherol levels were 
comparable between GDM placebo and GDM active-treatment group, at baseline and 
delivery (P > 0.05). At delivery, no significant difference was found in cord plasma α-
tocopherol levels between GDM placebo and active-treatment groups. Plasma α-
tocopherol levels at baseline and delivery are presented in Table 5.2.  
 Within-group baseline and delivery comparison in plasma α-tocopherol 
revealed no significant changes in both GDM active-treatment and placebo groups (P 
> 0.05).  Table 5.5 shows plasma α-tocopherol levels compared within-group baseline 
and delivery. 
 
 
Table 5.2. Maternal and cord plasma α-tocopherol levels (Mean ± SD) at baseline 
and delivery.  
 
α-tocopherol (mg/dl) Baseline  Delivery-maternal Delivery-cord 
GDM placebo group (n = 41) 1.3 ± 0.3 1.3 ± 0.4 0.3 ± 0.1 
GDM active group (n = 44) 1.3 ± 0.4 1.4 ± 0.4 0.3 ± 0.1 
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5.4.1.2 Plasma retinol levels 
 Plasma retinol levels at baseline and delivery are presented in Table 5.3. At 
baseline, plasma retinol levels were comparable between healthy pregnant and GDM 
women (Figure 5.1), and between GDM placebo- and GDM active-treatment groups 
(P > 0.05). At delivery, no significant difference was found in plasma retinol levels of 
maternal (GDM placebo vs. active-treatment group) and cord blood (GDM placebo vs. 
active-treatment group).  
 Within-group baseline and delivery comparison, the plasma retinol levels 
were reduced significantly in GDM placebo (P < 0.001) and GDM active-treatment 
groups (P < 0.001). Table 5.5 presents within-group baseline and delivery comparison 
in plasma retinol levels. 
 
Table 5.3. Maternal and cord plasma retinol levels (Median (IQR)) at baseline 
and delivery.  
 
Retinol (µg/dl) Baseline  Delivery-maternal Delivery-cord 
GDM placebo 
group (n = 41) 
25.0 (8.4) 21.1 (6.6) 13.3 (6.3) 
GDM active group 
(n = 44) 
23.4 (7.5) 18.0 (6.5) 12.0 (5.7) 
Mann-Whitney U 426 451 454 
P - value 0.318 0.409 0.432 
 
 
5.4.1.3 Plasma β-carotene levels 
 At baseline, plasma β-carotene levels were comparable between healthy 
pregnant and GDM women (Figure 5.1), and between GDM placebo- and GDM 
active-treatment groups (P > 0.05). At delivery, no significant difference was found in 
plasma β-carotene levels of maternal (GDM placebo vs. active-treatment group) and 
  120 
cord blood (GDM placebo vs. active-treatment group). Table 5.4. shows plasma β-
carotene levels at baseline and delivery. 
 Within-group baseline and delivery comparison, a significant decrease in 
plasma β-carotene levels was seen in GDM active-treatment group (P < 0.01). GDM 
placebo group exhibited no significant changes in plasma β-carotene levels. Within-
group baseline and delivery comparison of plasma β-carotene levels are given in Table 
5.5.   
 
Table 5.4. Maternal and cord plasma β-carotene levels (Median (IQR)) at 
baseline and delivery.  
 
β-carotene (µg/dl) Baseline  Delivery-maternal Delivery-cord 
GDM placebo 
group (n = 41) 
18.9 (28.0) 16.1 (24.6) 1.1 (2.1) 
GDM active group 
(n = 44) 
14.5 (28.1) 11.1 (14.1) 1.0 (0.9) 
Mann-Whitney U 466 425 508 
P - value 0.649 0.241 0.946 
 
Table 5.5. Changes in plasma antioxidant vitamins level (Median (IQR)) between 
the baseline and delivery within GDM (placebo and active) groups. 
 
Maternal baseline vs. delivery α-tocopherol 
(mg/dl) 
Retinol 
(µg/dl) 
β-carotene 
(µg/dl) 
GDM placebo 
group (n = 41) 
Baseline 1.3 (0.4) 25.0 (8.4) 18.9 (28.0) 
Delivery-maternal 1.3 (0.6) 21.1 (6.6)*** 16.1 (24.6) 
GDM active 
group (n = 44) 
Baseline 1.3 (0.4) 23.4 (7.5) 14.5 (28.1) 
Delivery-maternal 1.4 (0.5) 18.0 (6.5) *** 11.1 (14.1) ** 
Maternal baseline versus delivery within the group: *P < 0.05, **P < 0.01, ***P < 0.001  
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Figure 5.1. A bar graph showing differences in plasma α-tocopherol (1.3 (0.4) vs. 1.3 
(0.3)), retinol (27.7 (8.8) vs. 24.2 (8.5)) and β-carotene (26.4 (50.5) vs. 14.8 (27.9)) 
levels between healthy pregnant (n = 13) and GDM women (n = 85), at baseline. The 
levels of the vitamins were comparable between the groups (P > 0.05). values are 
given as healthy pregnant vs. GDM women (median (IQR)). 
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5.5 Discussion and conclusion 
 There are few studies dealing with the status of vitamin A, E and β-carotene 
in maternal and cord blood of gestational diabetic women. The majority of these 
studies have controversial findings. Therefore, we evaluated the aforementioned 
vitamins status in maternal and cord plasma samples of gestational diabetic women. In 
addition, the role of omega-3 LCPUFA (essentially DHA and EPA) on natural 
antioxidant status in gestational diabetic mothers and their offspring was also 
investigated. 
 In the current study, plasma α-tocopherol (vitamin E) level was comparable 
between healthy pregnant and GDM women. Similar findings have been shown in 
other studies (Sobki et al. 2004; Dey et al. 2008). There have been conflicting reports 
on plasma vitamin E concentrations in GDM. Contrary to our findings, a few studies 
reported that plasma vitamin E level was significantly lower in gestational diabetic 
women (Peuchant et al. 2004; Grissa et al. 2007). Another study showed a slight 
reduction in the plasma vitamin E level in GDM women (Kharb 2000). Suhail et al. 
(Suhail et al. 2010) also found decreased serum vitamin E concentrations in GDM 
women compared to the control group. On the other hand, Bates et al. (Bates et al. 
1997), Resende et al. (Resende et al. 2014) and Santra et al. (Santra et al. 2003) had 
reported an increase in serum vitamin E in GDM women.   
 This unchanged vitamin E status in GDM women as found in our and some 
other studies seem to represent an adaptive response to high oxidative stress. This 
increase in oxidative stress in the diabetic state has also been reported earlier (Silvana 
et al. 2004). As alpha-tocopherol acts as a potent antioxidant, it is oxidized and 
transformed into a free radical (tocopherol), thus requiring a regeneration system 
which promotes the recovery of its antioxidant function. Hence, other antioxidants 
such as; vitamin C, reduced-glutathione and Coenzyme Q10 remove the free radical 
from the tocopherol molecule. Giannubilo et al. determined a significantly higher 
plasma level of coenzyme Q10 in late pregnancy in GDM women, compared to the 
control group. To elucidate this difference, the authors proposed that there is a 
compensatory mechanism/adoptive response in response to high oxidative stress linked 
with hyperglycaemia and insulin resistance in GDM women (Giannubilo et al. 2011). 
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 The unchanged vitamin E level may also be related to metabolic changes, 
which occur in the maternal body due to gestational diabetes. At the end of the 
pregnancy, there should be decreased insulin secretion, leading to a hormonal response 
that make the tissues dependent on insulin to metabolize lipids in place of 
carbohydrates, starting a process of lipolysis (Resende et al. 2014), which culminates 
in the increased release of free fatty acids in the circulation (Fulop et al. 2006). Since 
the primary means of storage of vitamin E in the body is the adipose tissue (Herrera 
and Barbas 2001), this vitamin can be influenced by increased lipolysis, leading 
diabetic women to present with enhanced vitamin E status.  
 We also found that plasma retinol (vitamin A) and β-carotene levels tended to 
be lower in GDM women (although statistically insignificant) compared to healthy 
pregnant women. Again, we came across some controversial reports in regard to the 
status of these micronutrients. Also, the data available about vitamin A and β-carotene 
levels in diabetes mellitus is very limited. However, our findings are in harmony with 
the earlier reports showing that retinol was significantly less in GDM women as 
compared to their control (Peuchant et al. 2004; Suhail et al. 2010; Hekmat et al. 
2014). Some others reported no change in vitamin A level in GDM women (Bates et 
al. 1997; Grissa et al. 2007). To the best of our knowledge, no study has yet been 
conducted to determine any differences in the plasma concentrations of β-carotene in 
GDM women. According to a study, a low β-carotene level was observed in type I 
diabetic women compared to the healthy controls (Azar et al. 2011). Furthermore, 
there are studies showing inverse association between obesity and vitamin A and β-
carotene concentrations (Andersen et al. 2006; Kimmons et al. 2006). The low levels 
with increase obesity may result from inadequate intake and/or alterations in the 
nutrient metabolism since the plasma concentrations of β-carotene correlates with the 
consumption of vegetables and fruits. In addition, low level of vitamin A and β-
carotene was found in obese pregnant women as compared to healthy pregnant women 
(Tomedi et al. 2013). Since obesity is a one of the known risk factors for GDM so one 
can speculate that the relative low vitamin A and β-carotene levels in GDM women as 
found in our study could be negatively associated with their high BMI.  
 In our study, GDM women who were supplemented with omega-3 enriched 
formula did not exhibit any significant difference in plasma vitamins E, A and β-
carotene levels when compared with their GDM counterparts who received the 
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placebo, at delivery. Similar results were found when cord plasma levels of these 
micronutrients were compared between the groups. There is no consensus among the 
researchers on the antioxidant effects of omega-3 PUFA supplementation. It has been 
reported that excessive intake of omega-3 PUFA may affect the antioxidant status by 
enhancing the susceptibility to oxidative damage (Allard et al. 1997; Wander and Du 
2000; Grundt et al. 2003). Whereas, some investigators could not establish any 
changes in the antioxidant status in humans supplemented with omega-3 PUFA rich 
diet (Hansen et al. 1998; Nordoy et al. 1998). Another study found that treating 
diabetic patients with omega-3 PUFA significantly improves their antioxidant status 
(Kesavulu et al. 2002). A recent study conducted in Spain showed improved 
antioxidant status among normal pregnant women and their infants after omega-3 
LCPUFA enriched supplementation (Kajarabille et al. 2017).  We are unaware of any 
study which evaluated the effect of omega-3 supplementation on the antioxidant status 
in GDM women. While looking into the conflicting results of the above studies, it was 
found that dose of omega-3 rich-formula and duration of supplementation were 
different in each study (Table 5.1). Since the antioxidant effects are linked with dose 
and the antioxidant defence status of the subjects (Shoji et al. 2009; Di Nunzio et al. 
2011; Hajjaji and Bougnoux 2013), particularly in conditions of increase oxidative 
stress and/or impaired antioxidant defence such as GDM, one can speculate that anti-
oxidant effects of omega-3 supplementation are likely to be dose and duration 
dependent.  
 Kesavulu et al. (2002) showed improved antioxidant status in non-insulin 
dependent type II diabetic patients. Although this study was restricted to type II 
diabetes, their findings would be expected to be applicable to gestational diabetes as 
both conditions share many common metabolic features. Although, there was a 
minimal difference in the duration of supplementation but the dose of omega-3 
LCPUFA used in the study was much higher (Table 5.1) as compared to our study. 
Another difference was that Kesavulu et al. evaluated the enzymatic antioxidant status 
(GPx, CAT, SOD) whereas, we determined the non-enzymatic antioxidant status 
(Vitamin A, E and β-carotene).  
 Kajarabille et al. (2017) conducted a more comprehensive study on the 
antioxidant effects of omega-3 LCPUFA among normal pregnant women and their 
infants. Nevertheless, the studies on the antioxidant effects of omega-3 LCPUFA 
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supplementation in the mother and their neonates are really scarce. Although this study 
was restricted to normal pregnant women, however, a noteworthy aspect to consider 
during pregnancy (Diaz-Castro et al. 2015) is the oxidative stress which is even more 
worse in GDM (Suhail et al. 2010) affecting both mother and their neonates. The 
omega-3 supplement formula used in the study was different from our study and 
included Vitamin E (much higher than in our formula), C and D (Table 5.1). In 
addition, 2/3 portions of fish per week were recommended to the pregnant and 
lactating women based on their dietary data evaluation. Moreover, the total duration of 
supplementation was around 7 months which was much shorter (median 10 weeks) in 
our study. The study evaluated both the enzymatic and non-enzymatic components of 
antioxidant defense system at recruitment, delivery, 2.5 months postpartum and at 4 
months postpartum between mothers and babies of both groups (supplemented group 
vs. control group). The findings of the study included that the levels of plasma Vitamin 
A, E and β-carotene were comparable between the maternal and cord plasma of both 
groups at delivery (in corroboration of our findings), however increased significantly 
at 2.5 months postpartum. These findinds further strengthen our speculation that the 
antioxidant effects of omega-3 PUFA are dependent on dose and supplementation 
duration.   
 In our study, the antioxidant status did not improve yet not deteriorate in 
GDM active-treatment group despite of the less dose and duration of omega-3 
LCPUFA supplementation. Another aspect to be taken into account is that antioxidant 
defence system includes non-enzymatic antioxidants (vitamins A and E, β-carotene) 
and antioxidant enzymes such as; superoxide dismutase (SOD), glutathione peroxidase 
(GSH-Px), and glutathione reductase (GSSG-Red) (Yessoufou and Moutairou 2011). 
However, this study only determined the non-enzymatic antioxidant status (vitamins 
A, E and β-carotene). In summary, we can allude that the moderate amounts of omega-
3 LCPUFA in dietary intake for longer duration could enhance the anti-oxidant status 
in GDM women and their neonates. Our study has provided a base for future studies 
which could evaluate the effects of omega-3 LCPUFAs on the antioxidant stautus in 
GDM women more comprehensively taking into account all the above-mentioned 
factors. 
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6.1 Introduction 
Overweight and obesity are recognised as major public health issues among all 
ages and populations in Western countries (Haslam and James 2005; Song et al. 2014; 
Liu et al. 2015). An up to 30 % prevalence of obesity is reported among pregnant 
women (Callaway et al. 2006; Huda et al. 2009). A number of adverse pregnancy 
outcomes such as gestational diabetes mellitus, gestational hypertension, foetal death, 
and lager for gestational age infants are linked to obesity during pregnancy (Driul et al. 
2008; Kongubol and Phupong 2011; Gaillard 2015; Starling et al. 2015). However, the 
mechanisms underlying these increased risks for pregnancy complications are 
incompletely understood.  
Increase body mass index (BMI) is associated with alterations in lipid 
metabolism and insulin resistance during pregnancy, which may cause increased 
circulating free fatty acids concentrations (Nelson et al. 2010).  High levels of 
saturated fatty acids, low levels of ω-3 PUFA and high ω-6/ ω-3 ratio have been found 
associated with high BMI, in adolescents and adults (Karlsson et al. 2006; Micallef et 
al. 2009). A previous study conducted in USA on 129 pregnant women categorised by 
their pre-pregnancy BMI showed that pre-pregnancy obesity is associated with lower 
concentrations of DHA and AA but not of EPA. This study, however, did not provide 
information about concentrations of other fatty acids (Tomedi et al. 2013). There is 
also limited data available comparing fatty acid profiles between normal weight, 
overweight and obese women during pregnancy. Also, we are unaware of any previous 
studies that have compared the maternal plasma fatty acid profile in GDM women of 
different weight categories. Therefore, we conducted this analysis to evaluate the 
difference in plasma fatty acid levels of GDM women categorised on the basis of their 
pre-pregnancy BMI.  
6.2 Subjects and Methods 
 Participants were classified as normal weight, overweight and obese if their 
BMI were ≤ 25.0kg/m2, 25.1-30.0 kg/m2 and >30.0 kg/m2, respectively. The details of 
subjects and methods are described in Chapter 2.  
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6.3  Statistical analysis 
 The data are expressed as mean ± standard deviation (SD), n (%) and median 
(range) as appropriate. Statistical significance was assumed at P < 0.05 unless 
otherwise stated. One-way analysis of variance (ANOVA) was used to compare the 
differences in demographic data and plasma fatty acid levels of GDM women 
belonging to different BMI categories. A pairwise comparison was performed using 
Tukey’s honest significant difference (HSD, for equal variance) and Games-Howell 
(for unequal variance) tests for each dependent variable separately when the F-ratio 
was significant (P < 0.05). All statistical analyses were carried out with IBM SPSS 
Statistics version 24 (IBM Corporation, USA).  
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6.4 Results 
6.4.1 Demographic characteristics of the participants 
Table 6.1 shows the demographic characteristics of normal weight compared to 
overweight and obese GDM women. The obese GDM women tended to be older and 
of high parity, as compared to normal weight women. The education levels did not 
differ between the groups.  
The majority of the subjects were of asian (around 60.6%) and African/Afro-Caribbean 
(24.6%) origin. However, the African/Afro-Caribbean origin women dominated in 
obese group (43.1%).  
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Table 6.1.  Demographic characteristics of the participants. 
Maternal characteristics Normal weight (≤ 25.0 kg/m2) 
Over weight 
(25.1-30.0) Obese (> 30.0)  
Number of participants (n) 44 47 51 
Gestation at recruitment (weeks)a 26.5 (17.0-32.0) 28.0 (17.0-34.0) 28 (17-32) 
Age (years)a 30.0 (20-43) 32.0 (19-44) 32 (23-43) 
Height (m)b 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 
Pre-pregnancy weight (kg)b 57.4 ± 7.1*** 71.4 ± 7.9=== 89.3 ± 10.3+++ 
Pre-pregnancy BMI (kg/m2)b 23.2 ± 2.2*** 28.1 ± 1.5=== 35.3 ± 3.4+++ 
Education (n)c 
Higher education 14 (31.8) 19 (40.2) 18 (35.3) 
GCSE 15 (34.1) 8 (17.0) 13 (25.5) 
A-level 5 (11.4) 9 (19.1) 3 (5.9) 
None  5 (11.4) 5 (10.6) 9 (17.6) 
Unknown  5 (11.4) 6 (12.8) 8 (15.7) 
Racial Origin (n)c, d 
Asian 36 (81.8) 31 (66.0) 19 (37.3) 
African/Afro-Caribbean 3 (6.8) 10 (21.3) 22 (43.1) 
Caucasian 2 (4.5) 3 (6.4) 7 (13.7) 
Others 3 (6.8) 3 (6.4) 3 (5.9) 
Parity (n)c 
0 22 (50.0) 15 (31.9) 18 (35.3) 
1-2 18 (40.9) 23 (48.9) 17 (33.3) 
≥ 3 4 (9.1) 9 (19.1) 16 (31.4) 
Folic acid use (n)c 26 (59.1) 26 (55.3) 29 (56.9) 
Smoker (n)c 0 (0.0) 1 (2.1) 1 (2.0) 
Glucose tolerance test 
Gestation (weeks)a 18.0 (15-29) 22.0 (12-31) 20.0 (13-31) 
Glucose at 0 min (mmol)b 5.4±1.3 5.4±1.3 5.9±1.8 
Glucose at 120 min (mmol)b 9.1±1.8 9.5±1.9 9.3±1.9 
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a Data are expressed as median (mininum - maximum) 
b Data are expressed as mean ± SD 
c Data are expressed as number of subjects (%) 
d We classified individuals according to the UK Home Office’s classification for an individual’s 
ethnicity which is based on person’s self-defination (African/Afro-Caribbean: Afro-Caribbean, Black 
African, Black British, Caribbean; Asian: Bangladesh, Bengali, Indian, Pakistani, Sri Lankan; 
Caucasian: English, European, Irish, Polish; Others: Arab, Filipino, Latin American, North African, 
mixed race).  
Normal weight versus overweight group: *P < 0.05, **P < 0.01, ***P < 0.001 
Normal weight versus obese group: +P < 0.05, ++P < 0.01, +++P < 0.001 
Overweight versus obese group: =P < 0.05, ==P < 0.01, ===P < 0.001 
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6.4.2 Plasma fatty acid composition in GDM women 
 This result reports plasma choline phosphoglycerides, cholesterol esters, and 
triglycerides fatty acids of the GDM women catagorised on the basis of their pre-
pregnancy BMI ≤ 25.0 (n = 44), 25.1-30.0 (n = 47) and > 30.0 (n = 51). Also, Plasma 
DHA and AA levels of the three groups are presented in graphical form (Figure 6.1, 
6.2, 6.3). 
 
6.4.2.1 In plasma CPG: Fatty acid composition of plasma CPG is given in Table 6.2. 
20:4n-6 (AA) level was higher in over-weight (P < 0.05) and obese groups (P < 0.01) 
compared to normal-weight group. There was an increase in Σ n-6 fatty acids in over-
weight group when compared to normal-weight group (P < 0.05). 18:3n-3 (α-linolenic 
acid) was decreased in both obese and over-weight groups than normal-weight group 
(P < 0.05). Total saturated and monounsaturated fatty acid levels were not different 
between the groups (all P values > 0.05).  
6.4.2.2 In plasma CE: Similar to the CPG composition, 20:4n-6 (AA) level was 
higher in over-weight (P < 0.05) and obese groups (P < 0.01) compared to normal-
weight group. 18:3n-3 (α-linolenic acid) was decreased in both obese and over-weight 
groups than normal-weight group (P < 0.05). Total saturated and monounsaturated 
fatty acid levels were not different between the groups (all P values > 0.05). Fatty acid 
composition of plasma CE is given in Table 6.3. 
6.4.2.3 In plasma TG: 14:0 (myristic acid; P < 0.05) level was lower in over-weight 
and obese groups compared to normal-weight group. There was also a decrease in 
16:1n-7 (palmitoleic acid) in over-weight group when compared to normal-weight 
group (P < 0.05). The level of 18:3n-3 (α-linolenic acid) was decreased in obese group 
than normal-weight group (P < 0.05). Fatty acid composition of plasma TG is given in 
Table 6.4.  
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Table 6.2. Mean (±SD) percent fatty acid composition of plasma choline 
phosphoglycerides in GDM women. 
Fatty acids Normal weight (n = 44) Over weight (n = 47) Obese (n = 51) 
14:0  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
16:0  30.3 ± 3.8 29.9 ± 2.9 30.3 ± 3.3 
18:0  9.8 ± 1.2 10.2 ± 1.4 10.4 ± 1.2 
20:0  0.04 ± 0.04 0.03 ± 0.02 0.03 ± 0.01 
22:0  0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
24:0  0.1 ± 0.03 0.1 ± 0.02 0.1 ± 0.02 
Σ Saturates 41.2 ± 3.8 41.2 ± 2.1 41.7 ± 2.5 
16:1n-7  0.5 ± 0.3 0.4 ± 0.2 0.4 ± 0.2 
18:1n-7  1.4 ± 0.5 1.3 ± 0.3 1.4 ± 0.2 
18:1n-9  9.8 ± 4.1 9.1 ± 1.8 9.4 ± 1.8 
24:1n-9  0.05 ± 0.02 0.04 ± 0.02 0.05 ± 0.03 
Σ Monoenes 12.0 ± 4.8 11.0 ± 2.0 11.5 ± 2.1 
18:2n-6  24.9 ± 3.7 25.4 ± 2.9 24.2 ± 3.0 
18:3n-6  0.1 ± 0.1 0.1 ± 0.04 0.1 ± 0.03 
20:2n-6  0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
20:3n-6  3.5 ± 0.8 3.7 ± 1.0 3.6 ± 0.9 
20:4n-6  9.8 ± 2.1 10.9 ± 1.9* 11.1 ± 1.9++ 
22:4n-6  0.3 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 
22:5n-6  0.5 ± 0.5 0.4 ± 0.2 0.4 ± 0.2 
Σ n-6 39.5 ± 3.6 41.3 ± 3.2* 40.1 ± 3.2 
18:3n-3  0.4 ± 0.2 0.3 ± 0.1* 0.3 ± 0.1+ 
20:5n-3  0.8 ± 0.7 0.6 ± 0.5 0.7 ± 0.7 
22:5n-3  0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 
22:6n-3  4.6 ± 1.1 4.1 ± 1.0 4.4 ± 1.1 
Σ n-3 6.5 ± 1.7 5.7 ± 1.5 6.0 ± 1.8 
Normal weight versus overweight group: *P < 0.05 
Normal weight versus obese group: +P < 0.05, ++P < 0.01 
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Table 6.3. Mean (±SD) percent fatty acid composition of plasma cholesterol esters 
in GDM women. 
Fatty acids Normal weight (n = 44) Over weight (n = 47) Obese (n = 51) 
14:0  0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 
16:0  9.6 ± 1.8 9.2 ± 1.9 9.8 ± 1.6 
18:0  0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
20:0  0.05 ± 0.03 0.04 ± 0.02 0.04 ± 0.02 
22:0  0.03 ± 0.02 0.02 ± 0.02 0.03 ± 0.02 
24:0  tr tr tr 
Σ Saturates 12.7 ± 3.3 11.3 ± 2.9 12.3 ± 3.1 
16:1n-7  1.9 ± 1.3 1.4 ± 0.8 1.5 ± 0.8 
18:1n-7  1.1 ± 0.3 1.0 ± 0.2 1.1 ± 0.2 
18:1n-9   15.8 ± 3.2 15.3 ± 2.3 16.2 ± 2.8 
24:1n-9  0.6 ± 0.4 0.8 ± 0.3 0.7 ± 0.4 
Σ Monoenes 19.4 ± 4.1 18.5 ± 2.8 19.5 ± 3.3 
18:2n-6  55.4 ± 5.8 56.8 ± 5.3 54.7 ± 4.9 
18:3n-6  0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 
20:2n-6  0.1 ± 0.02 0.1 ± 0.02 0.05 ± 0.02 
20:3n-6  0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.3 
20:4n-6  7.9 ± 1.9 8.9 ± 2.0* 9.2 ± 2.0++ 
22:4n-6  0.1 ± 0.1 0.05 ± 0.03 0.04 ± 0.02 
22:5n-6  0.1 ± 0.1 0.1 ± 0.04 0.1 ± 0.1 
Σ n-6 64.9 ± 5.8 67.3 ± 5.3 65.4 ± 4.9 
18:3n-3  0.8 ± 0.3 0.6 ± 0.3* 0.6 ± 0.3+ 
20:5n-3  0.8 ± 0.6 0.6 ± 0.6 0.7 ± 0.7 
22:5n-3  0.1 ± 0.02 0.1 ± 0.1 0.1 ± 0.03 
22:6n-3  0.9 ± 0.3 0.9 ± 0.2 0.9 ± 0.3 
Σ n-3 2.6 ± 0.9 2.3 ± 0.8 2.4 ± 1.0 
Normal weight versus overweight group: *P < 0.05 
Normal weight versus obese group: +P < 0.05, ++P < 0.01 
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Table 6.4. Mean (±SD) percent fatty acid composition of plasma triglycerides in 
GDM women.  
Fatty acids Normal weight (n = 44) Over weight (n = 47) Obese (n = 51) 
14:0  1.4 ± 0.7 1.1 ± 0.7* 1.1 ± 0.6+ 
16:0  27.0 ± 4.3 26.0 ± 3.7 26.8 ± 3.9 
18:0  2.8 ± 0.5 3.0 ± 0.7 3.1 ± 0.5 
20:0  0.1 ± 0.1  0.1 ± 0.04 0.1 ± 0.02 
22:0  0.04 ± 0.02 0.04 ± 0.03 0.05 ± 0.03 
24:0  tr tr tr 
Σ Saturates 32.7 ± 4.9 31.3 ± 4.4 32.3 ± 4.7 
16:1n-7  2.2 ± 0.9 1.8 ± 0.7* 1.9 ± 0.9 
18:1n-7  2.1 ± 0.5 2.1 ± 0.4 2.2 ± 0.4 
18:1n-9   32.4 ± 5.0 34.0 ± 4.9 34.0 ± 4.9 
24:1n-9  0.03 ± 0.02 0.03 ± 0.02 0.03 ± 0.02 
Σ Monoenes 37.2 ± 5.3 38.2 ± 5.2 38.5 ± 5.2 
18:2n-6  23.3 ± 6.1 23.9 ± 5.9 22.8 ± 5.3 
18:3n-6  0.3 ± 0.1 0.3 ± 0.2 0.3 ± 0.1 
20:2n-6  0.3 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 
20:3n-6  0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
20:4n-6  1.3 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 
22:4n-6  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
22:5n-6  0.3 ± 0.1 0.3 ± 0.2 0.2 ± 0.1 
Σ n-6 26.1 ± 6.4 26.9 ± 6.3 25.7 ± 5.7 
18:3n-3  1.5 ± 0.6 1.2 ± 0.6 1.2 ± 0.5+ 
20:5n-3  0.2 ± 0.2 0.2 ± 0.1 0.2 ± 0.3 
22:5n-3  0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
22:6n-3  1.0 ± 0.5 0.8 ± 0.5 0.9 ± 0.7 
Σ n-3 3.2 ± 1.0 2.6 ± 1.1 2.7 ± 1.3 
Normal weight versus overweight group: *P < 0.05 
Normal weight versus obese group: +P < 0.05 
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Figure 6.1. A bar graph showing AA and DHA levels in plasma CPG of GDM women 
belonging to different pre-pregnancy BMI categories. AA (20:4n-6) levels were higher 
in over-weight (P < 0.05) and obese (P < 0.01) GDM women compared to normal-
weight GDM women. DHA (22:6n-3) levels were comparable between the three 
categories. 
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Figure 6.2. A bar graph showing AA and DHA levels in plasma CE of GDM women 
belonging to different pre-pregnancy BMI categories. AA (20:4n-6) levels were higher 
in over-weight (P < 0.05) and obese (P < 0.01) GDM women compared to their 
normal-weight counterparts. DHA (22:6n-3) levels were comparable between the three 
categories.  
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Figure 6.3. A bar graph presenting AA and DHA levels in plasma TG of GDM 
women categorised on the basis of their pre-pregnancy BMI. Although not 
significantly (P > 0.05), AA (20:4n-6) levels were high in both over-weight and obese 
GDM women compared to the GDM women of normal-weight. DHA (22:6n-3) levels 
were comparable between the three categories. 
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6.5 Discussion 
 Most of the GDM women who participated in this study were of Asian 
(approximately 60%) and African/Afro-Caribbean (approximately 25%) origin, 
however, African/Afro-Caribbean GDM women dominated the obese group (43.1%). 
In a study, African/Afro-Caribbean women were found more likely to be obese when 
compared to South Asian and European women, though reasons for high rates of 
obesity in this group remain to be established (Pomerleau et al. 1999). Though the 
sample size of the present study was small, however, this disproportionate 
representation of African/Afro-Caribbean women in high BMI category might have 
placed them at increased risk of developing GDM. In fact, a recent study showed that 
the African-American pregnant women had the greatest increased risk of GDM 
(>76%) as compared to Latinas (58%), Caucasians (46%) and Asians (25%) (Shah et 
al. 2011). It will also be reasonable to suggest that more extensive and focused studies 
need to be carried out to explore further this association. 
Overweight and obesity during pregnancy are associated with adverse maternal 
and neonatal outcomes (Huda et al. 2010; Gaillard et al. 2014). Various studies have 
reported that high pre-pregnancy BMI is associated with increased risks of GDM, 
neonatal mortality, and obesity in children (Kongubol and Phupong 2011; Johansson et 
al 2014; Starling et al. 2015). Previous studies found that obesity is associated with 
alterations in fatty acid levels. A study conducted in Australia among 124 adults 
showed that the levels of ω-3 PUFA were lower in obese subjects (Micallef et al. 
2009). A systematic review based on 21 studies found that overweight or obese adults 
had lower levels of ω-6 PUFAs (Fekete et al. 2015). Very few studies have evaluated 
the associations of BMI with fatty acid levels among pregnant women. The study 
among 129 pregnant women in USA showed that obese pregnant women had lower 
DHA and AA concentrations as compared to lean pregnant women (Tomedi et al. 
2013). Another study shows high level of AA in obese pregnant women (Scifres et al. 
2014). Another population based cohort study showed that obese pregnant women had 
higher AA, total ω-6 PUFA and lower LA concentrations. All ω-3 PUFA 
concentrations tended to be low in obese pregnant women, particularly α-linolenic 
acid. In SFAs, 14:0 (myristic acid) was low in obese pregnant women, whereas in 
MUFAs, obese women had high palmitoleic acid concentrations (Vidakovic et al. 
2015). In line with the above-mentioned results, we found that higher BMI was 
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associated with higher total ω-6 PUFA levels in GDM women. Obese GDM women 
had higher AA level. All ω-3 PUFA levels tended to be lower among over-weight and 
obese GDM women, particularly α-linolenic acid. In SFAs, over-weight and obese 
GDM women had lower 14:0 (myristic acid) levels, whereas in MUFAs, over-weight 
GDM women had lower 16:1n-7 (palmitoleic acid) concentrations.  
From the current study, it is difficult to establish whether BMI causes adverse 
fatty acids profile, or whether the direction of this association is other way around. It 
has been shown that higher ω-6 PUFA levels lead to higher adipose tissue 
development by promoting pre-adipocyte differentiation and that high ω-3 PUFA 
levels suppresses development of obesity by reducing adipose tissue mass (Buckley 
and Howe 2009; Muhlhausler and Ailhaud 2013). In the other direction, obesity causes 
alterations in adipose tissue metabolic and endocrine function leading to an increased 
release of fatty acids, thus affecting subsequent adiposity and finally creating a vicious 
cycle (Kishino et al. 2008). Further experimental studies are needed to explore the 
underlying mechanism.  
We conclude that higher pre-pregnancy BMI is associated with higher ω-6 
PUFA and lower ω-3 PUFA levels in GDM women. However, we took blood sample 
once at the time of recruitment (median 28 weeks) and analysed on the basis of pre-
pregnancy BMI which could have changed over the course of pregnancy. The timing 
of these measurements makes it difficult for us to draw conclusions about the direction 
of any association. Studies with longitudinal measurements of both BMI and fatty acid 
levels before and during gestation may help to clarify the direction of these 
association.   
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7.1 Overview 
 The impacts of gestational diabetes mellitus (GDM) on the short and long-
term health of women and their offspring are increasingly recognized. In Europe, the 
estimated prevalence of GDM ranges from 2 to 6% and it is expected to rise with 
increasing obesity, a strong risk factor for developing the condition. Our research 
group had previously reported that the levels of docosahexaenoic acid (DHA) and 
arachidonic acid (AA) are reduced in maternal red blood cell, and foetal red blood cell 
and plasma phospholipids. DHA and AA are highly unsaturated fatty acids of the 
omega-3 and omega-6 family, respectively. They are vital structural and functional 
components of cellular and sub-cellular membranes as well as precursors of diverse 
bioactive compounds.  
 The importance of DHA and AA in foetal life has been extensively 
documented. Of these two fatty acids, DHA is considered to be the most limiting 
nutrient in pregnancy and lactation because it is scarce or absent in land animal and 
plant food sources. Moreover, its synthesis from the parent compound -linolenic acid is 
inefficient. In normal pregnancy, DHA is preferentially transferred by placental 
selection from maternal to foetal circulation. However, recent studies have reported 
that placental uptake and transfer of DHA is impaired in pregnancy complicated by 
GDM.  
 One of the earliest abnormalities observed in diabetes is the involvement of 
oxidative stress. Foetuses from mothers with gestational diabetes are at increased risk 
of developing foetal macrosomia, platelet hyperaggregability and oxidative stress. 
High blood glucose levels in these new-borns induce the oxidative stress, which, in 
turn, provokes the high production of highly reactive oxygen radicals, being toxic to 
cells, especially to the plasma membranes where these free radicals interact with the 
lipid bilayer. Endogenous antioxidant vitamins and enzymes are responsible for the 
detoxification of deleterious oxygen radicals. GDM adversely affects the antioxidant 
status. Treatment with antioxidants may prevent or reverse abnormalities associated 
with increased oxidative stress in GDM. Contradictory studies have reported that 
dietary ω-3 LCPUFA supplements may prevent or enhance the organic deterioration, 
caused by excessive oxidative stress in GDM. 
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This research study investigated whether; 
a) GDM compromises plasma omega-3 and omega-6 fatty acid status of pregnant 
women and their neonates.  
b) High pre-pregnancy body mass index alters the plasma fatty acid profile in GDM 
women. 
c) Impaired status of DHA in GDM pregnant women and their neonates can be 
ameliorated by DHA-enriched supplementation. 
d) DHA-enriched formula enhances the plasma antioxidant vitamins status in 
gestational diabetic women and their neonates.  
7.2  Conclusion 
7.2.1 Study 1 (chapter 3)   
 Consistent to the previous findings by our research group, the levels of DHA 
and AA were not reduced in plasma lipids in GDM women. It could be due to the 
failure of incorporation the nutrients into red cell phospholipids. Also, the possibility 
of impaired placental transport could not be ruled out. Moreover, the samples were 
collected at diagnosis, and it is plausible that the duration of the diabetes was very 
short to produce an obvious adverse effect on the plasma DHA and AA levels.    
 A novel finding of the study is that omega-3 LCPUFA supplementation is 
effective in enhancing the maternal DHA status in GDM women. Furthermore, it 
showed that the decline in maternal DHA, which occurs in the final stages of gestation 
and was thought to be a physiological response to pregnancy, can be halted by 
supplementation. We suggest that the provision of a DHA supplement should be 
integrated with the antenatal care of pregnant women with gestational diabetes to 
optimize foetal development and avert maternal DHA depletion in pregnancy.  
7.2.2. Study 2 (chapter 4)   
Cord plasma fatty acid levels were comparable between the women with and 
without gestational diabetes. Nevertheless, the trend was for a relative reduction in 
omega-6 and omega-3 fatty acids in the cord of the GDM women, although some of 
the values were not statistically significant. The foetus is reliant on the maternal status 
and placental uptake. Since there was no obvious evidence of dietary insufficiency or 
reductions in plasma fatty acids, the reduced DHA and AA levels in the cord plasma of 
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GDM women could be due to impaired placental uptake. Given the importance of 
these nutrients, this abnormality may have adverse effects on foetal growth and 
development as well as health in adulthood. There is a need for further studies to 
understand the underlying mechanism for this abnormality and its developmental and 
health implications. 
This double blind, placebo-controlled, randomized study demonstrated that 
supplementation of women with GDM is effective in enhancing maternal but not foetal 
DHA status. The failure of the supplementation to improve the foetal DHA status is of 
some concern because the offspring of the women with GDM are born with a lower 
level of the nutrient and the condition is thought to be link with a risk of neuro-
developmental deficits. It is plausible that maternal supplementation with more than 
600mg of DHA may trickle down to the foetus and mitigate the insufficiency, or an 
increased duration of maternal supplementation may improve the neonatal DHA status. 
Regardless, we suggest that babies of gestational diabetic women, particularly those 
not suckling, similar to the babies who born prematurely require formula-milk fortified 
with a higher level of DHA. 
7.2.3 Study 3 (chapter 5)   
 Increased oxidative status is associated with gestational diabetes. No study is 
available on the improvement of antioxidant vitamin status by omega-3 LCPUFA 
enriched fish oil in GDM women and their neonates. Our study adds another aspect of 
omega-3 LCPUFA in the allied management of oxidative stress associated with GDM.  
 In this study, GDM women who were supplemented with omega-3 enriched 
formula had comparable plasma vitamins E, A and β-carotene levels when compared 
with their GDM counterparts who received the placebo, at delivery. Similar results 
were found when cord plasma levels of these micronutrients were compared between 
the groups. We observed that the antioxidant effects of the omega-3 supplementation 
are dose and duration dependent. In this study, the antioxidant status did not improve 
yet not deteriorate in GDM active-treatment group, however, the dose used and the 
duration of supplementation was much less in our study as compared to those studies 
which showed improved antioxidant status. Therefore, we can allude that a moderate 
dose of omega-3 LCPUFA may be recommended in foods to reduce the incidence and 
complications associated with oxidative stress in diabetic pregnancy. 
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7.2.4 Study 4 (Chapter 6)   
 Obesity during pregnancy is associated with adverse pregnancy outcomes. We 
evaluated the impact of pre-pregnancy body mass index on plasma fatty acid levels in 
GDM women. We categorised GDM women on the basis of their pre-pregnancy BMI 
in normal-weight, over-weight and obese group.  As compared to normal-weight 
women, obese women had higher omega-6 and lower omega-3 PUFA levels. We 
conclude that higher pre-pregnancy BMI is associated with an adverse fatty acid 
profile in GDM women.  
7.3 Limitations of the study 
 This study has provided some interesting information about the effect of 
DHA-rich fish oil on plasma fatty acids and antioxidant vitamin status in pregnancy 
complicated with gestational diabetes, but it had limitations that future studies may 
need to take into account.  
• It was difficult to recruit sufficient number of healthy control subjects and the 
low number had a negative implication on the outcome of the statistical analyses. 
In addition, some of the participants (GDM and Healthy Control) opted out of 
the study or did not take the supplements as instructed by the mid-wives (lack of 
compliance).  
• A significant number of delivery samples were lost because of unanticipated 
births before the due date, delivery at a different hospital, too busy labour or 
delivery midwives to collect samples and women moving out of the area without 
providing contact details.  
• Efforts were made to obtain information about a habitual diet of the women 
using a food diary, we were unable to extract valuable data about their nutritional 
intake. This was because most of the diaries returned were incomplete.  
• Failure to explain and educate family members about the potential benefit of the 
study. Most of the pregnant women who attend antenatal clinic in Newham 
Hospital are of Asian ancestry. In Asian community, decisions to participate or 
not in a study is a family affair.  
• The participants were heterogeneous with respect to genetic and possibly dietary 
backgrounds and duration of the supplementation period.    
  146 
 The aforementioned limitations, most of which were anticipated during the 
design of the study protocol, would have been reduced or avoided by recruiting 
additional research mid-wives and a dietitian, frequent home visits and conducting the 
study in more than one hospital. However, it was not possible to do so because of 
budgetary constraints.  
7.4 Future investigations 
 As evident from the conclusions of this study, omega-3 LCPUFA (chiefly 
DHA) has the potential to be an effective and affordable adjunct to the traditional 
treatment currently recommended for the management of gestational diabetes. 
However, further studies are required to be conducted to address the following issues;  
1. In the current study, a daily dose of 600 mg of DHA supplementation of GDM 
women did not enhance the foetal plasma DHA level. The failure of the 
supplementation to improve the level of foetal DHA is of some concern because the 
offspring of the GDM women are born with a lower level of the nutrient and the 
condition is thought to be linked with a risk of neuro-developmental deficits. So, a 
further study would need to explore;  
“Could an increased daily dose of DHA-enriched fish oil (more than 600mg) 
supplementation in women with GDM trickle down to the foetus and mitigate the 
insufficiency in plasma n-3 LCPUFA status”? 
2. It is reported that foetal LCPUFA insufficiency is associated with high incidence of 
congenital malformations and impaired neurological development. A direct 
relationship between deficiencies in LCPUFA and congenital malformations need to 
be determined. At birth, the adverse effects of gestational diabetes on the offspring 
may not be immediately apparent. Therefore; 
“Follow-up studies in childhood and beyond are necessary to determine the long-
term effect of gestational diabetes on the offspring.” 
3. Placental dysfunction and the consequential reduction in the transfer of the fatty 
acids from GDM mother may explain the abnormality in the neonates. Therefore; 
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“Further investigations are very important to determine the placental fatty acids 
and the activity and expression of placental fatty acid binding and transport 
proteins in gestational diabetic women.” 
4. Higher omega-6 and lower omega-3 PUFA levels lead to higher adipose tissue 
development. In the other direction, obesity causes alterations in adipose tissue 
metabolic and endocrine function leading to an increased release of fatty acids, thus 
affecting subsequent adiposity and finally creating a vicious cycle Therefore; 
“Further experimental studies are needed to explore the underlying mechanism 
and the direction of this association” 
5. As observed in our study, omega-3 LCPUFA supplementation did not deteriorate 
the anti-oxidative defence system in GDM. It has been shown in many studies that 
maternal diabetes significantly alters the “total antioxidant status” as demonstrated by 
decreased non-enzymatic antioxidants (vitamins A and E), anti-oxidant enzymes 
(superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and glutathione 
reductase (GSSG-Red)). In this study, we determined the non-enzymatic antioxidants 
status in GDM and their neonates. Therefore;  
“Further studies targeting gestational diabetic women and their offspring are 
recommended to further investigate the effect of omega-3 LCPUFA on total 
antioxidant status. Moreover, the application of the omega-3 LCPUFA as 
supplements in the management of oxidative stress associated with gestational 
diabetes need to be explored.” 
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Appendix 1. List of instruments. 
 
Gas-liquid chromatography (GLC) 
Product: 1800 series gas chromatography model 8533 (HRGC MEGA 2 Series) with 
dual flame ionization detector, split/splitless, amplifiers with A 200S auto-
sampler. 
Supplier Fisons Instruments (UK organic sales, Crewe Road, 
Wythenshaw, Manchester, M23 9BE) 
Column BPX-70 column 
Supplier  SGE Europe Ltd (UK) 
Length 60 meters 
Physical properties Highly Polar 
Material 70% Cyanopropyl Polysilphenylene-siloxane 
Type BPX70 
Film Thickness 0.25 µm 
Internal Diameter 0.32mm 
Operating temperature 150oC – 250oC 
Conditioning 
temperature 
250oC for 5 minutes 
Hydrogen generator 
Product Hygen 400  
Supplier Claind Brezza Generators. Jaytee BioSciences LtD. Uk 
§ This hydrogen generator produces up to 600 cc/min of pure dry hydrogen gas using 
deionised water and electricity. 
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High-performance liquid chromatography (HPLC) 
Product: Agilent 1100 series high performance liquid chromatograph system with a 
quaternary pump connected to an auto sampler, automatic fraction collector, 
and column thermostat and diode-array detector. 
Diode array detector 
Model Agilent 1100 Series diode array detector (DAD) 
Supplier  Agilent technologies (Agilent technologies Deutchland, 
Gmbh, Waldbronn analytical division, Waldbronn, Germany 
Light source  Deuterium and tungsten lamps 
Wavelength range 190-95-nm 
Diode width < 1nm 
Auto sampler 
Model Agilent 1100 series auto sampler 
Dimensions 200×345×435mm 
Ambient operating 
temperature 
4-40oC 
Humidity  95% at 25-40oC 
Hypersil gold HPLC column 
Length  250mm  
Diameter 4.6mm 
Particle size 5µm 
Pore size 175Å 
pH range 1-11 
Supplier  Thermo Scientific, UK 
 
 
 
 
 
 
  195 
Appendix 2. List of chemicals. 
 
Name Company Code 
Absolute Ethanol Hayman Ltd. 64-17-5 
Acetic acid Fisher scientific UK A/0400/PB08 
Acetyl chloride Acros organic 151270010 
Butylated hydroxytoluene (BHT) Sigma-Aldrich Co.UK B-1378 
Chloroform, HPLC grade Fisher scientific UK C/4966/17 
CPG standard Sigma-Aldrich Co.UK P5394 
2, 7-dichlorofluorescein Sigma-Aldrich Co.UK 410217 
Dichloromethane (DCM) Fisher scientific UK D143SK-4 
Diethyl ether Fisher scientific UK D/2450/17 
Dried methanol Fisher scientific UK M/4050/15 
FAME mix Sigma-Aldrich Co.UK 18919-IAMP 
Formic acid, 98/100% VWR international 101155F 
Heptane Fisher scientific UK H/0106/17 
Hexane  Sigma-Aldrich Co.UK H/0406/17 
Methanol HPLC grade Fisher scientific UK M/4056/17 
Methylamine (Extra pure, 40 wt. 
%) Acros organic 126230010 
Petroleum ether 60-80 degree Fisher scientific UK P/1800/17 
PBS 10X (Dulbecco) Sigma-Aldrich Co.UK D1408 
Potassium bicarbonate Fisher scientific UK P/5120/53 
Sodium chloride Sigma-Aldrich Co.UK S 7653 
Sodium sulphate (Granular, 
anhydrous) Fisher scientific UK S/6600/53 
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Thin layer chromatography plates 
Product TLC silica gel 
Cat No. 1.5721.0001 
Size 20×20 cm 
Layer thickness 210-270 µm 
Pore volume 0.74-0.84 m/g 
Supplier Merck KGaA, Germany 
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Appendix 3. Fatty acids standard mix: 100 mg ampule contains the following with 
weight percentages indicated. 
 
 
Trivial Names Abbreviation Weight(%) 
 
Butyric acid methyl ester 
Caproic acid methyl ester 
Caprylic acid methyl ester 
Undecanoic acid methyl ester 
Lauric acid methyl ester 
Tridecanoic acid methyl ester 
Myristic acid methyl ester 
Myristoleic acid methyl ester 
Pentadecanoic acid methyl ester 
Cis-10-Pentadecenoic acid methyl ester 
Palmitic acid methyl ester 
Palmitoleic acid methyl ester 
Heptadecanoic acid methyl ester 
Cis-10-Heptadecenoic acid methyl ester 
Stearic acid methyl ester 
Oleic acid methyl ester 
Elaidic acid methyl ester 
Linoleic acid methyl ester 
Linolelaidic acid methyl ester 
α-Linolenic acid methyl ester 
γ-Linolenic acid methyl ester 
Arachidic acid methyl ester 
Cis-11-eicosenoic acid methyl ester 
Cis-11,14-eicosadienoic acid methyl ester 
Cis-11,14,17-eicosatrienoic acid methyl ester 
Arachidonic acid methyl ester 
Cis-5,8,11,14,17-eicosapentaenoic acid methyl ester 
Heneicosanoic acid methyl ester 
 
     4:0 
     6:0 
8:0 
10:0 
12:0 
13:0 
14:0 
14:1 
15:0 
15:1 
16:0 
16:1 
17:0 
17:1 
18:0 
18:1 
18:1 
18:2 
18:2 
18:3 
18:3 
20:0 
20:1 
20:2 
20:3 
20:4 
20:5 
21:0 
 
4 
4 
4 
2 
4 
2 
4 
2 
2 
2 
6 
2 
2 
4 
4 
4 
2 
2 
2 
2 
2 
4 
2 
2 
2 
2 
2 
2 
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Behenic acid methyl ester 
Erucic acid methyl ester 
Cis-13,16-docosadienoic acid methyl ester 
Cis-7,10,13,16-docosatetraenoic acid methyl ester 
Cis-7,10,13,16,19-docosapentaenoic acid methyl ester 
Cis-4,7,10,13,16,19-docosahexaenoic acid methyl 
ester 
Tricosanoic acid methyl ester 
Lignoceric acid methyl ester 
Nervonic acid methyl ester 
22:0 
22:1 
22:2 
22:4 
22:5 
22:6 
23:0 
24:0 
24:1 
4 
2 
2 
2 
2 
2 
2 
4 
2 
 
 
 
 
 
Appendix 4. Vitamins standards. 
 
α-tocopherol, purity > 97.0% 
(HPLC) 
Fluka 95240 
Retinol, purity > 99.0% (HPLC) Fluka 95144 
β-carotene, purity> 95.0% (HPLC) Sigma-Aldrich C4582 
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Appendix 5. Thin layer chromatography separation of plasma phospholipids on silica 
gel plate by single vertical development. Original sample applied at the base point. 
(The sequence of the bands from top to down is: 1= Neutral lipids, 2= Choline 
phosphoglycerides, 3= Sphingomyelin). 
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Appendix 6. Thin layer chromatography separation of plasma neutral lipids on silica 
gel plate by single vertical development. Original sample applied at the base point. 
(The sequence of the bands from top to down is: 1= Cholesterol esters, 2= 
Triglycerides, 3= Free fatty acids). 
 
 
 
 
 
 
 
 
 
 
 
  201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7. A specimen chromatogram of plasma fatty acid methyl esters (CPG 
fraction) of a test sample. 
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Appendix 8. A specimen chromatogram of plasma fatty acid methyl esters (CE 
fraction) of a test sample. 
 
 
 
